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Multiproduct manufacturing facilities running on a campaign basis are increasingly 
becoming the norm for biopharmaceuticals,  owing to high risks of clinical  failure, 
regulatory pressures and the increasing number of therapeutics in clinical evaluation. 
The need  for  such  flexible plants  and  cost-effective  manufacture  pose  significant 
challenges for planning and scheduling, which are compounded by long production 
lead  times,  intermediate  product  stability  issues  and  the  high  cost  -   low  volume 
nature  of biopharmaceutical  manufacture.  Scheduling  and  planning  decisions  are 
often  made  in  the  presence  of  variable  product  titres,  campaign  durations, 
contamination rates  and product  demands.  Hence  this  thesis  applies  mathematical 
programming techniques to the planning of biopharmaceutical manufacture in order 
to identify more optimal production plans under different manufacturing scenarios. A 
deterministic  mixed  integer  linear  programming  (MILP)  medium  term  planning 
model  which  explicitly  accounts  for  upstream  and  downstream  processing  is 
presented.  A  multiscenario  MILP  model  for  the  medium  term  planning  of 
biopharmaceutical manufacture under uncertainty is presented and solved using an 
iterative  solution procedure.  An  alternative  stochastic  formulation  for the medium 
term planning of biomanufacture under uncertainty based on the principles of chance 
constrained programming is also presented. To help manage the risks of long term 
capacity planning in the biopharmaceutical industry, a goal programming extension 
is presented which accounts for multiple objectives including cost, risk and customer 
service level satisfaction. The model is applied to long term capacity analysis of a 
mix of contractors and owned biopharmaceutical manufacturing facilities. In the final 
sections  of this  thesis  an  example  of a  commercial  application  of this  work  is 
presented,  followed  by  a  discussion  on  related  validation  issues  in  the 
biopharmaceutical industry.
The  work  in  this  thesis  highlighted  the  benefits  of  applying  mathematical 
programming  techniques  for  production  planning  of  biopharmaceutical 
manufacturing facilities, so as to enhance the biopharmaceutical industry’s strategic 
and operational decision-making towards achieving more cost-effective manufacture.Acknowledgements
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Introduction
1.1.  Biopharmaceutical Development
The discovery of recombinant DNA  and monoclonal  antibody technologies  in the 
1970s  marked  the  birth  of  the  biopharmaceutical  industry.  Biopharmaceuticals 
include  protein  hormones,  engineered  protein-based  vaccines,  and  monoclonal 
antibodies.  They  have  proven  highly  successful  in  modifying  patient  physiology 
often  with  greater  success  and  fewer  side  effects  than  traditional  small-molecule 
drugs or vaccines;  in fact Walsh reports that since 2000,  over a quarter of all new 
drugs approved have been biopharmaceuticals (Walsh, 2003). However they are fast 
becoming victims of their own success. As the industry matures companies continue 
to  face a long and  costly product development lifecycle,  with  an  average time-to- 
market  of  7-8  years  (Foo  et  al.  2001),  high  risks  of  clinical  failure,  regulatory 
pressures and the inherent complexities of biopharmaceutical manufacture all present 
real challenges for companies wishing to remain competitive by achieving more cost- 
effective  biomanufacturing.  This  need  to  reduce  costs  and  make  better  use  of 
resources provides the impetus for the development of decision support tools (DST) 
for the biopharmaceutical industry and the motivation for this EngD.Chapter 1. Introduction
1.2.  Biopharmaceutical Manufacture
Biopharmaceutical  manufacture  or  “biomanufacturing”  refers  to  the  process  of 
producing a biologic or biopharmaceutical, and is generally taken to be the process 
which ensues subsequent to the stages of research and process development (Sofer & 
Hagel,  1997).  A  typical  biomanufacturing  process  is  likely to  be  comprised  of a 
number  of  steps,  typically  cell  culture/fermentation,  cell  harvesting,  recovery, 
purification and formulation through to a product with regulatory approval. Each step 
comprises a number of unit operations, surrounded by a number of ancillary but vital 
processes such as cleaning, sterilisation, media/buffer preparation and quality control 
and quality assurance steps.
Bioprocessing is characterised by a number of manufacturing challenges shared with 
the  traditional  chemical  batch  processing  industries,  where  typically  the  major 
operational  challenges  are  the  need  to  speed  up  process/product  development, 
increase productivity, and satisfy safety and product quality requirements (Allgor et 
a l,  1996).  However  there  are  additional  challenges  in  the  biopharmaceutical 
industry, such as higher variations in process behaviour due to the biological nature 
of the  materials  used,  more  stringent  quality  control  regulations  and  higher  end- 
product purity requirements (due to the sensitive therapeutic nature of many of the 
products).  Other  challenges  in bioprocessing  include the  ongoing  improvement  of 
fermentation  titres  and  downstream  purification  yields,  management  of  utilities 
which are often shared between different process equipment and a general need for 
ongoing process optimisation.
Much  of  biopharmaceutical  production  has  traditionally  been  undertaken  in 
dedicated  facilities  due  to  the  stringent  regulatory  constraints  associated  with 
biopharmaceutical manufacture which stems from the need to  avoid product cross­
contamination. However, in the  1990’s this started to change as smaller companies, 
unable to cope with the capital outlay associated with building their own facilities, 
were driven to use the services of contract manufacturers (Sofer,  1995).  This gave 
rise to the now widespread use of multiuse,  multiproduct facilities.  The trend was 
accelerated in 1998 when the Food and Drug Administration (FDA) started to allow 
companies to manufacture different products in the same building, with some shared
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facilities, since this was found to result in increased efficiency and facility utilisation 
(Chemical Market Reporter, 1998). The high risks associated with drug development 
coupled with increasing demands for certain therapeutics has meant that an increased 
use  of the  more  flexible  and  cost-effective  multiproduct  contract  manufacturing 
facilities, and in 2004 Langer reported that 35% of all biomanufacturers outsourced 
at least some of their production, expecting that by 2008 nearly half would do this 
(Langer,  2004).  Given  the  flexibility  offered  by  multiproduct  facilities,  contract 
manufacturers  are  not  alone  as  the  majority  of biomanufacturing  companies  are 
employing multiproduct facilities. Multiproduct facilities pose a significant cleaning 
validation challenge. Products are typically run one at a time on a campaign basis, 
this poses a serious risk of cross-contamination if the necessary precautions are not 
taken or detection methods are not sufficiently sensitive and validated. Furthermore, 
equipment  may  be  disposable,  dedicated  or  shared.  Each  presents  different 
advantages  and  disadvantages,  in  terms  of  cost  effectiveness  and  risks  of 
contamination,  and  frequency  of  maintenance  and  cleaning.  At  a  higher  level, 
biomanufacturers need to think about capacity availability for products which may or 
may not be successful.  Challenges are particularly great in larger companies which 
may have a very large portfolio of drugs going through their development pipeline at 
any one point in addition to  their existing marketed  drugs.  Manufacturers have to 
decide whether to build or buy capacity,  which is a particularly sensitive financial 
decision given the associated costs and risks such as potential loss of market.
1.3.  Planning and Scheduling of Biopharmaceutical 
Manufacture
As  was  discussed  in  Section  1.2,  the  biopharmaceutical  industry  is  increasingly 
employing multiproduct manufacturing facilities.  Challenges include the significant 
burden of cleaning validation and the risk of cross contamination.  Other challenges 
include the time and cost associated with campaign changeovers due to  equipment 
setup  and  cleaning.  The  particularly long  lead  times  associated  with  changeover, 
coupled with sensitive and costly intermediate storage product conditions present a
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significant  challenge  for  production  planning  and  scheduling.  These  are  often 
compounded by inherent technical uncertainties that can impact costs and delivery. 
These  include  fluctuations  in  fermentation  titres,  purification  yields,  campaign 
lengths,  product  demands  and  contamination  rates  (Farid  et  al.,  2005).  Gosling
(2003)  notes that significant economic benefits can be expected if these planning and 
scheduling challenges can be overcome. Better scheduling and planning is likely to 
improve plant capacity utilisation and thereby lead to increased productivity.  In fact 
recent industrial reports (Fox, 2005) confirm that improved plant utilisation leads to 
increased sales and profitability.
An  increasing  number  of  large-scale  biopharmaceutical  companies  have  a 
portfolio of commercial products on the market as well as a pipeline of candidates 
under  clinical  evaluation.  Developing  a  comprehensive  manufacturing  strategy  to 
meet anticipated demands for both clinical trial and market material requires careful 
capacity planning. The launch of successful commercial products has often triggered 
companies  to  bridge  in-house  capacity  via  strategic  partnerships  with  contract 
manufacturing organisations (Gottschalk 2005, Kamarck 2006). Consequently, more 
effective  methods  are  required  to  manage  and  align  production  across  several 
multiproduct  facilities,  including  third  party  organisations,  so  as  to  ensure  the 
availability  of  sufficient  capacity.  However,  determining  capacity  needs  for 
biopharmaceutical  production  is  often  a  difficult  process  requiring  predictions  of 
product doses, market forecasts, production rates (titres, yields) and clinical/technical 
success rates. The issue of planning and scheduling is a major component within the 
key business and strategic issue of long term capacity management which remains at 
the forefront of the minds of the biopharmaceutical industry’s decision-makers since 
Immunex’s  capacity  shortage  for  the  manufacture  of  its  highly  successful  drug 
Enbrel and the resulting financial losses (Thiel, 2004).
1.4.  Modelling Biopharmaceutical Manufacture
Many benefits are to be reaped through the implementation of computer modelling 
(as  will  be  discussed  in  Section  1.5),  however  the  effectiveness  of  computer
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modelling is often limited by the complexity of the process which is to be modelled. 
Saraph (2001) notes some of the key features of biomanufacturing from a modelling 
perspective:
•  A  typical  biomanufacturing  process  is  a  mix  of  discrete  and  continuous
processes.
•  The batch sizes vary from stage to stage.
•  Different  production  stages  are  physically  and  temporally  separated  by
intermediate quality control and quality assurance processes.
•  Storage capacities at each stage differ.
•  Product has limited shelf life at each stage of production and product potency is 
adversely affected by storage.
•  Production capacity differs from stage to stage and so does staffing.
•  There is no re-entrant flow of material.
•  There are elaborate controls to ensure required cleanliness, which create further 
operational constraints.
•  Sharing of common utilities.
Mustafa et al (2006) note the scarcity of trained personnel and limited availability of 
fundamental physical property data as being some of the factors attributing to a lack 
of  modelling  work  in  the  biopharmaceutical  industry  as  compared  to  more 
established industries such as the chemical industry.
1.5.  Objectives of Decision Support Tools
A decision support tool or system (DST) is defined broadly by Finlay (1994) as “a 
computer-based system that aids the process of decision making".  Computer based 
tools which meet this definition are used extensively within the biopharmaceutical 
industry for a vast number of purposes ranging from accounting,  lab-management, 
process  development,  risk-management,  cost-benefit  analysis,  process  scheduling
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and ongoing process optimisation. However in this thesis the focus is on those used 
to aid manufacturing decisions.
Saraph (2001) proposed some relatively generic objectives for a DST that was used 
to aid biomanufacturing decision-making:
•  To develop a better understanding of the existing manufacturing operations and 
capability.
•  To identify the root causes, and potential solutions of operational problems.
•  To analyse proposed solutions.
•  To  help  in  forecasting  in  order  to  identify  potential  opportunities  and  avoid 
potential pitfalls.
•  To support the strategic decision making process which may consider a variety of 
features whether process, logistical or financial.
Williams  (1999)  proposed  some  typical  objectives  more  specific  to  mathematical 
model building:
•  To gain insight into the problem. The actual exercise of building a mathematical 
model often reveals relationships that were not apparent previously. As a result 
greater understanding of the problem is achieved.
•  To identify non-obvious solutions to the problem. Having built a model it is then 
possible to  analyse it mathematically and help  suggest a course of actions that 
might not otherwise be obvious.
•  To investigate extreme aspects of the problem.  Computational  experiments  can 
be  conducted when it is not possible or desirable to  conduct  an  experiment in 
real-life (e.g. accident simulation models) and provide us with useful information 
concerning the problem under investigation.
Between the two sets of objectives, a good idea of the value decision support tools 
can add within the biopharmaceutical industry can be seen.
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1.6.  Aims and Objectives
The aim of this work is to facilitate the biopharmaceutical industry’ s strategic and 
operational decision-making by applying mathematical programming techniques for 
production planning of biopharmaceutical manufacturing facilities.  It is motivated 
by the need for improved cost-effectiveness and better capacity management in the 
biopharmaceutical industry.
In order to achieve these goals, the following areas will be addressed:
•  Medium  term  planning:  this  area  is  concerned  with  determining  the  optimal 
medium term production plans for a multiproduct multi-suite biopharmaceutical 
manufacturing facility. It will do so by capturing the characteristic bioprocessing 
features of the production planning problem in the biopharmaceutical industry.
•  Medium term planning under uncertainty: this area is focused on understanding 
the impact of uncertainty on biopharmaceutical manufacturing production plans 
and  the  development  of  alternative  approaches  for  the  determination  of  the 
optimal  medium  term  production  plans  for  a  multiproduct  biopharmaceutical 
manufacturing  facility  under  uncertain  manufacturing  conditions.  Solutions 
should  be  achieved  within  a  reasonable  computational  time  without 
compromising the quality of the obtained solution.
•  Long term planning:  this  area deals  with longer term  capacity management  of 
biopharmaceutical facilities and the need to understand better existing capacity 
capabilities and to quantify the impact of different strategic operating polices on 
capacity decisions.
1.7.  Thesis Outline
The thesis is structured as follows:
Chapter 2 presents a critical review of past work on production planning within the 
biopharmaceutical  and  associated  industries,  considering  deterministic  planning
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works in the medium and long term timescales,  followed by a review of planning 
under uncertainty.
In  Chapter  3,  a deterministic  mathematical  programming  formulation  for medium 
term planning of biopharmaceutical manufacture is presented. The model is applied 
to two illustrative examples and is compared with an industrial rule-based approach.
Chapter 4 proposes  a  stochastic mathematical programming  formulation based  on 
two-stage  programming  for  the  medium  term  planning  of  biopharmaceutical 
manufacture under uncertainty. A hierarchical algorithm for the efficient solution of 
the problem is also presented and compared with the full space problem and a rolling 
horizon algorithm via a number of illustrative examples.
An  alternative  stochastic mathematical programming  formulation based  on  chance 
constrained  programming  for  the  medium  term  planning  of  biopharmaceutical 
manufacture  under  uncertainty  is  presented  in  Chapter  5.  The  deterministic 
equivalent  formulation  is  derived  and  compared  to  the  approach  presented  in  the 
previous chapter.
A multiobjective optimisation  framework based on goal programming is proposed 
and  used  to  tackle  the  problem  of long  term  planning  in  the  biopharmaceutical 
industry in Chapter 6. The problem is applied to an industrial case study and insights 
are drawn through a variety of studies.
Chapter  7  presents  a  plan  for  the  commercialisation  of this  work  and  Chapter  8 
discusses the related validation and regulatory issues.
Finally, Chapter 9 concludes the thesis summarising the work that has been done and 
outlines  possible  directions  for  future  work  in the  area  of production planning  of 
biopharmaceutical manufacture.
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Planning  and  scheduling  is  a  vital  component  of  cost-effective  manufacturing 
operations in the biopharmaceutical and process industries in general. Planning and 
scheduling activities are very closely related, as the decisions made at the planning 
level  have  a  strong  influence  on  scheduling.  Hence,  it  is  necessary  to  make  a 
distinction between the two activities as the focus of this work is that of production 
planning  rather  than  scheduling.  Usually,  planning  means  the  generation  of 
production plans for longer periods of time typically months to years, given forecasts 
for prices and product demands.  In contrast, scheduling refers to the assignment of 
resources  to  activities,  sequencing  of activities  and  determination  of starting  and 
ending times for the execution over a short period of time, typically days to weeks.
In this chapter the key works of relevance to the problem of production planning of 
biopharmaceutical manufacture are reviewed. First the general problem of planning 
and scheduling in the biopharmaceutical industry is discussed highlighting some of 
the  related  works  in  this  area  (Section  2.1).  Deterministic  planning  works  in  the 
closely related process industries are then presented (Section 2.2), this is followed by 
works in the area of planning under uncertainty (Section 2.3).  Finally,  concluding 
remarks are drawn whereby the scope and the motivation of this work are clarified in 
the light of earlier work (Section 2.4).
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2.1. Planning and Scheduling in the 
Biopharmaceutical Industry
Planning  and  scheduling  of biochemical  processes  has  received  relatively  little 
attention.  To  date,  custom  planning  methods  used  by  biomanufacturers  remain 
relatively  simplistic  e.g.  spreadsheets  and  t-cards  using  industrial 
experience/common sense approaches, typically supported by enterprise and material 
requirement planning (ERP  & MRP)  software which are often limited to  customer 
order, inventory and resource management. To some extent this can be attributed to 
the lack of relevantly trained personnel (Mustafa et al., 2006).  However,  given the 
potentially  vast  number  of  possible  solutions  due  to  the  combinatorial  nature 
(exponential  growth  in  solution  space  with  linear  growth  in  problem  size)  of 
scheduling  and  planning  problems,  it  is  clear  that  there  is  significant  scope  for 
improvement.  General and specialist bioprocess simulation software packages have 
been  used  for  solving  planning  and  scheduling  problems  within  the 
biopharmaceutical industry.The packages have mostly been used for debottlenecking 
of equipment and utility usage, examples include Batch Plus (Shanklin et a l, 2001), 
Chemsim  (Gosling,  2003)  and  SuperPro  designer  (Petrides  and  Siletti,  2004). 
However  industrial  accounts  highlight  their  inadequacy  when  challenged  with 
dealing with larger problems involving multiple products and suites. These packages 
probably  remain  best  suited  to  “what  if’  scenario-based  analysis,  whereby 
manufacturing challenges such as the impact of resource bottlenecks and delays on 
schedules are evaluated through discrete event simulation techniques.
Most  recent  published  optimisation/mathematical  programming  approaches  for 
planning and  scheduling of biochemical processes have  focused  on the  short term 
time scale. Examples of such approaches include the work of Iribarren et al.  (2004), 
where  an  approach  for  simultaneous  process  development  and  short  term  process 
scheduling  for  recombinant  protein  production  is  developed.  Samsatli  and  Shah
(1996)  devised  a  scheduling  approach  for  short  term  batch  process  scheduling  of 
biochemical processes based on the State Task Network (STN) formulation proposed 
by Kondili et al  (1993). Most recently Tsang et al  (2006) presented a planning and
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scheduling model applied to a flu vaccine manufacturing facility whereby planning 
for  upstream/downstream  production  was  tackled  via  a  heuristic  scheduler  and 
detailed scheduling via an optimisation model based on the  STN  formulation.  The 
applicability of the model was demonstrated via a number of debottlenecking studies 
on cleaning operation and installation of new equipment items.  Industrial  accounts 
also indicate that more recently mathematical programming based systems are being 
considered for deployment in the industry,  especially for larger scale planning and 
supply chain problems.
2.2.  Production Planning:
Deterministic Optimisation Models
The bulk of relevant research in the area of production planning has been conducted 
on and applied to the traditional batch process industries. Of particular relevance and 
similarity  are  the  pharmaceutical,  food  and  beverage  and  speciality  chemicals 
industries, which share some of the key features of the biopharmaceutical production 
planning problem. The main similarity between these industries is the use of a batch 
mode of operation to produce often small quantities of a large number products using 
multipurpose  equipment.  Batch production  involves  an  integer number  of batches 
where a batch is the smallest quantity produced, with batches often produced in long 
sequences, referred to as a “campaign”, to avoid changeover delays,  contamination 
risks and cleaning costs.
Kallrath (2002) notes some of the key structural objects in planning models used in 
the process industries which are also shared with the biopharmaceutical industry:
•  Locations are often used for production and storage sites.
•  Facilities  are  often  characterised  by  functional  properties  such  as  capacity, 
throughput  rates,  product  recipes,  yields,  fixed  and  variable  costs  or  storage 
limitations.
•  Demand  points  are  used  to  represent  customers,  regional  warehouses  or 
distributors who specify the amount of product they request.
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•  Inventories may be tanks or warehouses which can be fixed or movable entities, 
with product storage being either product specific or global.
•  Products may be classified as raw materials, intermediates or finished and salable 
products, where product demands may be characterised by volume, selling price, 
package type, time, origin and/or location.
•  Suppliers which may provide product under different offering schemes.
Models used for planning in the process industries may involve a very large variety 
of manufacturing and logistical  features.  Some of the key features  shared with the 
biopharmaceutical manufacturing planning problem are detailed below:
•  Batch production enforcing the production of an integer number of batches at a 
predefined batch size.
•  Buying, building, closing or selling manufacturing sites.
•  Campaign production enforcing the production of a minimum number batches in 
sequence.
•  Penalty costs applied if deliveries arrive after their due dates.
•  Multiple  locations  can  be  used  for  production  sites,  storage  sites  or  demand 
points.
•  Multi-stage production allowing for the production of multiple intermediates and 
their intermediate storage before the manufacture of the final product.
•  Multiple time periods for definition of the time horizon which can be continuous 
with non equidistant time periods or discrete fixed size time periods.
•  Product Shelf-life allowing for product aging to be traced and product disposal 
for expired products.
Planning is part of the supply chain management problem and typically focuses on 
medium term sales and inventory planning or more long term strategic planning and 
capacity  analysis.  Hence  we  divide  the  review  of the  key  works  into  two  parts, 
medium term planning and long term planning.
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2.2.1.  Medium Term Planning
The medium term planning timescale typically refers to a duration of a few months 
up to  a few years and is also often referred to  as production scheduling,  campaign 
planning  or  medium  term  planning.  The  research  in  this  area  is  often  hard  to 
distinguish  as  planning  or  scheduling  as  many  works  attempt  to  address  both 
simultaneously  or  address  a  hybrid  problem  composed  of  features  from  both 
problems.
The  production  planning  problem  in  the  process  industries  has  received  great 
attention over the years with one of the earliest noted works being that of Mauderli 
and Rippin (1979), but has since come a long way as practitioners have continually 
adapted to the industry changes and trends.  Some excellent reviews of recent work 
have been conducted by Applequist et al.  (1997), Shah (1998), and Kallrath (2002). 
Many approaches have been used for planning in the process industries, and are often 
divided into heuristic and mathematical programming approaches.
Heuristic  methods  are  concerned  with  formulating  rules  for  the  determination  of 
sequences of activities and include dispatching rules or rule-based approaches. They 
are often derived from industrial rules of thumb and used in combination with other 
methods to reduce the resulting problem size and complexity when solving real-life 
problems, often at the cost of achieving sub-optimal solutions. Dispatching rules are 
more commonly associated with scheduling problems; however, they have also been 
applied to planning problems.  Some relevant dispatching rules are:  First come first 
served  (FCFS),  Earliest due date  (EDD),  Shortest processing  time  (SPT),  Longest 
processing time (LPT), Earliest release date (ERD) and Weighted shortest processing 
time (WSPT). Pinedo (2002) details some useful dispatching rules commonly used in 
scheduling practice.
Meta-heuristic  or  Stochastic-search  methods  are  products  of  the  evolution  of 
heuristic-based  approaches  and typically involve  the  simulation of a given  system 
and the evaluation of its objective function. They have been used to tackle planning 
problems in the process industries; examples include Genetic Algorithms, Simulated 
Annealing and Tabu Search. These methods have in common that they lack proof of 
convergence and a dependable measure of solution quality. However, they can often
- 25-Chapter 2. Literature Survey
be  effectively used  to  improve  a  given  solution by performing  a local  search  and 
achieve  sub-optimal  solutions  within  reasonable  time-scales  where  more  rigorous 
mathematical  programming  based  methods  may  fail.  Examples  of  Metaheuristic 
methods are detailed below.
Genetic  algorithms  (GA)  (Goldberg,  1989)  are  Metaheuristic  methods  that  use 
techniques inspired by evolutionary biology such as inheritance, mutation, selection, 
and crossover. GA’s are typically implemented as a computer simulation in which a 
population of abstract representations  (called  chromosomes)  of candidate  solutions 
(called individuals) to an optimisation problem evolves toward better solutions. Lohl 
et  al.  (1998)  compared  a  GA  and  a  mathematical  programming  approach  for 
sequencing and scheduling of a polymer production process and found the GA to be 
a better approach if an improved solution was needed quickly. However, it generally 
underperformed in terms of solution quality when compared with the mathematical 
programming  approach.  More  recently,  Beming  et al.  (2004)  presented  a  Genetic 
algorithm  for planning  and  scheduling  within  a  general  framework  for  integrated 
supply  chain  management  in  the  chemical  process  industry.  Their  algorithm 
considered the production  schedules  of all  the plants  involved  simultaneously and 
provided  a  better  overall  solution  than  one  obtained  by  individually  optimising 
production schedules.
Simulated annealing (SA) (Kirkpatrick et al., 1983) links the probability of accepting 
a solution which is worse than the reference solution to a temperature-like parameter 
based  on  an  analogy  which  describes  the  cooling  of metals.  One  of the  earliest 
applications to planning and scheduling was by Ku and Karimi  (1991) in which it 
was  applied to  the scheduling problem of chemical batch processes.  Tandon et al. 
(1995)  presented  an  SA  algorithm  for  minimising  tardiness  (difference  between 
completion time of late products  and their prior due dates)  in  a network  of single 
stage, unrelated parallel units. The algorithm was found to outperform an established 
heuristic  improvement  method  in  larger  test  problems.  Lee  and  Malone  (2000) 
proposed an SA algorithm for batch process planning of a multi-plant structure and 
compared  the  approach  with  a  number  of  dispatching  rules,  whereby  the  SA 
algorithm was  found to be  superior in terms of solution quality.  Ryu et al.  (2001) 
presented an SA algorithm for production scheduling based on the minimisation or
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earliness and tardiness when meeting due dates.  They demonstrate the approach to 
find good solutions in relatively short computational times.
Tabu  search  (TS)  (Glover  and  Laguna,  1997)  is  essentially  an  adaptive  local 
neighbourhood  search procedure.  It hierarchically directs  one or more local  search 
procedures  in  an  aggressive  pursuit  of the  global  optimum,  while  using  memory 
functions to avoid being trapped in local  optima.  The work of Barnes  and  Laguna 
(1993) was one of the first successful  applications of TS  to production scheduling. 
Oh and Karimi  (2001) developed  a TS  implementation for the solution of a mixed 
integer  non  linear  programming  (MINLP)  formulation  applied  to  campaign 
sequencing and scheduling of an industrial sized problem. A more recent application 
is  that  of  Bhushan  and  Karimi  (2004)  in  which  TS  and  SA  algorithms  were 
developed  for the solution of a continuous-time mixed integer linear programming 
(MILP)  formulation  for  scheduling production an  automated wet-etch  station.  The 
TS  algorithm  was  found  to  outperform  the  SA  algorithm,  achieving  near  optimal 
solutions.
Shah  (1998)  notes  that  although  heuristic  approaches  are  more  representative  of 
current  industrial  practice,  the bulk  of planning  and  scheduling research  has  been 
more directed towards the development of mathematical programming approaches as 
they  are  able  to  represent  the  majority  of the  interactions  present.  Some  of the 
general benefits of mathematical programming were discussed in Section  1.5. More 
specifically mathematical  programming problems  with  a convex  solution  structure 
are  able to provide  a proof of convergence  and  a dependable measure  of solution 
quality.  For these  reasons  planning  and  scheduling problems  are  most  commonly 
formulated  as  mixed  integer  linear  programming  (MILP)  problems  in  which  an 
objective  function  is  maximised  or  minimised  subject  to  constraints.  The  most 
common  planning  applications  in  the  batch  process  industries  include  campaign 
planning  and  sequencing models  in  which  the  optimal  quantities  and  sequence  of 
manufacturing  campaigns  is  determined,  and  aggregate  planning  and  scheduling 
approaches in which a rough cut production plan is determined which forms the basis 
of input data for detailed short term scheduling.
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Papageorgiou  and  Pantelides  (1996a)  presented  a comprehensive review  of earlier 
work on campaign planning and proposed a general formulation for the problem. In a 
companion paper (Papageorgiou and Pantelides,  1996b), where computational issues 
were  discussed,  a  decomposition  approach  for  the  efficient  solution  of 
larger/practical  problem  instances  was  presented.  McDonald  and  Karimi  (1997) 
presented  a  medium  term  planning  model  for  parallel  semicontinuous  processors 
(multiple facilities or production lines) where they incorporated minimum-campaign- 
length constraints in their formulation, but did not consider the detailed timings  of 
campaigns.  Karimi  and  McDonald  (1997)  also  presented  two  multiperiod, 
continuous-time formulations for the detailed timings of campaigns using time slots 
in a companion paper. Ierapetritou and Floudas (1998a) introduced a continuous time 
formulation for production scheduling of batch processes, which was later extended 
and applied to  continuous and semicontinuous processes  (Ierapetritou and Floudas, 
1998b).  In the previous two formulations demands were due at the end of the time 
horizon; the authors later extended the work to allow for multiple intermediate due 
dates  (Ierapetritou  and  Floudas,  1999),  and  found  their  proposed  approaches  to 
perform  favourably in  each  case when  compared to  similar work in  the  literature. 
Gupta and Maranas (1999) developed a hierarchical Lagrangean relaxation procedure 
for the solution of the earlier medium term planning model by McDonald and Karimi
(1997).  When applied to  tackling large-scale problems  the  approach was  found  to 
make  considerable  computational  savings  as  compared  to  direct  solution  via 
commercial  MILP  solvers.  Oh  and  Karimi  (2001a)  presented  an  MILP  model  for 
production planning assuming a single production line and sequence dependent set­
up  times  for  in  optimal  lot  (batch)  sizing.  An  equivalent  MILP  formulation  was 
derived and solved using three different problem specific heuristic-based algorithms. 
Oh and Karimi  (2001b) later developed an MINLP  formulation for the sequencing 
and scheduling of the lot sizing problem with a Tabu search implementation for its 
solution. Whereas the previous models of Oh and Karimi (2001a, 2001b) were based 
on  a  single  production  line  assumption,  Lamba  and  Karimi  (2002a)  presented  an 
MILP  model  for  scheduling multiproduct  facilities  with multiple production  lines. 
They later introduced (Lamba and Karimi, 2002b) a two-step decomposition scheme 
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sequencing  and  scheduling.  Lim  and  Karimi  (2003)  used  asynchronous  time  slots 
and showed improvements on the work by Lamba and Karimi (2002a, 200b) which 
assumed  synchronous  timeslots  (such  that  the  total  resource  usage  or  the  total 
production at any time within a period can be seen). Jackson and Grossman (2003) 
proposed a multiperiod nonlinear programming model  for the production planning 
and  product  distribution  of  several  continuous  multiproduct  plants  located  at 
different  sites  and  supplying  different  markets.  They  developed  spatial  (between 
plants and markets) and temporal (between time periods) solution techniques based 
on Lagrangean decomposition for the problem’s efficient solution.
In many planning formulations reported in the literature a discrete representation of 
time is used; however this often presents difficulties when a very large number of 
time periods are required for the modelling of the necessary time granularity. Hence, 
a number of authors have presented temporal  aggregation methods in which larger 
time-slots are used at the planning level and more detailed time-periods are used for 
short  term  scheduling  decisions.  Wilkinson  et  al.  (1995)  were  one  of the  first  to 
apply  such  approaches  in  the process  industries.  They  applied  a  general  temporal 
aggregation scheme for planning and scheduling to the RTN (resource task network) 
scheduling formulation approach presented by Pantelides (1994), later applying their 
time aggregation /disaggregation approach to  a three-plant and  100 product supply 
network problem based on an industrial case-study (Wilkinson et al., 1996). Basset et 
al.  (1996a,  1996b) presented an aggregation procedure based on a similar temporal 
aggregation  concept  similar  to  that  of  Wilkinson  et  al.  (1995,  1996)  for  the 
aggregation  of  large-scale  problems  using  the  STN  formulation.  Both  authors 
implemented  a backward rolling horizon  algorithm,  however Basset  et al.  (1996a, 
1996b) also aggregated tasks and units. Dimitriadis et al.  (1997) proposed a similar 
aggregation  approach  based  on  the  RTN  formulation;  however  their  concept  was 
based  on  fixing  binary  variables  in  the  MILP  model  for  the  time  window  under 
consideration.  A  more  recent  application  of  aggregation  techniques  in  the 
pharmaceutical industry is that of Grunow et al. (2003), where they employ a number 
of different  aggregations,  specifically  aggregating  processing  tasks  into  cascades, 
equipment  units  into  sub-plants,  and  individual  material-flows  into  material-flow 
patterns, while also employing a demand disaggregation procedure.
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2.2.2.  Long Term Planning
Long term planning  is  concerned with  strategic planning  decisions  often  taken  in 
years ahead of time. The most commonly tackled long term planning problem is that 
of capacity planning and product portfolio management (although the focus here is 
on the former),  and is typically concerned with the best use of limited resources in 
the  strategic  decision-making  related  to  new  product  development,  the  associated 
investments decisions for new manufacturing capacity and the necessary planning of 
production runs.  This problem is of particular relevance in the pharmaceutical and 
biopharmaceutical  industries  where  new  products  represent  the  lifeblood  of  the 
industry. A recent review of the pharmaceutical supply chain problem which covers 
relevant capacity planning work in the pharmaceutical industry is presented by Shah
(2004). Shah (2005) later presents a review of process industry supply chains where 
more general work on capacity planning in the process industries is covered.
One  of the  earlier  works  presented  in  the  process  industry  literature  is  that  of 
Sahinidis  et al.  (1989)  where they presented  a multi-period model  for the optimal 
process selection from a network of competing processes, the determination of the 
timing and sizing of any necessary process  expansions  and the optimal production 
amounts.  Liu  and  Sahindis  (1996a)  presented  a  tighter  linear  programming  (LP) 
relaxation of the earlier model by Sahinidis  et al.  (1989)  and used a cutting plane 
approach  for  the  efficient  solution  of  a  problem  involving  a  large  network  of 
chemical  processes.  Jain  and  Grossmann  (1999)  presented  two  different  MILP 
formulations  for  the  resource  constrained  scheduling  of testing  for  new  product 
development.  Papageorgiou et al.  (2001) considered the capacity planning problem 
in the pharmaceutical industry where new manufacturing capacity could be allocated 
to existing or new sites. The focus of the work was that of modelling financial flows 
and taxation issues pertinent to  global  trading.  Most recently  Sundaramoorthy and 
Karimi (2004) presented a multi-period, continuous-time, MILP model that addresses 
the  campaign  planning  problem  in  pharmaceutical  production  and  considered 
strategic  decisions  surrounding the potential  outsourcing  of production  tasks,  they 
illustrated  the  effects  of new product  introductions  on plant  production  plans,  the
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benefits  of outsourcing,  and  sudden  plant/demand  changes  through  a  number  of 
illustrative examples.
Given  the  considerable  uncertainty  associated  with  long  term  decisions  many 
relevant capacity planning works in the literature allow for the impact of uncertainty 
in making strategic decisions. Hence the remaining works on long term planning will 
be  covered  in  the  following  section  where  relevant  work  considering  the 
representation and solution of problems involving uncertain parameters  and related 
issues will be reviewed.
2.3.  Production Planning under Uncertainty
The  applications  discussed  thus  far  clearly  illustrate  the  utility  of  optimisation 
models  in  improving  productivity  and  profitability  in  manufacturing  operations. 
However,  the  presence  of  various  uncertainties  in  the  process  industries  (e.g. 
uncertainty in production rates  and costs,  demand, raw material  availability,  prices 
etc.) complicates the optimisation process.  This is particularly true of planning and 
scheduling problems  where plans  or  schedules  that do  not  account  for uncertainty 
may be rendered unsatisfactory in quality or even infeasible. Hence, in cases where 
uncertainty  is  found  to  have  a  considerable  impact  on  performance,  planning 
approaches should incorporate the relevant uncertainties in their proposed modelling 
assumptions.  In the next sub-section relevant works in the bioprocess literature are 
highlighted, and in the following sections the application of general approaches  for 
optimisation under uncertainty to production planning in the process  industries  are 
reviewed and discussed.
2.3.1.  Uncertainty in the Biopharmaceutical Manufacture
The planning  and  scheduling of biopharmaceutical  manufacture  is  complicated  by 
inherent  technical  uncertainties  that  can  impact  costs  and  delivery.  These  include 
fluctuations  in  fermentation  titres,  purification  yields,  campaign  lengths,  product 
demands  and  contamination  rates  (Farid  et al.,  2005).  Many  of these  fluctuations 
directly impact the  core  decisions  taken  in planning and  scheduling.  For example,
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variable fermentation titres (grams of product per litre of broth) directly determine 
the  number  of batches  required  to  satisfy  product  demands  and  hence  impact  on 
customer demand satisfaction and profitability.
Recently, discrete event simulation techniques have gained popularity for modelling 
the  logistics  of  operations  and  studying  the  impact  of bioprocess  uncertainties. 
Recent  work  includes  simulation  studies  which  look  at  the  impact  of  various 
uncertain  parameters  on  both  operational  and  financial  outputs.  Most  recently, 
Brastow  and  Rice  (2003)  used  simulation  modelling  to  help  answer  a  variety  of 
strategic questions associated with the drug development lifecycle, they considered a 
number  of different  case  studies  based  around  analysing  different  manufacturing 
capacity  strategies  and  quantifying  the  impact  of  uncertainty  via  Monte-Carlo 
simulation. Farid et al. (2005) used Monte-Carlo simulation to consider the impact of 
uncertainty  in  product  titres,  demands  and  market  penetration  on  different 
manufacturing  strategies  for the  production  of biopharmaceutical  drug  candidates. 
Lim et al.  (2005) used a similar technique to consider the impact of uncertainty in 
product  titres,  downstream  processing  yield  and  contamination  rates  on  different 
pooling  strategies  for perfusion  culture  type  processes,  while  Biwer  et  al.  (2005) 
investigated the impact of uncertainty in various technical, supply chain and market 
related parameters on penicillin V production. The work of Rajapakse et al.  (2005) 
employed Monte-Carlo  simulation to study the impact of key technical  and market 
uncertainties  on the biopharmaceutical  drug portfolio  problem  and highlighted  the 
benefits  of incorporating  uncertainties  when  ranking  different  manufacturing  and 
capacity planning strategies. The aforementioned works share the focus of improving 
decision  making  given  the  key  sources  of  uncertainty  within  the  commercial 
biomanufacturing  environment  and  demonstrate  that  the  modelling  of  key 
uncertainties can aid risk mitigation and result in more effective use of resources and 
improved overall economic performance.
2.3.2.  Optimisation under Uncertainty
For  simplicity  in  modelling  large-scale  optimisation  problems,  variability  can  in 
some cases be ignored and modellers can assume that the parameters of the problem 
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margin of error.  This  is  done because it results  in a model  that is  easier to  solve. 
However, in most cases these parameters have an underlying probability distribution 
and should be modelled as random variables.  This clearly complicates the problem 
but, on the other hand, makes the results obtained more realistic. There are a number 
of different ways of incorporating this randomness into the overall model.
Traditionally,  the treatment of uncertainty is realised through the use of stochastic 
optimisation approaches.  These approaches recognise the presence of multiple data 
instances that might be potentially realised  in the  future.  The  optimisation models 
then  attempt  to  generate  a  decision  that  maximises  (or  minimises)  an  expected 
performance measure,  where the  expectation is taken over an  assumed  probability 
distribution.  In many cases, when multiple uncertain factors exist in the input data, 
assumptions of distributional independence among factors are made.  After possible 
scenarios  (data  instances)  or  probability  distributions  are  fed  into  a  model,  a 
stochastically  optimal  solution  is  generated.  Sahinidis  (2004)  presented  a  recent 
review of the literature on optimisation under uncertainty. The topics covered include 
two-stage  programming,  probabilistic  (chance)  programming,  fuzzy  programming 
and  dynamic  programming.  Biegler  and  Grossmann  (2004)  presented  a  general 
review  of past  optimisation  work  where  the  key  advances  in  optimisation  under 
uncertainty were covered.
Most optimisation under uncertainty problems are typically represented via two-stage 
or multistage (more than two stages) stochastic programming formulations (We refer 
the  reader  to  Kail  and  Wallace  (1994)  and  Birge  and  Louveaux  (1997)  as  basic 
references for the theory and application of two-stage stochastic programs).  In two- 
stage programming strategic decisions are made in a first stage (here and now) while 
operational  decisions  are  made  in  a  second  stage  (wait  and  see)  through  the 
introduction of future “scenarios” for different realisations of uncertain events.  The 
characteristic challenge of such problems is the inevitable explosion in the number of 
scenarios  with  increasing  products  and/or  outcomes.  Hence,  multi-stage 
programming problems  typically require  solution  via  efficient  solution  procedures 
such as  scenario  aggregation (whereby certain scenarios  are  strategically identified 
and aggregated) and problem decomposition procedures (for example the breakdown 
of the overall problem into smaller sub-problems where decisions are fixed, and then
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later solving a larger problem with binary variables fixed) which exploit the specific 
problem’s  structure  (Kali  and Wallace,  1994).  The resulting  explosion  in problem 
size often leads to large-scale combinatorial optimisation problems which can be also 
be solved though the use of heuristic algorithms which have been discussed above in 
Section 3.2.1.  Reeves (1995) presents a number of modem heuristic techniques for 
large-scale  combinatorial  problems  (simulated  annealing,  Tabu  search,  Genetic 
algorithms,  Lagrangean  relaxation  and  decomposition),  while  Wolsey  (1998) 
discusses  several  heuristic  algorithms  for  the  solution  of  integer  programming 
problems (dive-and-fix, relax-and-fix, cut-and-fix).
There  have  been  many  applications  of  two-stage  and  multistage-programming 
techniques to planning in the process industries in recent years.  Such work includes 
that of Ierapetritou and Pistikopoulos (1994a) who present two-stage programming 
models  for  short  term  production planning  and,  long range planning  and  capacity 
expansion. They present a decomposition-based solution approach for the problems 
solution which was later extended by Ahmed et al.  (2000) by introducing remedial 
measures  for  the  avoidance  of  local  minima.  Ierapetritou  et  al.  (1994b)  also 
investigated the effect of uncertainty on future plant operation and expansion using 
two-stage  stochastic  programming  formulations,  they  also  investigated  the 
behavioural  issues  surrounding  the  here-and-now  and  the  wait-and-see  models 
through  the  concept  of  the  value-of-perfect-information  (VPI).  This  value  is 
described as the difference between the two alternative behavioural models of actions 
under  uncertainty.  Liu  and  Sahinidis  (1996b)  presented  a  two-stage  stochastic 
programming  approach  for  process  planning  under  uncertainty  and  devised  a 
decomposition algorithm incorporating Monte-Carlo sampling for the solution of the 
stochastic  model.  They  also  proposed  a  method  for  the  comparison  of two-stage 
programming and fuzzy programming approaches, which was found to favour two- 
stage  programming.  Clay  and  Grossmann  (1997)  developed  a  methodology  that 
considered  stochastic  linear  programming  models  for  production  planning  where 
coefficient  costs  and  uncertainties  were  represented  by  finite  discrete  probability 
distribution  functions.  They proposed  a sensitivity-based  successive disaggregation 
algorithm  for  the  problem’s  solution  was  based  on  applying  mean-value 
approximations over partitions of the problem space, and was found to outperform a
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number of Bender’s decomposition variants. Rotstein et al.  (1999) presented a two- 
stage stochastic programming model  for the capacity planning, investment strategy 
and  product  selection  decisions  in  the  pharmaceutical  industry.  They  proposed  a 
hierarchical  scenario  tree  aggregation  procedure  for  the  solution  of the  resulting 
multiscenario problem and illustrated its applicability through a case study from the 
pharmaceutical industry.
Other more recent works addressing these problems include the work of Gupta and 
Maranas (2000) who formulated a two-stage stochastic model composed of a here- 
and-now  production  model  and  a  wait-and-see  inventory  and  distribution  model 
based  on  the  deterministic  production  planning  model  of McDonald  and  Karimi 
(1997). Maravelias and Grossmann (2001) presented a multi-period MILP model for 
the  simultaneous  resource  constrained  scheduling  and  planning  of  batch 
manufacturing facilities. They also developed a heuristic algorithm for the problem’s 
solution based on Lagrangean decomposition which provided near optimal solutions. 
Balasubramanian  and  Grossmann  (2002)  proposed  an  aggregation/disaggregation 
branch and bound algorithm. The problem was solved in time stages, disaggregating 
a given stage at each stage, while aggregating the remaining stages and replacing the 
remaining  scenarios  with  the mean  values  of the uncertain  parameters.  Gupta  and 
Maranas  (2003) tackled the supply chain under demand uncertainty problem.  They 
extended their previous work (Gupta and Maranas, 2000) to incorporate some of the 
key  features  of the  supply  chain  decision-making  process  under  uncertainty  and 
demonstrated the model’s applicability through a planning case study.  Gatica et al. 
(2003a)  presented  a  multi-stage  programming  formulation  for  capacity  planning 
under uncertainty in the pharmaceutical industry. The authors later developed (Gatica 
et  al.,  2003b)  a  scenario  aggregation-disaggregation  approach  for  the  problem’s 
solution,  whereby  scenarios  were  grouped  into  predetermined  clusters  based  on 
mapping  between  products  and  clinical  trials  outcomes.  Balasubramanian  and 
Grossmann (2004)  compared deterministic,  two-stage and multi-stage  formulations 
with a shrinking horizon multistage programming approximation algorithm for batch 
scheduling based on STN type formulations. The algorithm solved a number of two- 
stage  problems  fixing  the  schedule  as  it  moved  along  the  time  horizon.  Oh  and 
Karimi  (2004)  presented  an  MILP  model  for  deterministic  capacity-expansion
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planning and material sourcing in chemical supply chains, which was also extended 
to  incorporate  regulatory  features  (corporate  tax  and  import  duty)  and,  uncertain 
demands and import duties using a simply scenario-planning approach. The focus of 
the  work  was  on  the  modelling  of  the  regulatory  features  and  rather  than  the 
uncertain parameters. Finally, Levis and Papageorgiou (2004) proposed a two-stage 
programming  formulation  for  pharmaceutical  capacity  planning  and  developed  a 
hierarchical  algorithm  in  which  the  first  step  used  an  aggregated  version  of the 
model, with a reduced variable space. This problem was solved initially where first 
stage  (strategic)  decision  variables  were  calculated.  In  the  second  step,  a  detailed 
model was solved subject to the decision variables estimated in the previous step.
Given  the  considerable  efforts  involved  in  finding  efficient  solutions  to  multi­
scenario type representations alternative approaches to problem formulation without 
forgoing solution quality would be ideal.  Hence many practitioners have developed 
alternative  approaches  to  optimisation  under  uncertainty  and  applied  them  to 
problems involving planning under uncertainty. Some of these approaches have been 
considered  for planning  in the process  industries  and  include  Chance  Constrained 
programming, Fuzzy programming, Dynamic programming and Real-Options-based 
valuation.
The  Chance  constrained programming  (CCP)  approach  was  first  presented  by 
Chames  and  Cooper  (1959)  for  representing  uncertain  model  parameters.  The 
approach aims to satisfy constraints with a specified probability or confidence level 
and by leveraging concepts from probability theory provide the optimal  solution at 
that confidence level. Relevant works incorporating chance constraints in the area of 
planning  include  that  of Petkov  and  Maranas  (1997)  who  proposed  a  stochastic 
extension to the multiperiod planning and scheduling model proposed by Grossmann 
and Birewar (1990).  Faced with uncertain single or multiple product demands with 
prespecified  probability  levels  (chance  constraints),  they  proposed  deterministic 
equivalents to the stochastic elements and investigated different modelling features 
and  their  effect  on  computational  performance.  Gupta  et  al.  (2000)  developed  a 
combined  CCP  and  two-stage  stochastic  programming  methodology  which  was 
utilised  for  capturing  the  trade-off  between  customer  demand  satisfaction  and 
production  costs.  More  recently,  Wan  et al.  (2005)  developed  a  simulation based
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optimisation  framework  applied  to  supply  chain  management  and  accommodated 
chance constraints in order to ensure  service levels were met.  The aforementioned 
works share in common the employment of chance constraints for the specification 
that  an  objective  or  constraint  must  be  met  with  a  certain  probability.  The 
characteristic challenge associated with the majority of CCP  approaches within the 
process industry literature, including those mentioned above, involves the derivation 
of  the  appropriate  deterministic  equivalents  of  the  chance  constraints  and  the 
efficient solution of the resulting optimisation problem.
Fuzzy programming (Zimmermann,  1978) is a mathematical programming approach 
based  on  the  fuzzy  set  theory  of Zadeh  (1965),  where  uncertain  parameters  in  a 
mathematical model are considered fuzzy numbers defined on a fuzzy set associated 
with a membership function. The objective function may be a fuzzy goal or a crisp 
function  and  similarly  to  the  CCP  approach  the  constraints  may  allow  some 
violations. Models aim to take into account a) the decision maker's expectations of a 
target range of the objective value and b) soft constraints based on decision making 
in  a  fuzzy  environment  (Bellman  and  Zadeh,  1970).  Some  recent  applications  to 
planning  include  Liu  and  Sahinidis  (1997)  who  presented  a  fuzzy  programming 
model  for process  planning under uncertainty  and  proposed  a  global  optimisation 
algorithm for its solution. Balasubramanian and Grossmann (2003) proposed a fuzzy 
programming  formulation  using  interval  arithmetic  principles  and  applied  it  to 
flowshop scheduling and new product development problems. They also developed a 
Tabu search implementation for the solution of larger cases.
Decision-making  under  uncertainty  is  broadly  considered  to  have  two  major 
branches, stochastic programming techniques (which have thus far been covered) and 
stochastic  optimal  control  or  Markov  decision  processes  which  are  mathematical 
frameworks for modelling decision-making in situations where outcomes are partly 
random and partly under the control  of the decision maker.  More specifically they 
are processes  for the characterisation of sequential  decision problems  in which the 
decision-makers  choose  an  action  in  the  “state”  (of  a  system)  occupied  at  any 
decision  “epoch”  (fixed  point  in  time)  according  to  a  decision  rule  or  policy. 
Dynamic programming techniques  are  the  most  commonly used  approach  for the 
solution of these problems and are concerned with devising algorithms to compute an
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optimal  control  policy  to  a  given  Markov  decision  process.  Cheng  et  al.  (2004) 
presented a review and comparison of optimal  control  and  stochastic programming 
techniques.  The  authors  noted  that  stochastic  programming  is  more  suitable  for 
solving  long  term  strategic  planning  problems,  such  as  capacity  planning,  with  a 
relatively few number of periods and scenarios, while stochastic optimal control, on 
the other hand, works better for operational control problems such as production and 
inventory control.  An example of such work is  Cheng et al.  (2003) who posed the 
representation of multistage  stochastic problems  as  discrete  time  Markov  decision 
processes  with  recourse  and  suggested  their  possible  solution  using  a  dynamic 
programming strategy.  Discussing the previous work, Jung et al.  (2004) noted that 
while  such  a  strategy was  found to  be  conceptually very  attractive,  it  was  limited 
computationally  by  the  effects  of  “state”  dimensionality  and  the  presence  of 
constraints  which  involve  variables  from  different  stages,  as  is  the  case  with 
inventory balances in planning problems. The authors (Jung et al., 2004) proposed a 
simulation-based  optimisation  approach  for  supply  chain  management  under 
demands  uncertainty  in  which  they  combine  deterministic  mathematical 
programming planning and  scheduling formulations  with discrete  event  simulation 
and  employ  Monte-Carlo  simulation  to  account  for  various  uncertainties.  The 
approach  demonstrated  much  promise  for  applying  combined 
simulation/mathematical-programming  approaches  for  the  treatment  of  planning 
problems by leveraging the strengths of both approaches.
Real-option-based valuation (ROV) frameworks for hedging under uncertainty have 
also  been  applied  to  planning  in  the  process  industries.  This  concept  is  based  on 
arbitrage free pricing (financial option pricing theory) and risk-neutral valuation (risk 
free-rate  of return),  and  presents  an  alternative  to  traditional  NPV  analysis.  ROV 
replaces  the  rate  of return  with  a risk-free rate  of return,  and  the  true  probability 
distribution  (of the  uncertain  parameter)  with  a  risk-neutral  probability.  A  recent 
application  is  that  of  Gupta  and  Maranas  (2004)  where  they  proposed  a  Real- 
Options-based  framework  for  strategic  decision  making  under  uncertainty  and 
presented a number of illustrative examples including an application to supply chain 
planning under  demand  uncertainty.  A  comparison  with  traditional  NPV  analysis
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showed that considerable monetary savings  can be achieved though the application 
of ROV frameworks.
2.4. Concluding Remarks
In  Section  2.1,  the  works  relating  to  planning  and  scheduling  in  the 
biopharmaceutical  industry  were  presented.  Few  applications  of  planning  and 
scheduling  of  bioprocessing  have  been  considered  in  the  literature.  Of  those 
applications most were found to focus on the short term scheduling of bioprocesses, 
and with a few  exceptions were limited to  commercial  simulation tools directed at 
the biopharmaceutical  industry.  While  such  simulation  approaches  have  had  some 
success  in  aiding  decision-making  in  the  biopharmaceutical  industry  they  are 
reported to fall short when it comes to production planning, where the combinatorial 
problem of the optimal sequencing and timing of campaigns is required along with 
the  optimisation  of related production  variables  such  as  inventory  and  changeover 
costs.  There was  found  to  be  a distinct  lack  of mathematical  programming works 
published on planning and scheduling in the biopharmaceutical industry, particularly 
on production planning.
In Section 2.2, the problem of production planning in the process industries which 
shares many similar features to that of the biopharmaceutical industry was reviewed, 
while  in  Section  2.2.1,  short  and  medium  term  planning  works  in  the  process 
industries  were  presented.  A  vast  number  of works  on  production  planning  and 
aggregate planning works have been presented in the past, many of which have been 
applied within the closely related pharmaceutical industry which shares many of the 
features of the biopharmaceutical production planning problem, however none have 
been  applied  specifically  to  the  biopharmaceutical  planning  or  encompass  all  the 
characteristic features of the problem.
Given  the  shortcomings  of  simulation  tools  and  industrial  rule  based  methods 
reportedly used within the biopharmaceutical industry,  and the lack of any distinct 
models  within  the  process  industry literature  encompassing  all  the  features  of the 
biopharmaceutical  planning  problem,  Chapter  3  presents  a  mathematical
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programming  formulation  for  the  medium  term  planning  of  biopharmaceutical 
manufacture  incorporating  the  characteristic  features  of  the  production  planning 
problem in the biopharmaceutical industry.
In Section 2.3, the problem of production planning under uncertainty was introduced 
and relevant work in the area reviewed.  In the first part,  Section 2.3.1, some of the 
key issues and relevant works in the biopharmaceutical manufacturing industry were 
presented.  Most  of the  work presented  was  aimed  at  demonstrating  the  impact  of 
uncertainty  on  biopharmaceutical  manufacture  and  evaluating  the  performance  of 
different operating strategies under uncertainty. However there did not appear to be 
any  work  in  the  bioprocess  literature  which  could  determine  optimal  operating 
strategies  under  uncertainty,  this  paucity  was  also  true  for  both  planning  and 
scheduling under uncertainty.
In Section 2.3, approaches for tackling optimisation under uncertainty were reviewed 
and relevant applications to planning under uncertainty within the process  industry 
literature  presented.  The  majority  of works  for  planning  under  uncertainty  were 
based on stochastic programming techniques most notably two-stage programming, 
which  when  applied  to  practical  sized  problems  gives  rise  to  large-scale 
combinatorial  optimisation  problems.  Many  efficient  solution  approaches  for  the 
solutions  of these problems,  some  of which were  general  while  others  were more 
problem specific. The majority of stochastic programming approaches were aimed at 
tackling demand uncertainty in the medium term or investment and capacity related 
decisions  in  the  longer  term.  However,  there  did  not  appear  to  be  any  relevant 
models tackling the type of uncertainty faced in the biomanufacturing industry such 
as variable fermentation titres, adding to the lack of deterministic planning models 
aimed at tackling production planning in the biopharmaceutical industry.  Hence,  in 
Chapter  4,  a  two-stage  programming  approach  for  medium  term  planning  under 
uncertainty  is  presented  along  with  a  hierarchical  algorithm  for  the  problem’s 
efficient solution.
Alternative techniques for optimisation under uncertainty were also reviewed. Aimed 
at providing more  computationally  efficient  approaches  without  forgoing  solution 
quality,  a number of approaches including chance constrained programming,  fuzzy
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programming,  real-options-based  modeling  and  dynamic  programming  have  been 
applied to production planning under uncertainty in the process industries with much 
success. But again there is a distinct lack of relevant work for the biopharmaceutical 
industry.  Hence,  in  Chapter  5,  an  approach  based  on  the  concepts  of  chance 
constrained programming is presented as an alternative to traditional multi-scenario 
type stochastic programming techniques.
In  Section  2.1,  a number  of works based  on  discrete  event  simulation  techniques 
were presented as decision-making aids for the biopharmaceutical industry, however 
apart  from  the  work  of  Rajapakse  et  al  (2005),  which  focuses  on  the  product 
portfolio  problem,  there  appears  to  be  a paucity  of work  which  aid  the  decisions 
related  to  the  long  term  strategic  problem  of  capacity  planning.  Mathematical 
programming  approaches  aimed  at tackling long term  strategic  planning  problems 
were discussed in Section 2.2.2 and Section 2.3.2. A number of these works tackled 
the problem  of long term  capacity planning  in  the pharmaceutical  industry.  Some 
focused on the product portfolio problem, while others focused on meeting the long 
term  demands  given  the  considerable  uncertainty  associated  with  the  long  term 
timescale.  Generally, most of the work focused on developing detailed models  and 
algorithms  for  the  representation  and  solution  of such  problems.  In  Chapter  6,  a 
mathematical  programming  approach  for  long  term  capacity  analysis  in  the 
biopharmaceutical industry is presented where the focus is the representation of some 
of  the  characteristic  features  of  the  long  term  production  planning  problem  in 
biopharmaceutical manufacturing along with a methodology for the quantification of 
different operating strategies (through multi-objective optimisation techniques) in the 
long term time-scale. In Chapter 7, a commercialisation plan is presented which may 
serve  as  a  good  starting  point  for  biomanufacturers  wishing  to  incorporate 
simulation-based optimisation approaches in their decision-making.
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Deterministic Medium Term Planning 
of Biopharmaceutical Manufacture
3.1. Introduction
The work presented in this chapter addresses the biopharmaceutical manufacturing 
challenge  of optimal  planning  of production  i.e.  the  determination  of the  optimal 
amounts to be produced  and the  optimal  sequence  of products  needed  in order to 
maximise cost-effectiveness of a multiproduct facility. The proposed model aims to 
tackle problems over a “medium term” time scale of 1-2  years.  In the formulation 
presented  a multiproduct biopharmaceutical  facility is  required  to  satisfy  a  set  of 
customer  demands  while  minimising  operating,  storage  and  changeover  costs.  A 
penalty is introduced for late delivery of product. The problem formulation presented 
in this work is based on the capacity planning model developed by Papageorgiou et 
al.  (2001)  which  embodies  various  features  of the  pharmaceutical  industry.  The 
production constraints are defined so as to provide a more accurate representation of 
production time since this will be a key need in medium term planning as opposed to 
the case of longer term planning where a more relaxed description may be adequate. 
The production constraints address the issue of the long lead times (duration of setup 
and cleaning at the start of a new campaign) introduced during campaign changeover
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which can have a great impact on the overall plant capacity utilisation. The campaign 
planning  problem  is  formulated  as  an  MILP  problem  whereby  a  discrete  time 
representation is used and production is represented as a rate.
While a large proportion of production planning problems in the biopharmaceutical 
industry are adequately represented by assuming negligible intermediate storage post 
harvest and prior to purification, in many cases industrial practice allows for flexible 
intermediate storage.  Examples include perfusion processes where one fermentation 
batch is harvested in  a “feed  and bleed” mode  continuously feeding the  fermenter 
with nutrients and harvesting for pending downstream purification.  Cases also exist 
where  fermentation  throughputs  differ  to  those  of the  corresponding  downstream 
purification. This can arise when contract manufacturers are required to fit processes 
to  existing equipment with  fixed  sizes.  Here the harvest may be  divided into  sub­
batches  which  are processed  downstream  when  equipment  becomes  available.  To 
allow for such intermediate storage and differing throughputs between harvest and 
purification a similar dual production constraint representation to that of the capacity 
planning model of Gatica et al. (2003) was implemented.
To  demonstrate  the  approach  developed  in  this  chapter  two  examples  based  on 
industrial  data were  solved.  The first  example is that of a multiproduct production 
planning  problem  involving  a  typical  number  of  mammalian  cell  products 
manufactured  over  a  1   year  production  time  horizon.  The  second  example  again 
involves  mammalian  cell  products  but  this  time  with  suite-specific  manufacturing 
considerations and differing production throughputs, the products  are manufactured 
over 1.5 year time horizon. The results from both examples are compared with those 
obtained using an industrial rule-based approach.
3.2. Problem Features
The  problem  of biopharmaceutical  production  planning  is  characterised  by  some 
unique  features  of biomanufacturing.  These  features  and  their  role  in  production 
planning are discussed below:
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3.2.1.  Biomanufacturing and Plant Capacity
The problem of interest in this chapter is planning of primary manufacturing within 
multiproduct biopharmaceutical facilities. These facilities can have multiple suites or 
production  lines  and  are  usually  divided  further  into  rooms  separating  various 
sections of the manufacturing process  e.g.  upstream  fermentation  and  downstream 
purification.
Plant capacity utilisation is an important issue in the biopharmaceutical industry and 
optimal  planning  of  manufacture  offers  an  opportunity  to  improve  capacity 
utilisation  (Mallik  et al.,  2002).  It has  been  estimated  (Mallik  et al.,  2002)  that  a 
typical new mammalian cell-culture facility would increase annual revenues by $380 
million with a 25% increase in plant utilisation. Ransohoff (2004) estimates that the 
carrying  costs  (variable  costs  incurred  by  holding  inventories)  for  a  typical 
500kg/year monoclonal antibody (mAb) facility working at 50% under utilisation are 
$2-3 million/month, while 50% under capacity based on oncology mAb pricing can 
result  in  an  estimated  loss  of $40  -   50  million/month  in  operating  profit.  Hence 
optimising  plant  utilisation  is  crucial  for  both  cost-effective  manufacture  and  for 
maintaining  competitiveness  within  the  biopharmaceutical  industry.  It  is  likely  to 
become  even more  crucial  as  generics  enter  the  market  in  greater  numbers  (Coe, 
2001).
3.2.2.  Product Storage
Many biopharmaceutical industry products suffer from product instability (Li et al., 
1995) and hence must to be stored under specialised and costly storage conditions. 
Hence product shelf-life is  a major concern in biopharmaceutical manufacture  and 
can play an important role within production planning. Wilkins et al.  (2001) reports 
that  specialised  storage methods  such  as  cryopreservation  enable manufacturers  to 
de-couple  steps  in  production  processes  by  storing  and  transporting  intermediates 
and  products  under  defined,  stable  and  validatable  conditions,  hence  offering 
increased flexibility for scheduling and planning.  Storage of harvested intermediate 
products  can  have  an  impact  on  product  stability  and  result  in  shorter  product 
lifetimes, making optimal intermediate storage strategies paramount to the realisation
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of efficient capacity utilisation. Another important inventory issue is the very costly 
nature  of  manufacturing  biopharmaceuticals.  The  high  value  of  these  products 
imposes a limit on the size of any product inventory held as this may constitute tying 
up working capital which is required elsewhere.
3.2.3.  Regulations and Campaign Changeover
Validation within the highly regulated biopharmaceutical manufacturing industry is 
an  expensive  and  time  consuming  process.  Manufacturers  are  regulated  to 
demonstrate  the  ability  to  reproduce  consistently  a  process  which  meets 
predetermined  specifications  and quality attributes  at various  critical  stages  of the 
manufacturing process with a lot-to-lot consistency being realised (Lim et a l, 2004). 
These  stringent  regulations  lead  to  rigorous  cleaning  and  sterilisation  between 
individual  product  batches  as  well  as  between  new  campaign  start-ups. 
Contamination can lead to the introduction of long delays and unwelcome cost to the 
manufacturing process  as  a result  of lost product  due to  batch  failures.  Long lead 
times typical in biopharmaceutical manufacture due to upstream process bottlenecks 
and  the  required  validation processes  are  major  motivations  for  manufacturing  in 
long campaigns  and  avoiding  frequent  campaign  changeovers.  While  on  the  other 
hand  inventory  cost,  limited  product  lifetimes  and  multiple  orders  of  a  product 
constitute the necessity for campaign changeover.  This presents a genuine decision 
making challenge for biomanufacturers.
3.2.4.  Product Demand
Meeting demand dates in the biopharmaceutical industry is a highly sensitive issue 
due  to  the  high  value  of the products  involved.  Mallik  et  al.  (2002)  estimate  for 
example,  that the  lack of manufacturing capacity for Immunex’s highly successful 
arthritis  drug  Enbrel  cost  the  company more  than  $200  million  in  lost  revenue  in 
2001. Companies must therefore strive to capture every day of revenue generation by 
ensuring  an  adequate  supply  of  product.  Customer  demands  within  the 
biopharmaceutical  manufacturing  industry  are  typically the  result  of a  negotiation 
whereby order quantity,  delivery date  and any variability on this  is regulated by a
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contract. Customers and manufacturers will agree on this taking into account existing 
capacity and goodwill. Penalties and manufacturer liability are usually agreed for late 
deliveries.
3.3.  Problem Statement
A  formal  statement  for  the  problem  of campaign  planning  of biopharmaceutical 
facilities can be stated as follows.
Given:
•  A set of products.
•  A set of fermentation and purification suites.
•  Production  rates,  lead  times  and  production  throughputs  (correspondence 
factors).
•  Product lifetimes, storage costs and storage capacities.
•  Product demands, sales prices, and late delivery costs.
•  Manufacturing and campaign changeover costs.
•  Minimum and maximum campaign durations.
Determine:
•  Campaign durations and sequence of campaigns.
•  Production quantities along with inventory profiles.
•  Product sales and late deliveries profile.
Objective:
•  Maximise manufacturing profits.
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3.4. Mathematical Formulation
A mathematical  formulation  composed  of an  objective  function  and  constraints  is 
derived in order to represent and  solve the biopharmaceutical  production planning 
problem.  The  mathematical  formulation  along  with  the  modelling  assumptions  is 
explained in this section. One of the main assumptions employed in the development 
of the production constraints was the introduction of a continuous rate of production 
to  represent  the  batch  manufacture  of biopharmaceuticals.  In  this  each  batch  is 
treated as a “black box”  as this  captures the necessary level  detail required by the 
problem’s  time  scale  (1-2  years).  Figure  3.1  along  with  the  following  section 
explains the concept behind this.
The repeating period from tl to t5 shown in Figure 3.1  as EB is the effective batch 
time. A continuous production rate rp (batches per unit time) can be used to describe 
this repeating sequence of batches:
B = rpT  (1)
where B is the amount produced and T is the total campaign duration.
Despite the fact equation (1)  ignores the duration of the  first batch,  it can prove a 
valuable approximation in cases of planning over long timescales where there are a 
large number of batches and lead times (in this case the time it takes to generate the 
first batch of a campaign) are not particularly long. However in the case where there 
are not a sufficiently large number of batches being produced and a higher degree of 
accuracy is needed, the above rate approximation may not be acceptable as the lead 
time will skew the rate and may result in poor quality or infeasible plans.
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Figure 3.1: The black box approximation using an example Gantt chart of a process 
producing n = 5 batches of  a given product p, where a is the duration of the first batch and
EB is the effective batch time.
An extension to this rate constraint is proposed for more accurate representation of 
lead time a which is equal to the duration of the first batch of a campaign plus any 
start up time required for setup/cleaning.
The time taken for the production of n batches is described by constraint (2):
T = a + (EB*{n-\))  (2)
where T is the total campaign duration, n is the total number of batches and EB is the 
effective batch time, the repeating period within the campaign.
The representation shown above is extended to allow for cases where there is a need 
for intermediate storage. The black box rate approximation shown in Figure 3.1  has 
been  modified  to  incorporate  the  feature  of  intermediate  storage  post  upstream 
fermentation  and  pre-downstream  processing  (purification).  The  concept  of  this 
modification  is  shown  in  Figure  3.2.  The  proposed  biopharmaceutical  production
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planning  formulation follows below.  Figure  3.3  shows  example  configurations  for 
the upstream production.
Downstream
Changeover
Figure 3.2: The extension of the black-box model allowing  for intermediate storage.
Time Line
Bioreactor
Purification suite
Storage
Figure 3.3: Two possible scenarios where pooling is used to accommodate the different 
throughputs of the upstream and downstream manufacturing capacities running either one
(a) or two (b) bioreactor suites.
All  products  p  undergo  downstream  manufacturing  in  a  suite  i  and  upstream 
manufacturing in a suite j  over a time period t.
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3.4.1.  Production Constraints
As biopharmaceutical production takes place in individual manufacturing suites, it is 
separated  into  upstream  and  downstream by two  rate  equations  as  in  the  work  of 
Gatica et al.  (2003). Constraints (3) and (4) represent the production constraints for 
crwcfe/intermediate  product,  and  final  product.  Upstream  production,  CPipt,  and 
downstream  production,  FPjpt,  are  represented  by  continuous  production  rates  for 
crude/upstream,  CRP,  and  final/downstream  production,  FRP   which  are  combined 
with their respective upstream and downstream lead times, ap. This allows for set-up 
and cleaning time before the first batch of crude product is made. pp allows for the 
time it takes for the necessary amount of crude product to be produced in order to 
produce one batch of final product, and to hence calculate the appropriate production 
times. Upstream production time, CTipt, and downstream production time, FTjph show 
the duration of manufacture of each product p within each team period t. If a product 
p is selected for manufacture at a given suite i or j at time t a lead time, ap, and/or f3p 
will only be included to that campaign duration to account for the setup and cleaning 
if binary  variables  Zipt  and/or  W jpt  are  equal  to  1   (denoting  the  start  of  a  new 
upstream/downstream campaign).
Binary variables  Yipt, and Ujpt are introduced to denote whether or not a product p is 
manufactured in suite i or j  at time /. In order to enforce the relevant production lead 
times constraint (5) is introduced.  It enforces that Zipt in constraint (3) will only be 
activated if product p is not manufactured upstream in the previous time period M,
i.e. it is the start of a new campaign upstream. While constraint (6) enforces that W jpt 
in constraint (4) will only be activated if product p is not manufactured downstream 
in the previous time period M, i.e. it is the start of a new campaign downstream.
CFipt  —  %ipt + CRp (CTipt  a pZipt) Vi,p,t (3)
FPjPt  = WJPt  + F R P (FTjPt  ~ P pW jpt) (4)
(5)
^  jpt  -  F'   jpt  F jpJ~l Vj,p,t (6)
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In order to represent the lack of a lead time when existing crude product is held in 
storage, constraint (7) enforces that if any crude product p is held in storage prior to 
downstream  production/purification  then  the  inclusion  of  a  lead  time  /3P   to  the 
downstream production time will not happen. Hence the only instance in which  W Jpt 
is equal to 1  is when both Zipt and Xjpt are equal to 1.
IX'
w ip<  -   + Xjpl ~ 1   *j,p,t  (7)
In order for the production constraints to capture the required campaign changeover 
considerations, constraints (8) and (9) ensure that at most one product p undergoes 
manufacturing in any given suite i or j at any given time period t. This is necessary 
for the  effective  operation  of the  new  campaign  selection/changeover variables  in 
constraints (1-5).
YZ‘ P ‘-X   VM  (8)
p
Y/,<  (9)
3.4.2.  Timing Constraints
In some cases, manufacturers enforce minimum and/or maximum campaign lengths 
in  order  to  maximise  efficiency  or  to  allow  for  relevant  maintenance/slack. 
Constraints  (10-13)  represent  the  appropriate  minimum  and  maximum  production 
time constraints for both fermentation suites i and purification suitesy, where CTpmin, 
FTpm in,  are  the  minimum  upstream  and  downstream  campaign  durations,  CTpmax, 
FTpmax, are the maximum upstream and downstream campaign durations and Ht is the 
size of the time horizon. These constraints are only active if their respective binary 
variables Yipt and Ujpt are equal to 1, otherwise the production times are forced to 0.
C T fmYipt<CTipt  Vi.p,t  (10)
- 51-Chapter 3. Deterministic Medium Term Planning of  Biopharmaceutical Manufacture
(11)
FT’ T 'U   < FT, (12)
V j,P f (13)
3.4.3.  Storage Constraints
The  following  constraints  enforce  an  inventory  balance  for  upstream  and 
downstream  production  and  forcing total  downstream  production  to  meet  product 
demand.  In constraint (14) the amount of crude product p stored at the  end of the 
time period CIpt, is equal to the amount at the previous time period CIpt.i, plus the net 
amount  produced  during  the  time  period  CPipt,  less  the  amount  processed 
downstream FPjph and the amount wasted due to the expired product shelflife CWpt. 
In constraint (15) the amount of final product p stored at the end of time period FIpt, 
is  equal  to  the  amount  at  the  previous  time  period  FIpt.i,  plus  the  net  amount 
produced  during  the  time  period  FPJpu  less  the  amount  sold  Sph  and  the  amount 
wasted due to the expired product shelflife FWpt.
The  Ap  symbol  represents  a  production  correspondence  factor  which  allows  the 
specification of the respective throughputs of the crude (upstream fermentation) and 
final  (downstream  purification)  production.  Ap  may  be  an  integer  or  a  fraction 
depending  on  which  production  (upstream  or  downstream)  throughput  is  greater. 
Factors greater than  1   denote a relatively greater upstream throughput, while factors 
less  than  1   denote  a  relatively  smaller  upstream  throughput  e.g.  a  factor  of 0.5 
signifies that for every two upstream batches one downstream batch is produced.
CIpt = CIpM + Y JCpiP> Xp ) f j PiPt ~ CWP >   Vp,t  (14)
j
F Ip ,  =  p I P,t-\  + Y J F P JP‘  ~ S P‘  ~ F W p < \fp,t (15)
j
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The  amount  of upstream  and  downstream  product  stored  over period  t  cannot be 
negative and should not exceed the respective maximum available product storage 
capacities, Cp and Fp.
0 <CIp t<Cp  \/p,t  (16)
0 <FIp t<Fp  \/p,t  (17)
Both upstream and downstream product and final product are constrained by limited 
product lifetimes, the total amount of stored crude and final product p cannot be used 
after the next fp or pp time periods respectively.
d p t ~  T ^ p e   Vp,r  (18)
j   0=t+1
FIp, ^  Y j SP°  VP’<   (19)
e=t+ 1
Constraint  (18)  ensures  the  lifetime  of the  crude  product  by  enforcing  that  it  is 
processed downstream in less than C p time periods from when it is stored upstream, 
while constraint (19) ensures that final product is  sold in less pp time periods from 
when it is stored downstream.
3.4.4.  Backlog Constraints
Late deliveries  are undesirable,  and hence  a penalty Apt is  incurred  for every time 
period t that a given batch of product p is late meeting a product demand Dpt. This 
penalty is minimised in the objective function.
Apt =Apt_i + Dpt - S pt  V/?,£  (20)
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The strategic  obrichve in  this  I  c emulation  w  v~  nuvcimtse operating profit.  This  is 
represented  by  an  objective  toiedion  which,  is  considered  to  be  the  difference 
between “total  sales” with each batch sold a? a  price ;.y,  and “total  operating costs” 
which include batch rn&nnfaebiring costs of r;P  per batch,  changeover i/^, per batch, 
storage ry.per bemh and  catch, late delivery penalties Ap per batch, and waste
dispose.1  colts rpper cakb. Ah costs arc .,n AAati /e monetary units (imu)”.
[MoAT MP]
Maximize
prof •   F T . •   v  A  ■••'-y-f-  ->,w. -'^cW pt
P  !
y p p Fpjp.-+ « 'A * » »   121)
Subject to: constraints (1 - SO).
The  complete  formulation  h4P  encompassing  equations  (1  -  21.)  corresponds  to  a 
mixed-miegcr Unear programming (MTLF) model.
3.5.  Illustrative Examples
In  this  section  two  typical  hiophatriacemk-d  production  planning  problems  are 
solved using the mathematical formulation presented in Section. 3.3.
The data  used  was  based  on  real  industrial  information which  includes  lead  times 
(days),  production  rates  (batches/day'  and  product  demands  (hatches  of product). 
These were extracted from industrial case studies (BioPharm Sendees Ltd, London, 
U.K.; Farid, 2001). Commercial data such as sales prices, manufacturing and penalty 
costs were selected based on discussions with industrialists and are consistent with a 
recent review of the bmmcnu momring industry by Ginsberg ei al. (2002).
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Both  example  problems  were  implemented  in  GAMS  (1998)  using  the 
CPLEX/MILP solver with a 5% margin of optimality and were all performed on an 
IBM RS/6000 workstation.
3.5.1.  Example 1: General multiproduct multisuite 
manufacture.
This  first  example  encompasses  the  general  features  of  the  biopharmaceutical 
medium term planning problem and by comparison to industrial rule-based planning 
demonstrates  the  value  of  the  proposed  mathematical  formulation.  Example  l ’s 
problem definition and associated data are given below:
•  A multiproduct facility with two fermentation suites and two purification suites. 
All production suites do not have a product specific manufacturing functionality. 
Figure 3.4 illustrates the product manufacturing routes for three products PI, P2 
and P3.
•  Three “mammalian cell” products are assumed (P1-P3), with one or two product 
orders each.
•  A one year production horizon, with six time periods t each two months long, i.e. 
the production time horizon Ht, is 60 days long.
•  The  due  date  and  demands  profile  is  shown below  in  Table  3.1.  Orders  were 
assumed to be due at the end of each two month time period t.  Early delivery is 
infeasible and late deliveries are penalised for each late period.
•  Production  rates,  lead  times  and  related  parameters  used  in  this  example  are 
shown in Table 3.2.
•  Lead times ap and pp are in “days” and are assumed to be inclusive of seven days 
of product changeover related cleaning time.
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Table 3.1: Demand profile for Example 1, showing each product demand and the time
period it is due*.
Product Time Periods
1 2 3 4 5 6
PI 6 6
P2 6
P3 8 8
♦Note:  All demands are in number of batches
Table 3.2: All relevant parameters used in Example 1.
Product Parameter data for Upstream production i Parameter data for product p
Production Lead Product Storage Minimum Storage Sales Manufacturing Waste
rate time lifetime, Capacity campaign cost price cost Disposal
CRP a  p C p c p length Pp t)P nP cost
(batches/ (days) (time (batch/ CTm m  p (rmu/ (rmu/ (rmu/ tp
day) periods) time riod) (days) batch) batch) batch) (rmu/
batch)
PI 0.05 30 1 10 20 5 20 2 5
P2 0.045 32 1 10 21 5 20 2 5
P3 0.08 22.5 1 10 12.5 5 20 2 5
Product Parameter data for Downstream production j Parameter data for product p
Production Lead Product Storage Minimum Storage Lateness Changeover Production
rate, time, lifetime Capacity campaign cost penalty cost factor
FRP Pr o p Fp length w p 5 p Vp A , p
(batches/ (days) (time (batch/ FT^p (rmu/ (rmu/ (rmu/
day) periods) time (days) batch) batch) batch)
period)
PI 0.1 40 3 40 10 1 20 1 1
P2 0.1 42 3 40 10 1 20 1 1
P3 0.1 34.5 3 40 10 1 20 1 1
Note that the sales prices  and  associated  costs of production are identical  for each 
product. This is so not to bias the production of any particular product.
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Fermentation  suite  1 DSP suite  1
Fermentation  suite  2 DSP suite 2
Figure 3.4: The functionality of the multisuite biopharmaceutical facility in Example 1.
Our  proposed  mathematical  programming  (MP)  approach  was  compared  with  an 
industrial scheduling approach based on rules to demonstrate the effectiveness of the 
model.  Traditionally  much  of  the  planning  is  done  based  on  experience  or  on 
industrial  rules,  whereby typically products  will  be manufactured  in  singular  long 
campaigns on a first come first served basis (earliest demand first), unless there is an 
obvious reason not to do so. This heuristic is summarised into three rules, as shown 
below:
1.  Manufacture products in order of the product with the earliest demand first.
2.  Allow a campaign to be split if manufacturing a product violates product lifetime 
constraints.
3.  If a single campaign for a given product on a particular suite is unable to meet 
product demand on time, allow a campaign to be started on an alternative suite if 
available.
This industrial rule based (IRB) approach was used to develop a production schedule. 
A  comparison  of the  results  obtained  by  applying  MP  and  IRB  to  Example  1   is 
shown in Table 3.3.
An objective function value of 487 rmu is achieved for MP which corresponds to a 
72% profit margin, while IRB achieves an objective function value of only 430 rmu 
which corresponds to a 64 % profit margin. This was calculated as: the total profit as 
a  proportion  of  the  total  sales.  The  difference  in  objective  function  is  mainly
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attributed to the 4 late batch penalties and the extra storage cost incurred by IRB. The 
results in Table 3.3 clearly show MP outperforming IRB in terms of punctuality and 
therefore profitability. Capacity utilisation is comparable, with IRB having a slightly 
higher capacity utilisation for both upstream and downstream (though at the expense 
of late batches).
Comparative graphical representations of the results are shown below in Figures 3.5, 
3.6  and  3.7.  Note  that  in  Figure  3.5  each  box/instance  is  colour  coordinated  to 
represent  the  particular  product  selected  for  manufacture.  The  number  of batches 
produced is noted underneath each instance followed by the production time in days 
in brackets. The production suites are denoted i and j  for upstream and downstream 
respectively.
Table 3.3: Comparison between solutions from the industrial rule based (IRB) approach and 
the proposed mathematical programming (MP) approach for Example 1.
Approach Objective Upstream Capacity Downstream Capacity Cost incurred as a result
function (rmu) Utilisation Utilisation of late batches
(%) (%) (rmu)
IRB 430 85 67 80
MP* 487 89 71 20
* Note: This problem was solved in 16 seconds.
Production schedule for Example 1: (Generated using MP)  Production schedule for Example 1: (Generated using IRB)
Suite: i1 P3 |P3  | |P3 Suite: i1 P2 |P2 |P2
4(60) 4(50) 2(50) 3(60) 4(50) 2(50) 2(54) 2(44) 2(44) 2(50) 2(40) 2(60)
Suite: i2 P2 |P2  |P2 |P3 Suite: i2 P3 |P3 |P3 |P3
2(54) 2(44) 2(44) 4(60) 2(50) 3(60) 4(60) 4(50) 4(50) 4(50) 2(50) 3(60)
Suite: j1 P3 jP3  | Suite: j1 P2 |P2 |P2
3 (54.5) 5(50) 2(50) 3(30) 2(50) 5(50) 2(52) 2(20) 2(20) 2(50) 4(40) 6(60)
Suite: j2 P2 IP2  |P2____ |P3 JP3 I Suite: j2 P3 |P3 fP3 |P3 I
2(52) 2(52) 2(20) 3 (54.5) 5(50) 3 (54.5) 5(50) 4(40) 4(40)
0 1 2 3 4 5 6   0 1 2 3 4 5 6
Time Periods  Time Periods
Figure 3.5: Production schedules for Example 1. Coloured boxes show which product is 
being manufactured in which suite, followed by number of batches produced and production
time.
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Inventory chart for Example 1 (Generated by MP) Inventory chart for Example 1 (Generated by IRB)
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Figure 3.6: Inventory charts for Example 1. Each coloured bar shows how much product is
being stored and in which time period.
Sales and Demand Profile for Example 1 (Generated by MP) Sales and Demand Profile for Example 1  (Generated by IRB)
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Figure 3.7: Sales & demand profiles for Example 1. Each coloured bar shows the sales of 
different products, while the respective demand is shown via lines and markers.
A number of points relating to Example 1  can be made:
•  Production plans -  Figure 3.5  shows the production schedules for both MP and
IRB.  In  MP’s  production  schedule  product  2  is  manufactured in  one  long
campaign as  it has only one order date, however due to the  scattered demands 
there  is  value  in  a  changeover  for  both  products  1   and  3,  thereby  minimising 
inventory cost.
•  Campaign durations -  Table 3.4 shows that upstream plant capacity utilisation in
MP’s solution is particularly high at approximately 89 % (This is calculated as
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the  percentage  of potential  production  time  used  for  manufacture).  It  is  the 
upstream  capacity  utilisation  which  is  most  commonly  the  manufacturing 
bottleneck  in  biomanufacture  (Petrides  et  al.,  2004).  This  value  of  89%  is 
relatively high;  the  average biopharmaceutical  industry  capacity utilisation  for 
biopharmaceutical  manufacturing  in  2003  was  estimated  to  be  79%  (Langer, 
2004).
•  Inventory -  All intermediate and final product inventory for Example 1   is shown 
in  Figure  3.6.  In  MP,  intermediate  storage  is  required  for  product  3  in  time 
periods 1   and 4, as the crude product is stored until there is available downstream 
capacity in  the  next  time period.  The  ability to  reduce  intermediate  storage  is 
beneficial since costly specialist storage conditions are usually required.
•  Demand Vs Sales -  The product demands and Sales for Example 1   are shown in 
Figure 3.7. All product orders are met in full and on time apart from one batch of 
product  1  which  is  due  in  period  4  but  is  delivered  in  period  5.  There  is  no 
product wastage as production is forced to produce an integer number of batches 
and production correspondence is one to one.
3.5.2.  Example 2: Suite specific manufacturing and 
differing production throughputs.
In  this  example  another  typical  industrial  biopharmaceutical  planning  problem 
involving  intermediate  storage  is  represented  and  solved  using  the  mathematical 
formulation derived in this chapter. This example differs from Example  1   in that the 
upstream  fermentation  suites  are  product  specific  reflecting  differing  product 
manufacturing  requirements  and  validation  issues  common  to  contract 
biomanufacturers.  Secondly the product sales prices and manufacturing costs differ 
between products which results in the priority manufacturing of the more profitable 
products.  Also  P3  and P4 have  differing upstream production  throughputs,  which 
reflect another issue a contract biomanufacturer may have to deal with.  Finally the 
problem is  solved  over  a larger  1.5  year time horizon in order to  demonstrate the 
increased complexity that would result. Figure 3.8 shows the possible manufacturing 
routes of PI - P4.
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Figure 3.8: The functionality of the multisuite biopharmaceutical manufacturing in Example
Problem 2.
The features described below characterise the example being tackled to illustrate the
use of the proposed mathematical formulation. The problem definition and associated
problem data are given below:
•  A multiproduct facility with multiple production suites: three fermentation suites 
and two purification suites.
•  Four “mammalian cell” products with one or two product orders {PI, P2, P3 and 
P4).
•  The due date and demands profile is shown below in Table 3.4, where orders are 
assumed  to  be  due  at  the  end  of each  time  period  t,  where  early  delivery  is 
infeasible and late deliveries are penalised for each time period they are late.
•  Products  PI  and  P2  have  a  one  to  one  correspondence  of  upstream  and 
downstream  throughput;  i.e.  a  downstream  purification  batch  is  produced  for 
every fermentation batch. However for products P3 and P4 there is a two to one 
correspondence due to a lower fermentation throughput for both products. This is 
represented by production correspondence factors which are shown in Table 3.5.
•  A  1.5  year production horizon, with nine time periods t each two months long, 
i.e. the production time horizon H  t is 60 days long.
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•  Lead  times  are  adjusted  accordingly  to  represent  the  relevant  throughput 
correspondences between upstream and downstream.
•  Production  rates,  lead  times  and  related  parameters  used  in  this  example  are 
shown in Table 3.5 below, sales prices and manufacturing costs are not identical 
which is realistic to industrial practice.
Table 3.4: Due date profile for Example 2*:
Product Time Period
1 2 3 4 5  6 7 8 9
PI 6 4 4
P2 4
P3
4
P4 6 8 10 10
*Note:  All demands are in number of batches
Table 3.5: Parameters used in Example 2.
Product Parameter data  for Upstream production i Parameter data for product p
Production Lead Product Storage Minimum Storage Sales Manufacturing Waste
rate time lifetime, Capacity campaign cost price cost Disposal
CR P a  p Cp C p length P p t>P Tip cost
(batches/ (days) (time (batch/ CTm m  p (rmu/ (rmu/ (rmu/ Tp
day) periods) time
period)
(days) batch) batch) batch) (rmu/
batch)
PI 0.05 30 1 10 20 5 25 5 5
P2 0.045 32 1 10 21 5 20 2 5
P3 0.08 22.5 1 10 12.5 5 17 1 5
P4 0.08 22.5 1 10 12.5 5 17 1 5
Product Parameter data for Downstream production j Parameter data for product p
Production Lead Product Storage Minimum Storage Lateness Changeover cost Production
rate, time, lifetime Capacity campaign cost penalty factor
FRP Pr o p F p length w p 5 P (rmu/ ^ p
(batches/ (days) (time (batch/ F T ^ p (rmu/ (rmu/ batch)
day) periods) time
period)
(days) batch) batch)
PI 0.1 40 3 40 10 1 20 1 1
P2 0.1 42 3 40 10 1 20 1 1
P3 0.1 44.5 3 40 10 1 20 1 0.5
P4 0.1 44.5 J 40 10 1 20 1 0.5
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A similar IRB approach was used to generate a production schedule for Example 2. 
Table 3.6 shows a comparison of the main results obtained by IRB  and MP, while 
Figures  3.9,  3.10  and  3.11  show  graphical  representations  of  the  production 
schedules, inventory charts and sales & demand profiles.
Table 3.6: Comparison between solutions from the industrial rule based (IRB) approach and 
the proposed mathematical programming (MP) approach for Example 2.
Approach
Objective
function
(rmu)
Upstream Capacity 
Utilisation 
(%)
Downstream 
Capacity Utilisation 
(%)
Cost incurred as a result 
of late batches 
(rmu)
IRB 384 84 66 340
M P* 539 84 78 180
* Note: This problem was solved in 284 seconds.
MP’s objective function of 539 rmu corresponds to a profit margin of approximately 
50 %, while IRB’s objective function of 384 a considerably lesser value of 35 %. The 
difference in profitability in this case is almost entirely due to the extra late demand 
penalty cost incurred by IRB. In the absence of the late demand factor, the resultant 
profits  would  be  very  comparable.  The  slightly  lower  downstream  capacity 
utilisation  of  IRB  is  due  to  individual  hatches  of  product  being  processed 
downstream in bulk rather than when they are required to be processed, resulting in 
late  deliveries.  MP  comfortably  outperforms  IRB  in  this  case  which  is  consistent 
with industrial perspectives that increasing size and complexity of planning problems 
limit the value of industrial rule based approaches.
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Production schedule for Example 2: (Generated using MP) 
Suite: i1
Suite: i2 
Suite: i3 
Suite: j1 
Suite: j2
P2  |P2 P1  P1  P1  P1 |P2  |P2~
2 (54)  2 (44)  2 (50)  3 (60)  3 (60)  3 (60)  2 (54)  2 (44)  2 (50)
TP3~  |P3  |P3  |P3  |P3
4 (60)  4 (50)  4 (60)  4 (60)  4 (60)  4 (50)  3(37.5)  4 (50)  4 (50)
P4  |P3  |P3  |P3  |P3  |P3  I
4 (60)  4 (50)  4 (50)  4(50)  4(60)  4 (50)  1(12.5)  4(50)  4(50)
P2  |P3 |P3  |P3  |P3  |P3  |P3
2(54.5)  4(40)  2(54.5)  5(50)  2(54.5)  4(40)  2(54.5)  4(40)  4(40)
2(54.5)  4(40)  2(54.5)  4(40)  2(54.5)  6(60)  2(52)  2(20)  2(50)
0  1  2  3  4  5
Time Periods
Production schedule for Example 2:  (Generated using IRB) 
Suite: i1
Suite: 12 
Suite: i3 
Suite: j1 
Suite: j2
P2 |P2 P2 |P2
2(54) 2(44) 2(50) 3(60) 3(60) 3(60) 3(60) 2(54) 2(44)
P4 1F4  P4  IP4  P3 |P3 |P3 P3 |P3  I
4(60) 4(50) 4(50) 3 (37.5) 4(60) 4 (60) 4(50) 4(50) 4(50)
P4 |P4  |P4 |P3 |P3 |P3 |P3 P3 |P3
4(60) 4(50) 4(50) 1  (22.5) 4 (50) 4(50) 4(50) 4(50) 4(50)
P2 |P2  | |P2 |P2  I
2(52) 2(20) 2(50) 3(30) 3(30) 3(30) 3(30) 2(52) 2(20)
P4 |P4 IHIIIIIIlHlll |P4 |P3 |P3 |P3 |P3 |P3  |
2 (54.5) 6 (60) 4 (40) 2 (20) 2 (54.5) 6 (60) 4(40) 4 (40) 4(40)
1  2  3
Time Periods
Figure 3.9: Production schedules for Example 2. Coloured boxes show which product is 
being manufactured in which suite, followed by number of batches produced and production
time.
Inventory chart for Example 2 (Generated by MP)
IP1  □ P3  □ P4  Hlrrt.P1  Bint. P2
1  1   1
Time periods
Inventory chart for Example 2 (Generated by IRB)
IP1  0P2  DP3  EDP4  Hint. P3  BInt. P4
Tim# periods
Figure 3.10: Inventory charts for Example 2. Each coloured bar shows how much product is
being stored and in which time period.
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Sales and Demand Profile for Example 2 (Generated by MP)
I Sales P1  52QQ Sales P2 
- Demand P1  ---X-  Demand P2
Sales P3  E2Z3 Sales PA 
Demand P3  --O - Demand P4
Sales and Demand Profile for Example 2 (Generated by IRB)
Sales P1 szsz Sales P2 r~— i Sales P3 i ^ m  Sales P4
—9 — Demand P1 -• X  -  Demand P2 Demand P3 --Q-- Demand P4
1 2 3 4 5 6 7 8 9  
Time Periods
Figure 3.11: Sales & demand profiles for Example 2. Each coloured bar shows the sales of 
different products, while the respective demand is shown via lines and markers.
•  Production plans -  Figure 3.9 shows the production schedules for MP and IRB. 
The production plan for MP is a mix of changeovers and long campaigns in order 
to  avoid  violation  of  product  lifetimes.  Downstream  production  is  not 
campaigned as often due to the considerably shorter production times associated 
with downstream production.
•  Campaign durations - Plant capacity utilisation is approximately 84% which is 
higher than the industry average (79%).
•  Inventory -  All intermediate and final product inventory for Example 2 is shown 
in Figure 3.10. Intermediate storage is utilised giving the model a valuable extra 
degree of freedom, thus helping to avoid late deliveries. Two batches of product 
2 are stored in period 1, two batches of product 1  are stored in period 3, and three 
batches of product 1  are stored in period 5.
•  Demands Vs Sales - The product demands and sales for Example 2 are shown in 
Figure  3.11.  All  demands  are  eventually  met  in  full  apart  from  one  batch  of 
product  1, which would inevitably be met in the next (tenth) time period.  Late 
deliveries of product  1,  2  and 3  are observed,  with the number of late batches 
being 3, 2 and 4 respectively. This is attributable to the distribution of the product 
demands and the respective product profit margins. The relative profit margin on
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each  of products  1,  2  and  3  is  15,  16  and  14.  Prioritisation  by  profitability 
explains the resulting order of the late batches of product.
The second example is intended to capture certain features of the biopharmaceutical 
manufacturing  industry  such  as  managing  plant  manufacturing  capacity  given 
multiple manufacturing suites and differing production throughputs.  In the example 
solved the  solution  returned  is  in  agreement with typical  industrial  manufacturing 
strategies; however certain aspects such as inherent client relationships which usually 
influence manufacturing strategies are not taken into consideration.
3.6. Conclusions
In  this  chapter  a  mathematical  programming  (MP)  approach  using  an  MILP 
formulation for medium term planning of biopharmaceutical manufacture has been 
presented.  An  improved  formulation  has  been  used  to  represent  and  solve  two 
example  problems  based  on  real  industrial  data.  Solutions  to  both  examples 
generated using MP  were compared to those generated by an industrial rule based 
(IRB)  approach  and  demonstrated  the  value  of the  proposed  approach.  In  both 
Examples  1   and 2 MP were shown to outperform IRB in terms of profitability, the 
difference in profitability can be mainly attributed to extra late batch penalties and 
storage costs  due to  the  campaigning  style  employed.  In the larger more  complex 
Example 2 the profitability achieved by MP was considerably higher demonstrating 
the necessity for calculated decisions regarding campaign changeovers and inventory 
profiles. This confirms the ineffectiveness of IRB type approaches for solving larger 
more  complex  examples.  In  both  examples,  plant  utilisation  was  high  relative  to 
typical  industrial  expectations,  which in terms  of manufacturing cost-effectiveness 
translates to improved profit margins.
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3.7.  Nomenclature
Indices
i fermentation suites
j purification suites
P product
t,e time periods
Parameters
C p storage capacity of crude product /?, batches
CRip production rate of product p in suite i, batches per unit time
CTm inp minimum production time for product p at time period t
max maximum production time for crude product p
D pt demand of product p at time period t
Fp storage capacity of final product p, batches
FRjp production rate of product p in suite j, batches per unit time
min r 1   p minimum production time for product p at time period t
j-’rji max r 1   p maximum production time for final product p
H t available production time horizon over time period t
ap lead time for production of first batch of crude product p
P  p lead time for production of first batch of final product p
CP life time of crude product p, in number of time periods t
- 67-Chapter 3. Deterministic Medium Term Planning of  Biopharmaceutical Manufacture
ap   life time of final product p , in number of time periods t
v p  unit sales price for each batch of product p
rj p  unit cost for each batch produced of product p
y p  unit  cost for each new campaign of product p
S p  unit  cost charged as penalty for each late batch of product p
p p  unit  cost for each stored batch of crude product p
co p  unit  cost for each stored batch of final product p
tp  unit cost of disposing of a batch of product waste p
X p  production correspondence factor for cmde to final production of
product p
Binary Variables
U  jpt  1 if final product p is produced in suite j over period  t\ 0 otherwise
Wjpt   1  if one or more campaigns are starting on i and j   at any given  time
period t\ 0 otherwise
Xjpt  1   if a new campaign of final product p is started in suite  i over period
t; 0 otherwise
Y iPt  1 if crude product p is produced in suite i over period t; 0 otherwise
Z ipt  1   if a new campaign of crude product p is started in suite i over period
t; 0 otherwise
Continuous Variables
Clpt  amount of crude product p stored in suite i over period t
CT ipt  production time for product p on suite / at time period t
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CTtotu  total production time for suite i over period t
CWp t  amount of crude product p on suite i which is wasted over period t
FI pt  amount of crude product p stored in suite j  over period t
FT  jpt  production time for product p on suite j  at time period t
FTto tjt  total production time for suite j  over period t
FWpt  amount of final product p on suite j  which is wasted over period t
S pt  amount of product p which is sold over period t
Prof  operating profit
A pt  amount of product p which is late over period t
Integer Variables
CP ipt  amount of crude product produced in suite i over period t
FP jpt  amount of final product p produced in suite j  over period t
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Medium Term Planning of 
Biopharmaceutical Manufacture 
using Two-Stage Programming
4.1. Introduction
In the previous chapter,  an optimisation-based approach for medium term planning 
of biopharmaceutical manufacture was presented using a deterministic mathematical 
programming  formulation  which  determines  the  optimal  production  plans  for  a 
biopharmaceutical  facility given fixed/known parameters. The overall problem was 
formulated as an MILP model based on a discrete time representation.
The deterministic approach was compared to an industrial rule based approach and 
was  able  to  achieve  considerable  improvement  in  operating profits.  However,  the 
model  did  not  account  for  an  inherent  feature  of biopharmaceutical  manufacture 
which is the uncertain conditions associated with this environment, namely variable 
batch titres  (yields),  contamination rates  and campaign length  (Farid et al.,  2005). 
Schedules that do  not  account  for these uncertainties  are likely to  lead  to reduced 
operational performance. For example, variable fermentation titres (grams of product
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per  litre  of broth)  directly  determine  the  number  of batches  required  to  satisfy 
product demands  and  hence  impact  directly on  customer  demand  satisfaction  and 
profitability.
Hence,  focus  of this  chapter  is  the  medium  term  planning  of biopharmaceutical 
manufacture  under  uncertainty.  The  problem  is  formulated  as  a  two-stage 
programming (multiscenario) MILP problem and an iterative algorithm is proposed 
for its  efficient  solution.  This  is  tested  on  three  illustrative  examples  of differing 
sizes  and computational results  are presented for the deterministic model,  the full- 
space multiscenario  model,  a rolling horizon  algorithm  and  the proposed  iterative 
algorithm.
4.2. Problem Description
As was discussed in Section 3.2, the problem is characterised by some features fairly 
typical of process planning and scheduling problems such as late delivery penalties, 
multiproduct manufacture, inventory and capacity utilisation challenges, while other 
features are more specific to bioprocessing such as long lead times, specialist storage 
considerations and variable fermentation titres.
In recent work, (Farid et al., 2005; Lim et al., 2005; Biwer et al., 2005) the impact of 
some  common  uncertainties  on  biopharmaceutical  manufacture  were  explored 
through the use  of Monte-Carlo  (MC)  simulations,  and  the  fermentation  titre was 
found to be the most critical driver affecting both the cost of goods and the facility 
throughput.  Hence, the focus of this work is improving decision making given the 
aforementioned key source of uncertainty within the commercial biomanufacturing 
environment.  In  this  chapter the  deterministic  model  presented  in  section  (3.2)  is 
extended to allow for variable fermentation titres which are reflected as fluctuations 
in the production rate of product p, rp.
As  was  mentioned  previously,  when  tackling  optimisation  problems  under 
uncertainty,  parameters  assumed  to be uncertain  are  often represented by discrete 
outcomes using a multiscenario stochastic (two-stage) programming approach. This
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approach is utilised by introducing three discrete outcomes (low, medium and high) 
for uncertain parameter rpit, where k, the number of possible scenarios is a function of 
the number of products p and the number of outcomes o for uncertain parameter rpk. 
The total number of scenarios is equal to <f, hence in our problem the total number 
of  scenarios  is  3^.  This  exponential  relationship  explains  the  combinatorial 
explosiveness  that  makes  the  solution  of  larger  instances  of  this  full-space 
multiscenario problem computationally intractable. This presents a genuine need for 
the efficient solution of this problem, ideally without sacrificing solution quality.
The  overall  problem  of medium  term  planning of biopharmaceutical  manufacture 
under uncertainty can be stated as follows:
Given:
•  A set of products.
•  Production rates and lead times.
•  Product lifetimes, storage costs and storage capacities.
•  Product demands, sales prices, and late delivery penalty costs.
•  Manufacturing and campaign changeover costs.
•  Minimum and maximum campaign durations.
•  Outcomes and associated probabilities.
Determine:
•  Campaign durations and sequence of campaigns.
•  Production quantities along with inventory profiles.
•  Product sales and backlog profiles.
Objective:
•  Maximise expected manufacturing profit.
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4.3.  Mathematical Formulation
The formulation presented in this chapter is based on the deterministic medium term 
planning problem presented earlier (Section 3.2), here however the focus is shifted to 
tackling the impact of uncertainty.
The  problem  is  formulated  as  a  two-stage  programming  formulation.  Index  k  is 
introduced  to  production  rate,  rPk.  Index  k  is  also  introduced  to  all  continuous 
variables rendering them second stage (wait and see) variables.  Binary variables for 
production, Ypt, and changeover, Zpt do not take on new index k as they are first stage 
decision  variables  (here  and  now)  and  allow  for  the  selection  of one  operating 
schedule  (production  sequence)  for all  scenarios.  The multiscenario  formulation is 
presented below.
4.3.1.  Production Constraints
Constraint  (1)  represents  biopharmaceutical  production.  The  number  of batches 
produced  of product p  at  time  period  t in  scenario  k,  Bptk,  an  integer  variable,  is 
calculated through production rate, rpk, which is combined with production lead time, 
ap. This lead time allows for the duration of the first batch of a campaign plus the set­
up  and  cleaning time before the  first batch  is  started.  Production  time,  Tptk, is  the 
duration of manufacture of each product p within each time period t in scenario k. 
The  logical  incorporation  of lead  time  is  enforced  by  a binary  variable  Zpt.  If a 
product p is selected for manufacture at time t a lead time, ap, will only be included 
in that campaign duration to account for the setup and cleaning if Zpt is equal to  1  
(denoting the start of a new campaign).
Bptk  = ^ pt ~^fpk(Bptk ~apZpt)  \/p,t,k  (1)
Binary  variable  Ypt,  is  introduced  to  denote  whether  or  not  a  product  p  is 
manufactured at time t.  In order to enforce the correct activation of binary variable 
Zpt, constraint (2) is introduced. It enforces that Zpl will only be activated if product p 
is not manufactured in the previous time period t-1, i.e. start of a new campaign.
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Zpt^Y pt~ Yp,t-1   Vp,t  (2)
Constraint (3) enforces that at most one product p undergoes manufacturing at any 
given time period, t.
v?  (3)
P
4.3.2.  Timing Constraints
In some cases, manufacturers enforce minimum and/or maximum campaign lengths 
in  order  to  maximise  efficiency  or  to  allow  for  relevant  maintenance/slack. 
Constraints (4) and (5) represent the appropriate minimum and maximum production 
time  constraints,  where  Tpm in  is  the  minimum  campaign  duration,  Tpm ax  is  the 
maximum campaign duration and Ht is the size of the time horizon. These constraints 
are only active if Ypt is equal to 1, otherwise the production times are forced to 0.
T™Yp t<Tptk  Vp,t,k  (4)
Tptk  < min{rp max,H, )rpt  Vp,t,k  (5)
4.3.3.  Storage Constraints
The  following  constraint  enforces  an  inventory balance  for production  and  forces 
production to meet demand.  In constraint (6) the amount of product p stored at the 
end  of the  time  period  t  in  scenario  k,  Iptk,  is  equal  to  the  amount  stored  at  the 
previous time period t-1, Ip,t-i,k, plus the net amount produced during the current time 
period t, Bptk, less the amount sold, Sptk, and the amount of product wasted, Wptk at the 
current time period t.
1ptk = Ip,t-l,k  Bptk ~ Bptk ~ Wptk  YP»  k  (6)
Constraint (7) bounds the amount of product p stored over period t in scenario k so as 
not to exceed the maximum available product storage capacity, Cp.
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Iptk —  Cp  Vp,t,k  (7)
In constraint (8) stored product is constrained by limited product lifetimes, whereby 
any product stored during time period t cannot be sold after the next  time periods.
tJ<P
I  ptk —   /   pQk  Vp,t,k  (8)
e=t+i
4.3.4.  Backlog Constraints
Late deliveries  are undesirable,  and hence a penalty Aptk is incurred for every time 
period  t  that  a  given  batch  of product p  in  scenario  k is  late  meeting  a  product 
demand Dpt. This is represented by constraint (9).  Late batches are penalised in the 
objective function.
A Ptk  = A P,t-\,k +DP t~ S  ptk  Yp, t, k  (9)
4.3.5.  Objective Function
The strategic objective in this formulation is to maximise expected operating profit, 
Eprof.  This  is  represented  by  an objective  function which  is  considered  to be the 
difference  between  “total  sales”  with  each  batch  sold  at  a  price  vp,  and  “total 
operating  costs”  which  include  the  batch  manufacturing  cost  at  rjp  per  batch, 
changeover  cost  at  \ f / p  per  batch,  storage  cost  at  pp  per  batch  and  late  delivery 
penalties of S p  per batch.  All costs and prices are in relative monetary units (rmu). 
All variables in the objective that contain index k are weighted by the probability of 
the occurrence of that scenario, probk.
[Model FULL]
Maximise
Eprof = 2 22  ]v^h (vpSptk-VpBp,k-Ppip,k-^iApik> -2 2 jw   (io)
p t k   p i
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Subject to: constraints (1-9).
The complete formulation FULL encompassing equations (1  -  10) corresponds to a 
mixed-integer  linear  programming  (MILP)  model.  A  specialised  iterative  solution 
approach is proposed in the next section.
4.4. Solution Methodology
Solving realistic size problems as full-space multiscenario problems often results in 
large scale MILP problems unsolvable in a realistic time scale by traditional branch 
and bound methods  (this  will be  demonstrated in the  following  section 4.4).  This 
presents the need for more efficient solution procedures. The algorithm proposed in 
this chapter is based on a similar concept to that introduced in the work of Werner 
and Winkler (1995). They present a heuristic algorithm with two parts; a constructive 
and  an  improvement  part.  The  algorithm  uses  heuristic  insertion  rules  in  order to 
construct a feasible schedule for the job-shop problem and iteratively improves the 
schedule by using a heuristic search method which utilises insights derived from the 
problem’s  solution  structure.  The  concept  of constructing  a  preliminary  schedule 
using a  first  stage  and  the  iterative improvement of it in  a second  stage has been 
applied to  industrial batch  scheduling by Roslof et al.  (2001),  Mendez  and  Cerda 
(2003) and most recently by Castro et al (2006).
Each of the aforementioned works utilise the construction improvement concept for 
the  efficient  solution  of  large  scale  deterministic  formulations.  Here,  a 
construction/improvement algorithm for the efficient solution of the large scale two- 
stage, multi-scenario,  mixed integer linear programming (MILP) model  detailed in 
the  previous  section  4.2  is  presented.  The  proposed  algorithm,  CON/IMP,  is 
composed of the following steps:
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Step  1  -   Construction  (CON):
(i)  Select  order  of  insertion  of  products  using  random  or
heuristic  rules.
(ii)  For  the  selected  product,  p*, expand  rp.   to rp. k   while
other products  remain as mean value,  Fp  .
(iii) Solve reduced two-stage model  (FULL).   Fix binary 
variables  yp,# t  and Zp*it.
(iv)  Reset  rp./ k  to mean value,  Fp  .
(v)  If  all  products  are  considered  go  to  step  2  (i) ,   else
insert next product,  p *:  Go to step 1  (ii) .
Step 2  -   Improvement  (IMP):
(i)  Using  random  or  heuristic  rules,  select,  n,  products  to 
be  released  by  unfixing  their  binary  variables  while 
keeping  fixed  the  binary  variables  of  the  remaining 
products  fixed to previous  solution.
(ii)  Construct  reduced  two-stage  model  (FULL)  with  on
scenarios  (with  only  the  variables  of  the  n  selected 
products being scenario dependant).
(iii) Solve  reduced  two-stage  model  (FULL) .   Fix  binary 
variables of  released products.
(iv)  Repeat  (i) ,   (ii)  &  (iii)  until convergence  is achieved.
(v)  Run  Monte-Carlo  simulation  to  validate
solution/schedule.
In  the  first  step  (CON)  of the  algorithm  a  schedule  is  constructed  by  way  of 
sequential  selection,  optimisation  and  fixing  of binary  variables.  The  production 
schedule  is  constructed by  consecutive  insertion  of products  where the number of 
construction/ insertion steps is equal to the total number of products to be produced. 
For example, if the first product to be selected is pi,  the production rate for p i, rpi, 
becomes  rPik  as  different  discrete  outcomes  for  production  rate  uncertainty  are 
introduced,  this  means  that  the  total  number  of scenarios  k  is  equal  to  the  total 
number of discrete outcomes, o \ a linear relationship which replaces the exponential 
relationship encountered in the full space problem, oP. After the reduced problem isChapter 4. Medium Term Planning of  Biopharmaceutical Manufacture using Two-Stage Programming
solved  the  binary  variables  associated  with  the pi,  Ypu  and  Zpit  are  fixed  and 
parameter rpi_k is reset to mean value,  Fp  . These steps are repeated until the binary
variables  for  all  products  are  fixed  and  a  full  schedule has been  constructed.  The 
order of insertion may influence the quality of the solution obtained at the end of the 
construction  stage,  however  this  issue  is  averted  by  the  introduction  of  the 
improvement stage, the second step of the algorithm. The solution schedule can be 
evaluated at this point, allowing the decision maker to decide if they wish to continue 
to the next step, as the current solution may be of sufficient quality.
In the second step (IMP) of the algorithm, n products are released iteratively in a bid 
to  improve  the  solution  achieved  at  the  end  of the  first  “construction”  stage,  n 
products  are  selected  for  release  whereby  the  binary  variables  for  the  selected 
products  are  unfixed  and  the  mean  production  rates  replaced  with uncertain  rates 
resulting in on scenarios. For example, for n = 2, and p = 1 & 2, two products p i and 
p2 are released, rpi is set to rpitk and rP2 set to rP 2,k, which results in a considerable 
reduction in problem size, o2 instead of cP where p is the total number of products. 
After this reduced problem is solved, parameters rpitk and rP 2,k are reset to the mean 
value,  Fp  and their associated binary variables are refixed. This process is continued
iteratively,  selecting  n  products  randomly  at  each  iteration  until  convergence  is 
reached.
Convergence is defined as SU consecutive iterations with no change to the solution 
schedule.  Finally  solutions  schedules  are  evaluated  via  Monte-Carlo  (MC) 
simulation. MC will be discussed further in the following section.
4.5. Illustrative Examples
Three  examples  of differing  size  are  solved  to  illustrate  the  applicability  of the 
proposed  construction/  Improvement  algorithm  (CON/IMP).  The  examples  are 
solved  for  two  different  variabilities  for uncertain parameter rp,  +/-  10%  and  +/- 
20%. The results achieved using CON/IMP are compared with those achieved by the
- 78-Chapter 4. Medium Term Planning of  Biopharmaceutical Manufacture using Two-Stage Programming
deterministic model (DET) which differs from the formulation presented in this work 
only  in  that  it  does  not  contain  the  index  k  (introduced  to  allow  for  uncertain 
production rates) and hence assumes mean values for the uncertain parameter rp, the 
full-space,  two-stage  programming  model  (FULL)  presented  in  this  work,  and  a 
rolling horizon algorithm (RH).
In the implementation of CON, the order in which products are selected for insertion 
is  decided  by  using  either  random  or  heuristic  rules.  In  this  work,  products  are 
inserted  in  numerical  order  1,  2,  3...n.  During  the  improvement  step  (IMP),  two 
products are randomly selected for release at each iteration (the number of products 
selected  for release  can be  decided by the user,  however  in the  authors’  personal 
experience keeping this number as low as possible is advised for reasonable solution 
times). The selection of an insertion approach for CON and the number of products 
to be released in the IMP  step is based on user experience.  For convergence of the 
IMP step, the criterion SU = 50 is used in all example problems.
We  also  compare  our  algorithm  with  an  iterative  algorithm  (RH)  based  on  the 
concept of rolling horizons (Pinedo, 2002). The full-space, two-stage programming 
model  is  solved  iteratively,  whereby  at  each  iteration,  i,  only  a  subset  of T time 
periods,  t, is solved.  In the first iteration,  i, the subproblem is solved for (i (T-l)  ) 
time periods, and the binary variables for (i (T-l) +  1   - T) are fixed. The algorithm 
proceeds in this manner until  all time periods,  t, have been solved. The number of 
time periods  in  the  subset,  T,  can be  chosen by the  decision maker  (whereby the 
larger the value of T the longer the solution time and the higher the likelihood of an 
achieved solution being optimal). Figure 4.1  shows a diagrammatic representation of 
the algorithm. A value of T = 3 is used in all example problems.
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RH algorithm,   where T =
tl  t2
Fixed
tl  t2  t3  t4
Optimised
tl  t2  t3  t4  t5  t6
Figure 4.1: Iterations, i: 1 - 3 of the rolling horizon algorithm (RH), where t is the number of 
time periods to be solvedfor and T is the subset of time periods.
Monte  Carlo  (MC)  simulation  is  used  in  order  to  better  quantify  the  impact  of 
variability on the deterministic schedules, as well as for the validation of the quality 
of solution  schedules  and  thus  the  realistic  expected  performance.  A  number  of 
simulation  loops  are  setup  in  GAMS  post  model  solution  to  create  an  improved 
approximation  of the  probability  distribution  assumed  for  uncertain  parameter  rp. 
This  presents  an  opportunity  for  the  validation  of  the  accuracy  of  the  discrete 
probability distribution used in the mathematical programming model. Subsequent to 
the solution of each optimisation model the resulting scheduling decision variables 
YP, and Zpt are fixed and MC simulation is conducted for uncertain parameter rp. We 
compute  the  expected  profit  (MCPROF)  until  a  convergence  criterion  is  met.  A 
minimum  number  of iterations  are  assumed,  after which the  standard  error of the 
mean and an overall mean expected profit are computed at each iteration. When the 
standard error of the mean is less than 1% of the overall mean profit, the mean output 
value is considered to have converged (Hung et a l, 2006).
The data used in the Monte-Carlo simulation assumes a mean of rp and a standard 
deviation  of unc*rp  where  unc  is  a fractional  value which  signifies  a symmetrical 
deviation representing the variability from the mean. For the two-stage programming 
model,  three  discrete  outcomes  (low,  medium  and  high)  are  assumed  and  their 
equivalent probabilities  are derived by truncation of a standard normal distribution
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with mean  ? p  and standard deviation unc*rp, by +/- 1   a and the results are shown in 
Figure 4.2.
Probability of Production Rate Outcome 
27.3%  45.4%  27.3%
(1-imc)  *rp   rp   (1+unc)  *rp
Production Rate Outcome
Figure 4.2: Equivalent discrete probability distribution of  production rate rp, where unc is
the variability in rP
All problems were implemented in GAMS  (Brooke et al,  1998) using the CPLEX 
MILP  solver,  solving all problems to optimality.  All runs were performed on a 1.8 
GHz Pentium 4 PC with 512 MB RAM.
4.5.1.  Example Problem Data
The sizes of each of the three examples tackled are shown below:
•  Example 1: three products, nine time periods (1.5 year production time horizon).
•  Example 2: five products, ten time periods (1.7 year production time horizon).
•  Example 3: ten products, eighteen time periods (3 year production time horizon).
Table 4.1:  Demand  profile for Example 1 *
Product Time Period
1 2 3 4 5 6 7 8 9
PI 3 2
P2 3 5
P3 2 5
♦Note:  All demands are in number of batchesChapter 4. Medium Term Planning of  Biopharmaceutical Manufacture using Two-Stage Programming
Table 4.2:  Demand profile for Example 2*
Product Time Period
1 2 3 4 5  6 7 8 9 10
PI 2
P2 3
P3 2 2 2
P4 2 3 2
P5 3
*Note:  All demands are in number of batches
Table 4.3: Demand profile for Example 3*
Time Period
Product  -----------------------------------------------------------------------------------------------
1   2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18
__  _
P2  3
P3  2
P4  2  3
P5  2  3
P6  3  4
P7  3
P8  3
P9  2
P10  3
*Note:  All demands are in number of batches
The data associated with Examples 1 to 3 are presented below.
•  A  multiproduct  facility  producing  p  mammalian-cell-derived  products  is 
assumed, with one, two or three product orders for each product.
•  A production horizon between 1.5 and 3 years long, split into t time periods each 
two months long, i.e. the production time horizon H(, is 61 days long.
•  The due date and demand profiles  are shown in Tables 4.1  to 4.3.  Orders were
assumed to be due at the end of each two month time period t. Early delivery is 
assumed to be infeasible and late deliveries are penalised for each late period.
•  Production rates, lead times and related parameters used in  Examples  1   to 3  are
shown in Table 4.4. Example 1   is assumed to include, P1-P3, Example 2, P1-P5, 
Example 3, PI-PI 0.
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•  All lead times  ap are in “days” and are each assumed to include seven days of 
product changeover related cleaning time.
Table 4.4: Parameters used in Examples 1-3, 1: P1-P3, 2: P1-P5, & 3: P1-P10
Product Parameter data Sales price and Costs
r p
(batches/
day)
a  p  
(days)
-pm m
(days)
Price/Cost Symbol Unit Value
PI 0.05 30 20 Product Cp time periods 3
lifetime,
P2 0.0909 28 11
Storage Cp batch/day 6
P3 0.0625 32 16 Capacity,
P4 0.05 30 20 Sales price, U p rmu/batch 10
P5 0.08 31 12.5
Manufacturing % rm u/batch 4
P6 0.05 30 20 cost
P7 0.0909 28 11 Storage cost P p rmu/batch 0.2
P8 0.08 31 12.5
Late penalty 5P rmu/batch 4
P9 0.05 30 20
P10 0.0909 28 11 Changeover V p rmu/batch 2
cost
4.5.2.  Example Problem Results
All three examples were solved using DET, FULL, CON, CON/IMP and RH at 10% 
and 20% production rate rp variability and the  computational  results  are shown in 
Table 4.5, while Figure 4.3 shows graphical representations of the achieved expected 
profits (MCPROF).  A discussion on the impact of uncertainty,  solution quality and 
solution times follows.
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Table 4.5: Computational results for Examples 1-3*.
Computational Optimisation Monte-Carlo
Results Simulation
Indicator OBJ CPU MCPROF
% variability for rp 10 20 10 20 10 20
DET 108.5 108.5 1 1 98.7 94.2
FULL 105.7 105.7 34 15 105.8 101.1
CON/ 105.5 105.5 1 1 105.7 101.1
Example 1
CON/IMP 105.8 105.8 20 15 105.8 101.1
RH 105.7 105.7 10 7 105.8 101.1
DET 109.5 109.5 1 1 93.9 84.8
FULL 110.7 99.3 1330 2203 100.3 89.0
CON 109.6 102.6 2 2 94.0 85.1
Example 2
CON/IMP 104.9 100.4 28 26 100.3 89.4
RH 105.3 98.3 98 202 100.3 87.3
DET 195.6 195.6 2.9 3.0 179.2 152.6
FULL - - - - - -
CON 193.8 195.8 8 8 183.7 155.3
Example 3
CON/IMP 195 195 40 39 191.7 168.2
RH - - - - - -
*Note:  Optimisation  objective  function  (OBJ),  Solution  time  in  seconds  (CPU)  and  Monte-Carlo  simulation 
objective function (MCPROF);  for results from DET (Deterministic model), FULL (the full space multiscenario 
problem),  CON  (the  construction  step),  CON/IMP  (Iterative  construction/improvement  algorithm)  and  RH 
(Rolling horizon algorithm).
The  impact  of  uncertainty  on  operating  profits  is  calculated  as  the  percentage 
difference  between  the  achieved  profit  in  the  absence  of  uncertainty  and  that 
achieved when introducing uncertainty via MC simulation. We calculate the impact 
for Examples  1, 2 & 3 to be a 9,  14 and 8% drop and a 13, 22 and 22% drop for the 
respective variabilities of 10 and 20%. This shows a significant negative impact on 
profits  which  increases  with  increasing variability  and provides  strong motivation 
and  support  for  methods  aiding  decision-making  under  uncertainty  in  the 
biopharmaceutical industry. Table 4.6 shows the percentage improvement in solution 
quality of FULL, CON, IMP and RH over that achieved by the deterministic model.
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Figure 4.3: Graphical representations of  achieved expected profits (MCPROF) for examples 
1, 2, 3 and 4 using DET (deterministic model), FULL (the full space multiscenario problem), 
CON (the construction step), CON/IMP (Iterative construction/improvement algorithm) and 
RH (Rolling horizon algorithm), where ♦ represents 10% variability and m  represents 20%
variability.
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Table 4.6  Percentage improvement in expected profit over the deterministic model solution
for Examples 1-3*.
% variability for r„ 10 20
FULL 7.2 7.3
Example 1 CON 7.1 7.3
CON/IMP 7.2 7.3
RH 7.2 7.3
FULL 6.8 5.0
CON 0.1 0.4 Example 2
CON/IMP 6.8 5.4
RH 6.8 2.9
FULL
CON 2.5 1.8 Example 3
CON/IMP
RH
7.0 10.2
DET (Deterministic model), FULL (the full space 
multiscenario problem), CON (the construction step),
CON/IMP (Iterative construction/improvement algorithm) and 
RH (Rolling horizon algorithm).
FULL  is  able  to  able  to  solve  Examples  1   and  2  to  optimality but  the  projected 
exponential  increase in problem  size and hence solution time leads to the machine 
running  out  of memory  and  no  solution  being  returned  for  Example  3  (1.8  GHz 
Pentium  4  PC  with  512  MB  RAM).  Table  4.7  shows  the  number  of  scenarios 
generated in the full space multiscenario problem in each of the examples. While RH 
is  able  to  make  a  considerable  reduction  in  the  computational  requirements  for 
Examples  1  and  2,  the reduction in problem size achieved by the algorithm is not 
sufficient to obtain a solution for Example 3  as the exponential increase in problem 
size again proves too challenging for the hardware employed.
Table 4.7: Exponential relationship between the number of  products and number of 
scenarios in the  full space multiscenario problem (FULL).
Example Number of Products,/; Number of Scenarios, k
1 3 27
2 5 243
3 10 59049
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CON achieved differing degrees of improvement over DET throughout each of the 
three examples tackled in particularly modest timescales never exceeding 8 seconds. 
The CON/IMP  algorithm is able to match the optimal  solutions of both FULL and 
RH in Examples  1  and 2, while making considerable savings in solution time over 
FULL.  In  Example  3  both  CON  and  CON/IMP  are  able  to  achieve  considerable 
improvements over DET where both FULL and RH  fail to  achieve a solution. The 
solutions  achieved  by both  CON  and  CON/IMP  for  Example  3  are  all  achieved 
within modest timescales never exceeding 40 seconds. The increase in solution time 
seen  by  CON/IMP  is  much  closer  to  linear  than  exponential  demonstrating  its 
effectiveness for tackling larger and more computationally challenging problems.
The  two-step  iterative  algorithm  CON/IMP  shows  that  by  using  step  1   CON, 
improved  solutions  can  be  achieved  within  particularly  modest  timescales  (<8s), 
while  step  2  IMP  can  make  further  improvements  and  is  able  to  match  solutions 
achieved by solving the full space problem within still relatively modest timescales 
(<32s).  Considering  the  size  of the  largest  example tackled,  this  demonstrates the 
exceptional  reduction  in  problem  size  achieved  by  CON/IMP  and  value  of this 
approach for two-stage programming problems.  This method is envisaged to be of 
value in other applications of two-stage programming.
4.6. Conclusions
In  this  chapter,  a  mathematical  optimisation-based  framework  for  medium  term 
biopharmaceutical manufacturing planning under uncertainty has been presented, and 
tested on three  illustrative  examples  of different  size  and  at different variabilities. 
The problems were all solved using a deterministic model (DET), the full-space two- 
stage  programming  model,  a  two-step  rolling  horizon  algorithm  (RH)  and  the 
proposed  construction/improvement  algorithm  (CON/IMP).  The  impact  of 
uncertainty on the  solution  schedules was  quantified  for both examples via Monte 
Carlo (MC) simulation. The results showed that CON/IMP consistently matched the 
results of FULL and RH while improving on DET for small and more modest sized
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examples  (1  and 2).  While in the larger more challenging example (3) where both 
FULL  and  RH  failed  to  achieve  any  solution,  CON/IMP  is  still  able  to  achieve 
considerable improvement on DET in particularly modest solution times.
4.7. Nomenclature
Indices
P product
t,0 time periods
0 outcomes
k scenarios
Parameters
Cp storage capacity of product p, batches
Dpt demand of product p at time period t
fpk production rate of product p , batches per unit time in scenario k
Ht available production time horizon over time period t
rp m ax 
1  P maximum production time for product p
rpmin
1  P minimum production time for product p
(Xp lead time for production of first batch of product p
C p life time of product p, number of time periods t
Vp unit sales price for each batch of product p
Vp unit cost for each batch produced of product p
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yjp  unit cost for each new campaign of product p
Sp  unit  cost charged as penalty for each late batch of product p
Pp  unit  cost for each stored batch of product p
SU  numbers of iteration with no change to  Ypt during improvement phase
unc  fractional deviation from the mean
Binary Variables
Yp'  1  if product p is produced over period t; 0 otherwise
Zpt  1 if a new campaign of product p is started in period t;  0 otherwise
Continuous Variables
Iptk  amount of product p stored over period t in scenario h
Eprof  expected operating profit
Sptk  amount of product p which is sold over period t in scenario k
Tptk  production time for product p at time period t in scenario k
Ttottk  total production time over period t in scenario k
Wptk  amount of product p wasted over period t in scenario k
Aptk  amount of product p which is late over period t in scenario k
Integer Variables
Bptk  amount of product produced over period t in scenario k
- 89-Chapter 5
Medium Term Planning of 
Biopharmaceutical Manufacture 
using Chance Constrained 
Programming
5.1. Introduction
In  the  previous  chapter,  a  two-stage  programming  approach  for  medium  term 
planning  of biopharmaceutical  manufacture  was  presented  using  a  mathematical 
programming  formulation  which  determines  the  optimal  production  plans  for  a 
biopharmaceutical  facility given uncertain fermentation titres.  The overall problem 
was  formulated  as  a  two-stage  MILP  model  based  on  discrete  scenarios  and  an 
iterative algorithm was developed for its efficient solution.
The  two-stage  programming  approach  was  compared  to  the  deterministic  model 
which demonstrated  the  value  of decision-making under uncertainty in production 
planning of biopharmaceutical manufacture.  The two-stage programming approach 
was  also  compared  with  the  full  space multiscenario  model  and  a rolling horizon
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algorithm where it was able to match or improve on both approaches in each of the 
example problems considered. The iterative algorithm presented was able to reduce 
considerably  the  computational  burden  associated  with  two-stage  programming 
approaches.  However,  there  are  more  ideal  approaches  for  planning  under 
uncertainty which  can  provide  an  alternative to  multiscenario  type representations 
and their associated computational burden.
In  this  chapter  an  alternative  optimisation-based  framework  for  medium  term 
planning of biopharmaceutical manufacture given uncertain fermentation titres will 
be presented. This optimisation framework is also based on the deterministic medium 
term planning model  presented  earlier (Section  3.2)  and leverages  the  concepts  of 
chance  constrained programming to  represent the uncertain  conditions.  A compact 
mathematical formulation for medium term planning under uncertainty is presented 
and compared with the results from the deterministic formulation as well as the two- 
stage programming approach (CON/IMP) presented in the previous chapter (Sections 
4.2 & 4.3). The results from four illustrative examples are presented.
5.2. Problem Description
As  was  discussed  in  Chapter  4,  when  tackling  optimisation  problems  under 
uncertainty,  parameters  assumed  to  be  uncertain  are  often  represented by  discrete 
outcomes using a multiscenario stochastic (two-stage) programming approach. Using 
a  multiscenario  approach  and  assuming  between  3  and  10  products  were  to  be 
produced,  and with three possible outcomes for uncertain parameter rp, resulted in 
between  27  and  59,049  possible  scenarios  (product/outcome combinations).  Given 
that  each  scenario  must  be  explicitly  incorporated  in  the  objective  function,  this 
exponential  growth  means  that  for  larger  examples  solving  the  full  space 
multiscenario  model becomes  computationally intractable.  Practically the approach 
often  adopted  is  to  solve  problems  suboptimally by  specially  developed  solution 
procedures such as that presented in Section (4.3).
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Chance  constrained  programming  (CCP)  provides  an  alternative  approach  which 
avoids the multiscenario representation. Further discussion on the CCP methodology 
and the derivation of the problem formulation follows in the next section.
5.3. Mathematical Formulation
The formulation presented here is based on the deterministic medium term planning 
problem presented in Section 3.2, however again here the focus is shifted to tackling 
the impact of uncertainty.  The deterministic formulation will first be presented and 
will be followed by the stochastic formulation.
5.3.1.  Deterministic Formulation
The multiperiod MILP model composed of an objective function and constraints is 
formulated for the representation and solution of the biopharmaceutical production 
planning problem as shown below.
5.3.1.1.  Production Constraints
Constraint  (1)  represents  biopharmaceutical  production.  The  number  of  batches 
produced, Bpt, an integer variable, is calculated through production rate, rp, which is 
combined with production lead time, ap. This lead time allows for the duration of the 
first batch of a campaign plus the set-up and cleaning time before the first batch is 
started.  Production time,  Tpt, shows  the duration of manufacture of each product p 
within each time period  t.  The logical  incorporation of lead time is  enforced by a 
binary variable Zpt. If a product p is selected for manufacture at time t a lead time, ap, 
will only be included in that campaign duration to account for the setup and cleaning 
if Zpt is equal to 1  (denoting the start of a new campaign).
Bpt=z pt+rp(T pt-apz pt)  0)
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Binary  variable  Yph  is  introduced  to  denote  whether  or  not  a  product  p  is 
manufactured at time t.  In order to enforce the correct activation of binary variable 
Zph constraint (2) is introduced. It enforces that Zpt will only be activated if product p 
is  not  manufactured  in  the  previous  time  period  t-l,  i.e.  it  is  the  start  of a  new 
campaign.
z Pt  ^ YPt ~ YP,t-1  V/?,*  (2)
In  order  for  the  production  constraints  to  capture  accurately  the  campaign 
changeover  considerations,  constraint  (3)  is  introduced  to  ensure  that  at most  one 
product p undergoes manufacturing at any given time period t.
Vf  (3)
P
5.3.1.2.  Timing Constraints
In some cases, manufacturers enforce minimum and/or maximum campaign lengths 
in  order  to  maximise  efficiency  or  to  allow  for  relevant  maintenance/slack. 
Constraints (4) and (5) represent the appropriate minimum and maximum production 
time  constraints,  where  Tpm in  is  the  minimum  campaign  duration,  Tpm ax  is  the 
maximum campaign duration and Ht is the size of the time horizon. These constraints 
are only active if Ypt is equal to 1, otherwise the production times are forced to 0.
T f*Y p t<Tpt  Vp,t  (4)
Tpl  H ,y pl  Vp.t  (5)
5.3.1.3.  Storage Constraints
The  following  constraint  enforces  an  inventory balance  for production  and  forces 
production to meet demand.  In constraint (6) the amount of product p stored at the 
end of the time period, Ipt, is equal to the amount stored at the previous time period, 
IPtt.u  plus  the  net  amount  produced  during  the  current  time  period,  Bpt,  less  the 
amount sold, Sph and the amount of product wasted, Wpt in the current time period.
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I  pt  Ip,t-l+Bpt  Spt  Wpt  Vp,t  (6)
Constraint (7) enforces that the amount of product p stored over period t cannot be 
negative and should not exceed the maximum available product storage capacity, Cp.
0< Ip t<Cp  vp ,t  (7)
In constraint (8) stored product is constrained by limited product lifetimes, whereby 
any product stored during time period t cannot be sold after the next C p time periods.
1  pt ~  Vp,t  (8)
0=t+1
5.3.1.4.  Backlog Constraints
To ensure that late batches are eventually produced a penalty is incurred for every 
time period t that a given batch of product p is late. For a given product p at time t 
the number of late batches, Apt is equal to the number of undelivered batches from 
the previous time period t-l, APit.j plus demand at time t, Dpt less the sales at time t, 
Spt.  Late  penalties  are  avoided  by  the  penalty’s  minimisation  in  the  objective 
function.
APt  = A Pt-\ +DPt~  s Pt  Vp> *   (9)
5.3.1.5.  Objective Function
The strategic  objective  in this  formulation is to maximise operating profit.  This  is 
represented  by  an  objective  function  which  is  considered  to  be  the  difference 
between “total  sales” with each batch sold at a price vp, and “total operating costs” 
which include the batch manufacturing cost at rjp per batch, changeover cost at y/p per 
batch, storage cost at pp per batch and late delivery penalties of Sp per batch. All costs 
and prices are in relative monetary units (rmu).
Prof  = ^   ~VpBpt~Vp^pt~Pplpt~5p&pt)  (10)
p  t
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The  complete  deterministic  formulation  [DET]  is  a  MILP  model  comprising 
constraints (1- 10). The following section derives the stochastic formulation.
5.3.2.  Stochastic Formulation
In this particular formulation the fermentation titres are considered to be uncertain as 
discussed in Section 5.1. They are captured as fluctuations in the production rate, rp, 
through the proposed CCP model.
The  CCP  approach  aims  to  satisfy  constraints  with  a  specified  probability  or 
confidence level  and provide the optimal solution at that confidence level (Chames 
and Cooper,  1959).  This requires the decision maker to  express a risk tolerance, in 
terms of a permissible probability of constraint violation which can be represented by 
a  corresponding  inverse  cumulative  distribution  factor  known  as  the  critical  K 
value,  . For the efficient solution of the problem formulation, the deterministic
equivalent  formulation  must  be  derived.  Deterministic  equivalent  formulations  of 
chance constraints can be derived using traditional probability theory concepts (Taha, 
2003). The case of uncertain production rates is now considered.
5.3.2.1.  Uncertain Production Rates
Consider the previous production constraint (1) from section 5.2.1.1 shown below.
where rp is an uncertain parameter with mean /u(rp) and standard deviation o{rp).
In order to set up the chance constraint, it must first be converted into an inequality. 
In a planning problem where production is maximised the logical replacement of the 
“equality” sign =, is the “less than or equal to” sign <, as production Bpt is maximised 
in order to satisfy demand.
Bpt ~ ~  Zpt + rp(Tpt  otpZpt) Vp,/ (1)
Bpt —  Zpt + rp (Tpt  a  pZ  pt) 01 )
Formulating this as a chance constraint:
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P r^ , < Zpt +rp(Tpt - a pZp,))> A (12)
where A, is a minimum prespecified probability that constraint (12) will hold true. 
The feasibility of constraint (12) is a “good” event as this ensures the correct number 
of batches are produced, hence A should be large (> 50%).
Rearranging constraint (12):
M BP t ~z pi^rP(Tpt - apz P t))s A (13)
Subtracting the mean of uncertain parameter y u(rp (Tpt - apZpt)) and dividing both sides 
of constraint (13) by the standard deviation o{rp (Tpt - apZpt)).
Pr
B Pt ~ z p t-M ^ p iT p t - a p z pt)) ^ rp (Tpt -<XpZ pt)-fJ-(rp (Tpt  ~ a p z p t) )  
a{ rp (Tpt - o cpZpt))  ”  ^pPpt ~apz pt))
> A
(14)
Call the right-hand side of the inequality K p^Tpl  apf pt^  ^T f> L\ apZpt ^ , h.
°\rp(Tpt ~aPzpt))
Pr
BPt ~z pt  - a pZpt))
< r ( r p{Tpt-apZpt))
> A (15)
Rearranging constraint (15):
1-Pr h<
B  pt  z   pt  / ^ (r p   pt  a   p Z   p t) )
°{rp(rpt - a pZpt))
> A (16)
Pr h<
Bpt  Zpt  M^piTpt  a p ^ p S ) ‘-pt  r*\’p\*pt
< r{rp(Tpt-apZpt))
< 1  - A (17)
Assuming  the  left-hand  side  of the  inequality  h,  is  a  stable  normally  distributed 
variable with  a mean  of 0  and  a variance  of 1,  the  chance  constraint  (17)  can be 
replaced  by  constraint  (18),  where  < f> ,  is  the  standardised  normal  cumulative 
distribution function.
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0f Bpt ~z pt -f^TpiTpt -  <XpZpt))A
v  airp ^pt  apZpt))  j
< 1  - A (18)
Applying the inverse of the standardised normal cumulative distribution function to 
constraint (18):
Bp, - Z  -d tp V p '-  < 0,-Vl - A)  (19)
Gyp^Tpt  apZpt))
Rearranging constraint (19), we get:
Bpt ^ z pt + W rp) + ° _1(1 - A).cr{rp)\Tpt - apZpt)  (20)
Finally, it follows naturally that  0 _1(1-A)  is equal to -0 _1(A). Hence in the chance 
constrained  programming  formulation,  constraint  (21)  below  becomes  the  new 
production constraint replacing constraint (1):
BP t ^Z pt+[^{rp)-<&-'(A).(T{rp))j'pt- apZpt)  (21)
The complete  deterministic  equivalent  formulation  [CCP]  becomes  a MILP  model 
comprising constraints (2 -   10) & (21). The following section illustrates the use of 
the proposed formulation through some illustrative examples.
5.4.  Illustrative Examples
Four  examples  are  solved  to  illustrate  the  applicability  of  the  proposed  CCP 
approach. All examples are solved assuming the production rate, rp is uncertain. For 
sensitivity purposes the examples are solved for two different variabilities, +/-  10% 
and +/- 20% variability in the production rate, rp. The results achieved using the CCP 
approach  are  compared  with  those  achieved  by  the  deterministic  model  (DET) 
presented in Section 5.2.1 which assumes mean values for the uncertain parameter rp,
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and the two-stage programming approach (CON/IMP) presented in Sections 4.2 and
4.3.
Similarly  to  Chapter  4,  Monte  Carlo  (MC)  simulation  was  used  to  conduct  a 
stochastic  analysis  for  each  of the  examples  solved  in order to  better quantify the 
impact of variability on the deterministic schedules, as well as for the validation of 
the  quality  of  solution  schedules  and  thus  the  realistic  expected  performance. 
Subsequent  to  the  solution  of  each  optimisation  model  the  resulting  scheduling 
decision variables Ypt and Zpt are fixed and a MC analysis is conducted for uncertain 
parameter  rp  and  the  expected  profit  (MCPROF)  is  computed.  The  convergence 
criteria for the MC simulation is a standard error of the mean of 1%.
The data used in the chance constrained programming approach assumes a mean of 
rp and a standard deviation of unc*rp where unc is a fractional value which signifies a 
symmetrical deviation representing the variability from the mean. For the two-stage 
multiscenario  model  three  discrete  outcomes  are  assumed  and  their  equivalent 
probabilities are derived by truncation of a standard normal distribution with mean rp 
and standard deviation unc*rp, by +/- 1  o and the results are shown in Figure 5.1.
Probabilitv of Production Rate Outcome
27.3%  45.4% 27.3%
(1 -unc)* rp  rp 
Production Rate Outcome
(1 +unc)* rp
Figure 5.1: Equivalent discrete probability distribution of  production rate rp, where unc is
the variability in rp
The  confidence  level  of chance  constraint  feasibility  for  A  is  assumed  to  be  90% 
which in standard normal distribution tables (Ott and Mendenhall, 1990) corresponds 
to a critical K value  of 1.282.  All problems were implemented in GAMS
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(Brooke  et  al.,  1998)  using  the  CPLEX  MILP  solver,  solving  all  problems  to
optimality. All runs were performed on a 1.8 GHz Pentium 4 PC with 512 MB RAM.
5.4.1.  Example Problem Data
The sizes of each of the four examples tackled are shown below:
•  Example 1: three products, nine time periods (1.5 year production time horizon).
•  Example 2: five products, ten time periods (1.7 year production time horizon).
•  Example 3: seven products, twelve time periods (2 year production time horizon).
•  Example 4: ten products, eighteen time periods (3 year production time horizon).
The data associated with Examples 1  to 4 are presented below.
•  A  multiproduct  facility  producing  p  mammalian-cell-derived  products  is 
assumed, with one, two or three product orders for each product.
•  A production horizon between 1.5 and 3 years long, split into t time periods each 
two months long, i.e. the production time horizon Ht, is 61 days long.
•  The due date and demand profiles  are shown in Tables 5.1  to  5.4.  Orders were 
assumed to be due at the end of each two month time period t. Early delivery is 
assumed to be infeasible and late deliveries are penalised for each late period.
•  Production rates, lead times and related parameters used in Examples  1   to 4 are 
shown in Table 5.5. Example 1   is assumed to include, P1-P3, Example 2, P1-P5, 
Example 3, P1-P7, and Example 4, PI-PI 0.
•  All lead times  ap are in “days” and are each  assumed to include seven days of 
product changeover related cleaning time.
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Table 5.1:  Demand profile for Example 1 *
Product Time Period
i  2 3 4 5 6 7 8 9
PI 3 2
P2 3 5
P3 2 5
*Note:  All demands are in number of batches
Table 5.2:  Demand profile for Example 2*
Product Time Period
1   2 3 4 5 6 7 8 9 1 0
PI 2
P2 3
P3 2 2 2
P4 2 3 2
P5 3
♦Note:  All demands are in number of batches
Table 5.3:  Demand profile for Example 3 *
Product  Time Period
1   2  3  4  5  6   7  8   9  10  U  12 _  _  _
P2  4
P3  2
P4  2  3
P5  2
P6   3  3
P7  3
♦Note:  All demands are in number o f batches
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Table 5.4: Demand profile  for Example 4*
Time Period 
Product  --------------------
1  2  3  4  5  6   7  8   9  10  11  12  13  14  15  16  17  18
PI  ~  4
P2  3
P3  2
P4  2  3
P5  2  3
P6   3 4
P7  3
P8   3
P9  2
P10  3
*Note:  All demands are in number o f batches
Table 5.5: Parameters used in Examples 1-4, 1: P1-P3, 2: P1-P5, 3: P1-P7 & 4: P1-P10
Product
Parameter data Sales price and Costs
r p
(batches/
day)
a  p  
(days)
'pmm
(days)
Price/Cost Symbol Unit Value
PI 0.05 30 2 0 Product Cp time periods 3
lifetime,
P2 0.0909 28 1 1
Storage Cp batch/day 6
P3 0.0625 32 16 Capacity,
P4 0.05 30 2 0 Sales price, v p rmu/batch 1 0
P5 0.08 31 12.5
Manufacturing h P rmu/batch 4
P6 0.05 30 2 0 cost
P7 0.0909 28 1 1 Storage cost P p rmu/batch 0 . 2
P8 0.08 31 12.5
Late penalty 8P rmu/batch 4
P9 0.05 30 2 0
P10 0.0909 28 1 1 Changeover V P rmu/batch 2
cost
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5.4.2.  Example Problem Results
All  four  examples  were  solved  using DET,  CCP  and  CON/IMP  at  10%  and  20% 
production rate rp variability and the computational results are shown in Table 5.6, 
while  Figure  5.2  shows  graphical  representations  of the  achieved  expected profits 
(MCPROF). A discussion on the impact of uncertainty, solution quality and solution 
times follows below.
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Figure 5.2: Graphical representations of achieved expected profits (MCPROF) for Examples 
1, 2, 3 and 4 using DET (deterministic model), CCP (Chance constrained programming 
approach) and CON/IMP (Iterative construction/improvement algorithm), where ♦ 
represents 10% variability and m  represents 20% variability.
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As was seen in Chapter 4 (which included Examples  1, 2 and 4 from this chapter) 
there is a considerable negative impact on operating profits when not accounting for 
uncertainty.  The CCP  approach is able to make considerable improvements on the 
deterministic  model  in  each  of  the  four  examples.  The  achieved  percentage 
improvement on the deterministic model by the CCP  and the CON/IMP  algorithm 
can be seen in Table 5.7.
Table 5.6: Computational results for Examples 1-4*.
Computational Optimisation Monte-Carlo
Results (CPU: in seconds) Simulation
Indicator OBJ CPU MCPROF
% variability for rp 10 20 10 20 10 20
DET 108.5 108.5 1 1 98.7 94.2
Example 1 CCP 106.7 96.7 1 1 106.9 102.9
CON/IMP 105.8 105.8 19 14 105.8 101.1
DET 109.5 109.5 1 1- 93.9 84.8
Example 2 CCP 102.9 76.9 1 3 100.9 93.8
CON/IMP 104.9 100.4 26 24 100.3 89.4
DET 135.7 135.7 1.3 1.3 110.8 98.5
Example 3 CCP 114.3 114.3 1 1 121.4 109.9
CON/IMP 135.8 131.2 18 17 114.4 102.1
DET 195.6 195.6 2.9 3.0 179.2 152.6
Example 4 CCP 193.6 171.8 4.3 18.8 191.6 168.0
CON/IMP 195 195 32 31 191.7 168.2
*Note:  Optimisation objective function (OBJ), Solution time in seconds (CPU) and Monte-Carlo 
simulation objective function (MCPROF); for results from DET (Deterministic model), CCP (Chance 
constrained programming approach) and CON/IMP (Iterative construction/improvement algorithm).
The  CCP  approach  is  found  to  make  considerable  improvements  over  the 
deterministic model as can be seen graphically in Figure 5.2 or numerically in Table 
5.7. Across all  examples the CCP  approach makes improvements of between 6.9% 
and  10.6%.  In all examples the higher variability scenario of 20% results in greater 
improvements in solution quality and hence higher potential monetary savings. The 
consistency  and  quality  of  the  improvements  can  be  attributed  to  improved 
scheduling decisions and hence more timely satisfaction of demands. Timely demand
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satisfaction  reduces  the  lateness  penalties  which  have  the  greatest  impact  on  the 
objective  function.  In  the  case  of  CCP  a  combination  of  improved  scheduling 
decisions and improved capacity utilisation leads to more timely demand satisfaction 
and lower productions costs, leading to an even greater improvement in profits.
Table 5.1: Percentage improvement in expected profit over the deterministic model solution
for Examples 1-4*.
% variability for rp 10 20
Example 1 CCP 8.3 9.2
CCP 7.5 10.6
Example 2
CON/IMP 6.8 5.4
CCP 9.6 11.6
Example 3
CON/IMP 3.2 3.7
CCP 6.9 10.1
Example 4
CON/IMP 7.0 10.2
CCP (Chance constrained programming approach) and 
CON/IMP (Iterative construction/improvement algorithm).
The  CCP  approach  consistently improves  on or matches  the  CON/IMP  algorithm. 
CCP  achieves up to  300% relative improvement over the solution quality achieved 
by the CON/IMP algorithm. However, the value of the CCP approach is not only in 
the  improved performance  of solution  quality under the  impact of uncertainty but 
also in the negligible increase in CPU time that is traditionally a cumbersome feature 
of typical multiscenario, stochastic programming models. When compared directly to 
the  CON/IMP  algorithm  from  a  solution  time  perspective,  CCP  generally 
outperforms  the  algorithm,  given  that  the  CCP  approach  does  not  employ  the 
scenario index k and hence generates a model size almost identical to that generated 
by the  deterministic  approach.  In  the  largest  example,  Example 4,  the number  of 
scenarios  that  would  be  generated  by  a  full-scale  multiscenario  representation 
assuming three discrete outcomes would be greater than 5.9 x  lCf4 scenarios, which 
would be difficult to solve in any reasonable timescale with conventional computer 
hardware. The computational requirements in all examples and variability scenarios 
are reasonable.  The  CPU  times  achieved by the  CCP  approach are  generally of a
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similar order of magnitude as  those  achieved by the deterministic model,  with the 
longest CPU time for CCP being less than  19  seconds.  Considering the size of the 
largest example solved,  this demonstrates the  exceptional  computational  efficiency 
of the proposed CCP approach.
5.5.  Conclusions
In  this  chapter,  a  mathematical  optimisation-based  framework  for  medium  term 
biopharmaceutical manufacturing planning under uncertainty has been presented, and 
tested on four illustrative examples of different size and at different variabilities. The 
problems  were  all  solved  using  a  deterministic  model  (DET),  a  two-stage 
programming model accompanied by an iterative construction algorithm (CON/IMP) 
and the proposed  chance constrained programming approach (CCP). The results of 
the MC  analysis  showed that CCP  consistently improved on the results of DET in 
terms of profitability. While when compared with the CON/IMP algorithm the CCP 
approach was able to match or improve on it in terms of both solution quality and 
computational time.
5.6.  Nomenclature
Indices
p  product
t, 0  time periods
Parameters
Cp  storage capacity of product p, batches
D pt  demand of product p at time period t
r  production rate of product p, batches per unit time
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H t available production time horizon over time period t
rp max 
1  P maximum production time for product p
rpmin
1  P minimum production time for product p
(X  p lead time for production of first batch of product p
Cp life time of product p, number of time periods t
Vp unit sales price for each batch of product p
nP unit cost for each batch produced of product p
v P unit cost for each new campaign of product p
s p unit cost charged as penalty for each late batch of product p
Pp unit cost for each stored batch of product p
P(rp) the mean value of production rate and is equivalent to rp
o(rP ) the standard deviation of production rate rp
0 1 inverse of the standardised normal cumulative distribution function
Binary Variables
YP« 1  if product p is produced over period t\ 0 otherwise
Z pt 1  if a new campaign of product p is started in period t; 0 otherwise
Continuous Variables
I pt amount of product p stored over period t
Prof operating profit
s pt amount of product p which is sold over period t
TPt production time for product p at time period t
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Ttott  total production time over period t
Wpt  amount of product p wasted over period t
A pt  amount of product p which is late over period t
Integer Variables
Bpt  amount of product produced over period t
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Multiobjective Long Term Planning 
of Biopharmaceutical Manufacturing
F acilities
6.1. Introduction
In  the  previous  Chapters  (3-5),  approaches  for  medium  term  planning  of 
biopharmaceutical  manufacture were presented,  whereby the focus was production 
planning  of a  single  biopharmaceutical  facility.  Both  deterministic  and  stochastic 
approaches  were  developed.  However the models  did not  account  for longer term 
strategic objectives, where multiple facilities are often considered simultaneously. As 
an increasing number of large-scale biopharmaceutical companies have a portfolio of 
commercial products on the market as well as a pipeline of candidates under clinical 
evaluation,  developing a comprehensive manufacturing strategy to meet anticipated 
demands  for  both  clinical  trial  and  market  material  requires  careful  capacity 
planning.  Consequently,  more  effective methods  are required to manage  and align 
production across several multiproduct facilities, including third party organisations, 
so as to ensure the availability of sufficient capacity. However, determining capacity 
needs  for  biopharmaceutical  production  is  often  a  difficult  process  requiring
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predictions  of product doses,  market forecasts,  production rates  (titres,  yields)  and 
clinical/technical success rates.
Hence in this chapter we consider the issue of long term production planning in the 
biopharmaceutical  industry.  The work  in this  chapter is motivated by an  industrial 
case study based upon a large-scale biopharmaceutical manufacturer who wishes to 
improve their long term  planning  decisions  and to  explore the impact of different 
strategic  decision  making policies.  We  present  an  MILP  formulation  for  the long 
term production planning of biopharmaceutical manufacture and later extend it via a 
goal programming formulation to account for multiple objectives. The industrial case 
study  is  solved  and  analysed  to  demonstrate  the  applicability  of the  model  and 
highlight  some  of  the  key  challenges  within  strategic  decision-making  in  the 
biopharmaceutical industry.
6.2.  Problem Features
The biopharmaceutical supply chain is comprised of two main stages much like that 
of  the  pharmaceutical  industry,  namely  primary  (or  bulk)  manufacture  which 
involves the production of the  active  ingredient  and secondary manufacture which 
involves formulation and packaging.  The focus of this chapter is on manufacturing 
production planning across  a network of facilities to satisfy bulk product demands. 
The  key  features  of the  problem  particularly  those  highlighted  in  this  work  are 
discussed below.
6.2.1.  Plant Capacity
For a good estimate of a manufacturer’s capacity availability and requirements the 
key features  of biopharmaceutical manufacturing must be captured.  These features 
include the long production lead times encountered and the level of time granularity 
used  for  the  planning  horizon.  This  should  be  sufficiently  fine  to  mimic  the 
“campaign”  style  manufacture  often  adopted  in  the  biopharmaceutical  industry, 
which is typically 2  to  3  months per campaign.  A manufacturer often uses owned
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facilities  and/or  contractors  with  differing  manufacturing  rates,  yields,  production 
capabilities and availabilities. These need to be represented explicitly and are often 
based on forecasted yields and product success rates.
6.2.2.  Product Storage
Product  instability  and  hence  shelflife  is  an  important and  often  costly feature of 
biopharmaceuticals.  Products are often frozen via specialised storage methods such 
as  cryopreservation  offering manufacturers  increased  flexibility for scheduling and 
planning  (Wilkins  et  al.,  2001).  Shelflife  is  of great  significance  to  the  effective 
management of inventory given that some products are required in very small doses 
but produced in larger bulk orders (economies of scale) requiring products to be held 
to meet future order dates.
6.2.3.  Product Pricing, Demand and Backlog
Product pricing is established through research with physicians, patients, payers, and 
advocacy groups and are also impacted by a drug’s uniqueness, competitive pricing 
strategies and socio-political factors (Snow et al., 2005). Meeting product demand in 
the biopharmaceutical industry is a highly sensitive issue due to the high value of the 
products involved.  Mallik  (2002)  estimates that the lack of manufacturing capacity 
for Immunex’s highly successful  arthritis drug Enbrel  cost the company more than 
$200 million in lost revenue in 2001, while Shah (2004) notes that Eli Lilly’s 20% 
drop in net profits coincided with Prozac coming off patent. Hence companies must 
therefore strive to capture every day of revenue generation by ensuring an adequate 
supply of product.  Penalties  should ensure that late deliveries are made as soon as 
possible.  If demands  are unmet by their order dates, backlog of demand  should be 
captured to ensure that demands are met as soon as possible. However, typically the 
importance  of satisfying  backlogged  orders  decays  with  time  as  new  orders  take 
precedence.
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6.2.4.  Strategic and Operational Objectives
There are many possible strategic and operational objectives for a biopharmaceutical 
manufacturer as there are many different stakeholders and both internal and external 
pressures.  Hence  the  strategic  decision making policies  a manufacturer  adopts  are 
likely  to  have  varying  consequences  on  different  performance  measures.  Even 
though the livelihood of a business is inevitably governed through the maximisation 
of its shareholder value,  there are many constraints to meeting this long term goal. 
Possible  objectives  include  maximising  profit,  maximising  sales,  maximising 
customer  service  level,  minimising  costs,  and  minimising risk to  name but a few. 
Other  objectives  are  to  meet  targets  such  as  satisfying  fixed  cost  or  capacity 
utilisation  targets  and  hence  might  not  be  expressed  as  outright  maximisation  or 
minimisation problems.
We  first  consider  a  common  single  objective  problem  where  operating profits  are 
maximised,  followed  by  a  multi-objective  problem  where  the  three  objectives 
considered  are:  operating  costs,  customer  service  level  and  capacity utilisation  of 
owned  facilities.  Operating  cost  targets  are  usually  dictated  either  by  budget 
constraints or a drive to be more cost-effective. Customer service levels may also be 
set  as  strategic  targets  to  ensure  that  customer  demand  is  met  on  time.  Another 
important issue from an operational perspective is plant capacity utilisation; Mallik 
(2002)  estimated  that  in  a  typical  new  mammalian  cell-culture  facility  revenues 
would be boosted by $380M by a 25% increase in plant utilisation.  Manufacturers 
often have strategic capacity utilisation targets for their owned facilities (adjusted for 
market uncertainty  and manufacturing risks),  in order to  ensure high utilisation of 
their facilities and hence minimise facility carrying costs (idle facility costs) and the 
need  for  outsourced  capacity.  Another  feature  incorporated  here  is  manufacturing 
risk,  whereby  it  is  defined  as  the  risk  of a  manufacturing  facility  outage  due  to 
unforeseen  circumstances  such  as  a  contractor  manufacturer  dispute  or  natural 
disaster.
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6.3.  Problem Statement
The problem of long term planning of biopharmaceutical manufacture may be stated 
as follows.
Given:
•  A set of facilities.
•  A set of products.
•  A production time horizon.
•  Production rates, yields and lead times.
•  Product lifetimes and storage capacities.
•  Product demands and sales prices.
•  Backlog decay factor.
•  Manufacturing, changeover, storage costs and late delivery penalties.
•  Minimum and maximum campaign durations.
•  Goal Target values and weights for: Cost, service level and capacity utilisation.
Determine:
•  Campaign durations and sequence of campaigns.
•  Production quantities along with inventory profiles.
•  Product sales and late deliveries profile.
•  Achieved goal levels vs. aspired goal targets.
So as to
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•  Maximise manufacturing profits (Single objective problem).
•  Minimise  the  total  adverse  deviations  from  the  selected  goal  targets 
(Multiobjective problem).
6.4. Mathematical Formulation
The formulation presented here is based on the work presented earlier (Section 3.2) 
where we tackled a deterministic medium term planning problem. Here the focus is 
shifted  to  longer  term planning allowing  for multiple  facilities.  A  single  objective 
formulation  is  presented  first,  before moving to  a  goal  programming  extension to 
allow for multiple objectives.
6.4.1.  Long Term Planning Formulation
An  index  i  denoting  facility  is  introduced  to  the  formulation  presented  earlier 
(Section  3.2)  to  allow  for multiple  facilities.  This  manufacturing representation  is 
more  akin  to  a  multisuite  configuration  than  that  of  a  multisite  one  with 
geographically  distinct  sites  as  features  such  as  transportation  costs  and  differing 
taxation regions are not considered. Subsets are introduced for facility manufacturing 
capability, PIt the set of products produced by facility i and for facility availability, 
product manufacturing capability, IPp the set of facilities that can produce product p 
Tf the set of time periods in which facility i is available for use.
6.4.1.1.  Production Constraints
Constraint  (1)  represents  biopharmaceutical  production.  The  number  of  batches 
produced  in  facility  i  of product  p  at  time  period  t,  Bipt,  an  integer  variable,  is 
represented by a continuous production rate, rip, which is combined with production 
lead time, aip. This allows for the duration of the first batch of a campaign plus the 
set-up and cleaning time before the first batch is started. Production time, Tiph shows 
the duration of manufacture in facility i of product p at time period t. Incorporation
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of lead  time  is  enforced  by  a  binary  variable  Zipt.  If  a  facility  i  is  selected  to 
manufacture  a  product p  at  time  t  a  lead  time,  aip,  will  only be  included  in  that 
campaign duration to account for the setup and cleaning if Zipt is equal to 1  (denoting 
the start of a new upstream/downstream campaign). Constraint (2) is introduced for 
the conversion of the integer number of batches produced, Bipt, into kilograms, Kipt, 
via a yield conversion  factor, ydiP,  specific to  every product p  and facility i.  (This 
differs  for  different  facilities  even  for  the  same  product  as  it  allows  for  different 
batch sizes and product titres).
Bipt  = Zipt  + nP  (Tipt  ~ a ipZipt)  \fi,p e PIt,t  e 77f  (1)
K iPt  =Bipt yd ip  V i> e PIt, t  e 77;  (2)
Binary  variable  Yiph  is  introduced  to  denote  whether  or not  a  facility  i  is  used  to 
manufacture a product p  at time t.  In order to  enforce the relevant production lead 
times constraint (3)  is introduced.  It enforces that Zipt in constraint (1) will only be 
activated if product p is not manufactured at a facility i in the previous time period t- 
1, i.e. it is the start of a new campaign upstream.
z iPt  ^ YiPi -  YiP,i-\  V‘>pe p ii’(  e n i  (3)
In order for the production constraints to capture the required campaign changeover 
considerations,  constraint  (4)  ensures  that  at  most  one  product  p  undergoes 
manufacturing in any given facility i at any given time period t.
Y / ‘P‘ - X   ViJeTf,  (4)
pzPli
6.4.1.2.  Timing Constraints
In some cases, manufacturers enforce minimum and/or maximum campaign lengths 
in  order  to  maximise  efficiency  or  to  allow  for  relevant  maintenance/slack. 
Constraints (5) and (6) represent the appropriate minimum and maximum production 
time  constraints,  where  Tipmin  is  the  minimum  campaign  duration,  Tipm ax  is  the
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maximum campaign duration and Ht is the size of the time horizon. These constraints 
are only active if Yipt is equal to 1, otherwise the production times are forced to 0.
Tb * Yipt  ^ TiPt  VUp e PIi9t g 77;  (5)
Tip, ^ m in ^ ax, H, \ ipt  Mi, p<EPIi>te TIt  (6)
Constraint (7) shows the facility production time, Tfittot for all products is equal to the 
summation of the individual production times for each product p.
rpr tot  rp
Jit  -   2 ^   ip1   Vi,fe77f   (7)
pzPf
6.4.1.3.  Storage Constraints
The  following  constraint  enforces  an  inventory balance  for production  and  forces 
total production to meet product demand.  In constraint (8) the amount of product p 
stored at the end of the time period Ipt, is equal to the amount at the previous time 
period Ipt.\, plus the total number of batches produced during the time period for all 
products  across  all  facilities  i,  Bipt,  less  the  amount  sold,  Spt,  and  the  amount  of 
product wasted,  Wpt in the current time period t.
Ipt = Ip,t-1 + ^ K ipt -  s pt -  Wpt  Vp  e  PI  I, t  e   77,-  (8)
i
Constraint (9) enforces that the amount of product p stored over period t  cannot be 
negative  and  should not  exceed  the maximum product storage capacity,  Cp.  While 
constraint (10) enforces that the sum of the total inventory held at any given time t 
cannot exceed the global storage capacity CPtot.
0 <Ipt<Cp  Vpf  (9)
0 < 'Y JI p ,± C P ,0‘  Mt  (10)
P
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In  constraint  (11),  the  duration  a  product  is  stored  for  (shelf-life)  is  limited  by 
product-lifetimes.  It effectively ensures that final product is sold in less than fp  time 
periods from when it is first stored.
Ipt-zl,sp e   vp,t   (ll)
0=t+1
6.4.1.4.  Backlog Constraints
To  ensure that late batches  are eventually produced a penalty is incurred for every 
time period t that a given batch of product p is late. For a given product p at time t 
the number of late batches, Apt is equal to the number of undelivered batches from 
the previous time period t-1  multiplied by a factor np which allows for the backlog to 
decay  (due  to  the  diminishing  importance  of the backlogged  orders),  KpAp_ t.i plus 
demand at time t, Dpt less the sales at time /, Spt.  Late penalties are avoided by the 
penalty’s minimisation in the objective function.
V   = V V - i+ zV _5p'  (12>
6.4.1.5.  Risk Constraints
The risk of a  facility outage  due to  an unforeseen circumstance such as  a natural 
disaster or a dispute with a contract manufacturer or any other circumstance must be 
mitigated.  A  facility  should  be  enforced  to  meet  demands  by  producing  a  given 
product  in  at  least  two  different  facilities  where  possible.  In  some  cases  product 
demands  may  be  too  small  or  only  one  facility  may be  capable  of producing  a 
particular product.  In such cases products to be constrained are included in a subset, 
RS,  the  set  of products  which  should  be  manufactured  in  at  least  two  different 
facilities.
A new set is introduced, TBb the set of time periods in a time block b. This allows the 
specification  of a  time  window  in  which  to  enforce  products  to  be manufactured 
more than once. A new binary variable Yipb ew which is activated if a facility i is used 
to  manufacture  a  product p  within  a  time  block  b.  Constraint  (13)  enforces  any
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product belonging to the set RS  to be produced in at least two different facilities i 
within any time block b.  Constraint (14) relates  YiPbnew to binary variable  Yipt while 
production time Tipt is related through constraints (5) and (6).
y n e w   ry
• r‘ >*  - z  \/peR S,b  (13) I
ieIPp
X  V  'b . vnew
2 ^   ipt ~  ipb  V/ e IPp,p e RS,b  (14)
teTBb n77f
6.4.1.6.  Objective Function
The objective function “maximise profit” is represented here and is considered to be 
the difference between  “total  sales”  with  each batch  sold  at  a price vp,  and  “total 
operating  costs”  which  include  the  batch  manufacturing  cost  at  rjp  per  batch, 
changeover  cost  at  yip  per  batch,  storage  cost  at  pp per  batch  and  late  delivery 
penalties of Sp per batch. All costs and prices are in relative monetary units (rmu).
[Model SINGLE]
Maximise
Prof = ^   ^  \vpfipt — pptpt — Sp/lpt~^  'jkpftipt+ySjffijpt))  (15)
p teTli  iIPp
Subject to: constraints (1 -  14).
The complete formulation SINGLE encompassing equations (1-15) corresponds to 
a mixed-integer linear programming (MILP) model.
6.4.2.  Goal Programming Formulation
Here we  consider the  case  of multiple  objectives.  Many methodologies have been 
proposed  for  treating  multiobjective  optimisation  problems  (Miettinen,  1999).  A 
general  review  of  the  application  of  multiobjective  optimisation  in  chemical
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engineering  is  presented  by  Bhaskar  et  al.  (2000).  A  number  of multiobjective 
optimisation  methods  have  been  applied  to  supply  chain  and  strategic  planning 
problems,  including  Life-Cycle  Assessment  (LCA)  (ISO,  1997)  which  is  a 
quantitative  environmental  performance  tool,  based  around  mass  and  energy 
balances  but  applied  to  a  complete  economic  system rather than  a  single process. 
Azapagic  and  Clift  (1999)  applied  LCA  across  supply  chains  to  improve 
environmental  performance,  by  generating Pareto  fronts  and trading  off economic 
performance.  The  s-constraint  method  (Haimes  et  al.,  1971)  is  based  on  the 
maximisation  of one  objective  function  while  considering  the  other  objectives  as 
constraints bounded by some allowable levels eo. Then, the levels so may be altered 
to  generate  the  entire  Pareto-optimal  set.  Sabri  and  Beamon  (2000)  presented  a 
multiobjective  supply  chain  optimisation  model  which  employed  the  s-constraint 
method  for  the  simultaneous  strategic  and  operational  supply  chain  planning. 
Multiobjective  decision  analysis  was  adopted  to  allow  the  use  of a  performance 
measurement  system  that  included  cost,  customer  service  levels,  and  flexibility 
(volume  or  delivery).  The  model  incorporated  production,  delivery,  and  demand 
uncertainty, and aimed to provide a multiobjective performance vector for the entire 
supply chain network. Guillen et al  (2005) combined the s-constraint method with a 
two  stage  programming  model  to  tackle  the  problem  of design  and  retrofit  of a 
supply  chain  network  consisting  of  several  production  plants,  warehouses  and 
markets,  and  the  associated  distribution  systems.  The  authors  considered  profit, 
demand  satisfaction  and  financial  risk  allowing  for  uncertainty  in  demand,  and 
generated  a  Pareto  set  of solutions  to  aid the  decision maker.  Another commonly 
utilised  approach  in  tackling  multiobjective  optimisation  problems  is  goal- 
programming  (Chames  and  Cooper,  1961)  which  is  a  generalisation  of  linear 
programming to handle multiple,  normally conflicting objective measures.  Each of 
these measures is given a goal or target value to be achieved. Unwanted deviations 
from this set of target values are then minimised as an achievement function. Zhou et 
al.  (2000)  presented  a  multiobjective  optimisation  framework  in  which  goal 
programming and  the  analytic hierarchy process,  a multiobjective decision making 
method used to  evaluate the priorities  of goals  and weights of deviation variables, 
were combined to tackle the issue of sustainability in supply chain optimisation and
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scheduling  of  a  petrochemical  complex.  Multiple  objectives  including  social, 
economic,  resources  and  environmental  sustainability;  some  of  which  were 
conflicting, were considered.
Each of the multi objective optimisation methods considered above is based on the 
conversion of a vector of objectives into a scalar objective. Given that optimisation 
of a  multiobjective  problem  is  a  procedure  looking  for  a  compromise  policy,  the 
resulting Pareto-optimal or noninferior solution set consists of an infinite number of 
options. In order to be able to suggest a specific point within this set, some attempts 
have been made to compare the objectives between them, for example optimising a 
Nash-type  function  (Gjerdrum  et  al.,  2001),  defining  the  objectives  as  fuzzy  sets 
(Chen et al.,  2003)  or  adding the  consideration of the decision-maker input in the 
problem formulation Rodera et al. (2002).
A goal programming approach has been adopted so as to demonstrate the trade-offs 
between selected objectives for the following reasons:  1) goal programming does not 
dramatically  increase  the  problem  complexity/size,  2)  no  specific  conditions  are 
required  to  achieve  the  solutions,  and  3)  goal-programming  is  simple,  since  it 
transforms the multi objective problem into a single-objective optimisation problem. 
There are several types of goal programming formulations (lexicographic, minimax, 
weighted,  extended  &  interval).  Tamiz  et  al.  (1995)  noted  that  lexicographic  and 
weighted goal  programming represented  85% of goal programming applications in 
the literature. Lexicographic goal programming was found to be too computationally 
intensive  given  the  size  of the  problem  considered  in  this  work.  Hence,  weighted 
goal  programming  (WGP)  is  the  method  presented,  whereby  the  normalised 
unwanted deviations  are  assigned weights according to their relative importance to 
the decision-maker and minimised as an Archimedean sum (sum up to 1).
Here,  three different  goals, g,  are considered:  cost,  service level  (csl)  and capacity 
utilisation (util). Three key variables are introduced to relate the goals and aid their 
attainment:  the goal target for each goal g,  GTg, the goal level of each goal g,  GLg, 
and the goal difference/deviation for each goal g, GDg dev. The deviation dev can be 
positive,  pos,  or  negative,  neg,  whereby  both  GDgi  p0S,  and  GDg >   neg,  are  positive 
variables.  The  goal  difference  GDg >   dev  is  equivalent  to  the  absolute  difference
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(differential) between the aspired goal target GTgj and the achieved goal level  GLg, 
for each goal, g.
6.4.2.1.  Operating Costs
Constraint (16) shows the cost goal which is defined as the total operating costs for 
all facilities, whereby the goal level for cost, GLcost is equal to the summation of the 
inventory,  late  delivery penalties,  manufacturing costs,  and  changeover costs.  This 
should be minimised to at least meet its aspired target level, GTC 0 S t-
6.4.2.2.  Customer Service Level
Constraint (17) shows the customer service level (CSL) goal which is defined as the 
proportion of the demand which is met on the due date. This is a similar concept to 
OTIF (on time and in full) (Gjerdrum et al., 2001).  Constraint (18) shows the CSL 
goal level, which is given as a percentage for each time period t, GLTcsi t and is equal 
to  the  difference  between  the  total  sales  minus  any  backlogged  batches  as  a 
proportion of the total demand. A subset DT is introduced and represents the set of 
time periods in which product demands are due.
GL cost ^   ^  '  (Pplpt + dp&pt)+ ^  ' (flipBipt ^Wjp’ Ljpt) (16)
p<=PI' te T f V y
gltcsK,  = ,o o * X
Spt  ^p,t-1
(17) VteDT
p
TcLTcsi,t
card(DT)
(18)
6.4.2.3.  Capacity Utilisation
Constraint (19) shows the capacity utilisation goal which is defined as the utilisation 
of available manufacturing time for each facility. Constraint (20) shows the capacityChapter 6. Multiobjective Long Term Planning of  Biopharmaceutical Manufacturing Facilities
utilisation goal level which is given as a percentage for each facility i, GLIutm and is 
equal  to  the  total  manufacturing  time  for each  facility,  Tfittot,  divided by the  total 
available  manufacturing  time  for  each  facility,  where  A[  is  a  scalar  denoting  the 
proportion of the time horizon that facility z  is available.
100*  >  Tf‘°'
GU  ~ , c a r dlA,  W  <19>
A subset OS is introduced and represents the set of facilities which are owned by the 
manufacturer and hence are required to meet strategic capacity utilisation targets. As 
shown in constraint (20) the goal level for capacity utilisation, GLutii, is equal to the 
average  capacity utilisation  over all  owned  facilities.  This  should be minimised or 
maximised to meet its aspired target level, GTutn, exactly.
TG U utU j
GLutil=i^ -----------  (20)
uM  card {OS)  V   '
6.4.2.4.  Normalisation Constraints
Constraint  (21)  and  (22)  represent  normalisation  constraints  for the  goals  and  the 
goal  deviations  respectively,  whereby  each  goal  is normalised to  100.  Goal  levels, 
GLg  and  goal  deviations,  GDgdev  are  multiplied  by  100  and  divided  by  the  goal 
targets  GTg. Normalisation is often desirable for the unbiased optimisation of goals 
of different magnitudes, meaning that the optimisation bias is completely transferred 
to the decision maker via the specification of goal weights.
GL„ *100
G Lnorm  =   g    y   (21)
g  G T   &
GD„dev *100
GZ)“ ™v= — — -------  Vg.rfev  (22)
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Constraint (23) represents the goal balance, where the normalised goal level for each 
goal, plus the negative and positive goal differences for each goal are equal to 100.
GLn gorm + GDn g°™  -  GD"g°™  = 100  G D ™  GD™™  > 0, Vg  (23)
6.4.2.5.  Objective Function
The objective function for the multiobjective optimisation problem (MULTI) is the 
minimisation of the weighted sum of the normalised deviations from all goal target 
values and is shown below, where WTgidev  is the weight of each goal deviation.
[Model MULTI]
Minimise
Sumd= Z Z ^ - G^ ™   (24)
g  dev
Subject to: constraints (1-14 & 16-23).
The  complete  formulation  MULTI  encompassing  equations  (1-14  &  16-24)  also 
corresponds to a mixed-integer linear programming (MILP) model. The applicability 
of the model will now be demonstrated via an industrial case-study.
6.5.  Industrial Case-Study
As an example of an industrial application, a case study based on a real-life planning 
problem  facing  a  large-scale  biopharmaceutical  manufacturer  is  presented.  This 
represents a typical capacity management problem in the biopharmaceutical industry, 
whereby a manufacturer has  a mix  of owned  and  contract manufacturing facilities 
available  to  them  and  must  decide  how  to  best utilise this  capacity.  A number of 
studies are presented based on the industrial case data and an analysis is conducted 
with relevant insights drawn.
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First  the  problem  data  is  presented,  followed  by  a  demand  analysis  and  a 
quantification of the impact of allowing for manufacturing risk through the activation 
of the risk constraint. A capacity analysis is then conducted in order to establish the 
manufacturer’s  capacity  needs.  Finally  the  multi objective  problem  is  presented, 
whereby  different  operating  policies  and  cost  target  levels  are  investigated  and 
discussed.
6.5.1.  Problem Data
This  problem  presents  a  challenging  long  term  planning  problem  in  the 
biopharmaceutical  industry,  whereby  a  manufacturer  needs  to  decide how  to  best 
utilise  ten  manufacturing  facilities  for  the  production  of fifteen biopharmaceutical 
products,  over  a  fifteen-year  time  horizon.  The  problem  definition  and  associated 
data are given below:
•  Ten  manufacturing  facilities  (il  -   ilO),  of which  il,  i4,  i6  and  i9  are  owned 
facilities while the rest are CMO, producing fifteen biopharmaceutical products 
(pl-pl5).
•  A fifteen year time horizon is assumed from 2006 -  2020, with 60 time periods t 
each  three  months  long,  i.e.  the  production  time  horizon Ht,  is  87  days  long 
(discounting 5% for maintenance time).
•  The due date and demand profiles are shown in Table 6.1. Orders are assumed to 
be due at the end year, i.e. every four time periods. Early delivery is assumed to 
be infeasible.
•  Table 6.2 shows the facility capabilities. All facilities are assumed to be available 
throughout the time horizon, apart from facility 6 (i6) which is unavailable until, 
2007 (t5), and facility 9 (i9) which is unavailable until 2016 (t41). Minimum and 
maximum campaign durations are assumed to be 0 and 87 respectively.
•  Production  rates,  manufacturing  yields  and  manufacturing  costs  are  shown  in 
tables 6.3, 6.4 and 6.5 respectively. All remaining parameters are shown in Table 
6.6.
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Table 6.1: Product demands for industrial case study
Year 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Pi 21 32 18 28 61 104 153 156 164 63 161 162 162 163 165
p2 6 5 4 4 4 3 3 3 3 3 3 3 2 2 2
P3 12 43 38 5 22 52 97 132 133 135 137 118 109 100 90
p4 583 628 655 687 758 921 989 941 993 649 621 573 521 468 421
p5 12 12 11 10 9 7 6 5 4 3 2 2 2 2 3
p6 211 200 245 246 257 266 284 274 226 180 166 151 137 123 110
P7 4 5 5 7 6 5 8 9 8 9 7 7 6 5 5
p8 5 5 5 7 6 5 8 9 8 9 7 7 6 5 5
p9 15 15 15 13 12 9 8 6 5 4 3 3 2 2 2
plO 72 99 104 102 111 120 130 139 188 120 106 93 81 69 58
pll 552 615 699 737 743 733 684 572 518 471 424 381 342 307 274
p!2 5 5 5 7 6 5 8 9 8 9 7 7 6 5 5
pl 3 211 252 290 298 286 216 169 153 150 145 110 100 93 84 102
pl4 2 2 4 3 3 3 16 11 13 16 16 16 16 17 17
pi 5 4 4 5 6 16 11 24 32 37 40 41 42 42 43 44
Note:  All demands are in kilograms
Table 6.2: Facility capability  for industrial case study
Pi p2 p3 p4 p5 p6 p7 p8 p9 plO pH pl 2 pl 3 pH pl 5
il Yes Yes No Yes No Yes No Yes Yes Yes Yes Yes No Yes Yes
i2 Yes No No Yes No Yes No Yes No Yes Yes No Yes Yes Yes
i3 No No No No No No No No No No No No Yes No No
i4 No No No Yes No No No No No No No No No No No
i5 No No No Yes No No No Yes No Yes Yes No No Yes Yes
i6 No No No Yes No No No Yes No Yes Yes No No Yes Yes
il No No No No No No Yes No No Yes No No No No No
i8 No No Yes No Yes No No No No No No No No No No
i9 Yes No No Yes No Yes No No No Yes Yes No No Yes Yes
ilO Yes Yes No Yes No Yes No Yes Yes Yes Yes Yes Yes Yes Yes
Note: il, i4, i6 and i9 are owned facilities
Table 6.3: Production rates for industrial case study
Pi P2 p3 p4 p5 p6 P7 p8 p9 plO Pll P12 pl 3 p 14 pl5
il 0.35 0.39 0 0.45 0 0.29 0 0.35 0.25 0.39 0.41 0.39 0 0.12 0.35
i2 0.6 0 0 0.61 0 0.6 0 0.6 0 0.43 0.56 0 0.6 0.6 0.6
i3 0 0 0 0 0 0 0 0 0 0 0 0 0.23 0 0
i4 0 0 0 0.12 0 0 0 0 0 0 0 0 0 0 0
i5 0 0 0 0.45 0 0 0 0.45 0 0.45 0.45 0 0 0.45 0.45
i6 0 0 0 0.45 0 0 0 0.45 0 0.45 0.45 0 0 0.45 0.45
il 0 0 0 0 0 0 0.45 0 0 0.45 0 0 0 0 0
i8 0 0 0.58 0 0.45 0 0 0 0 0 0 0 0 0 0
i9 0.45 0 0 0.45 0 0.45 0 0 0 0.45 0.45 0 0 0.45 0.49
ilO 0.45 0.45 0 0.45 0 0.45 0 0.45 0.45 0.45 0.49 0.45 0.45 0.45 0.45
Note: All rates are in batch/day and il, i4, i6 and i9 are owned facilities
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Table 6.4: Manufacturing yields for industrial case study
Pl p2 p3 p4 P5 p6 p7 p 8 p9 plO p ll p l 2 p l3 p l4 pl 5
il 10 1 0 8 0 6 0 10 2 9 7 1 0 12 12
i2 9 0 0 8 0 6 0 9 0 8 10 0 10 12 11
i3 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0
i4 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0
i5 0 0 0 10 0 0 0 10 0 8 8 0 0 11 11
i6 0 0 0 12 0 0 0 10 0 8 17 0 0 17 14
i7 0 0 0 0 0 0 10 0 0 10 0 0 0 0 0
i8 0 0 36 0 10 0 0 0 0 0 0 0 0 0 0
i9 10 0 0 12 0 5 0 0 0 8 16 0 0 12 13
ilO 9 1 0 12 0 5 0 10 2 8 14 1 10 12 12
Note: All yields are in kilograms/batch and il, i4, i6 and i9 are owned facilities
Table 6.5: Manufacturing costs for industrial case study
Pl p 2 p3 p4 p5 p 6 P7 p 8 p9 plO p ll pl 2 pl 3 p 14 pl 5
il 1 1 0 10 0 3 0 1 1 1 3 1 0 1 1
i2 10 0 0 5 0 2 0 5 0 10 2 0 2 5 2
i3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
i4 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
i5 0 0 0 2 0 0 0 0 2 0 0 2 0 2 0 0 0 5 2 0
i6 0 0 0 10 0 0 0 10 0 10 10 0 0 1 10
i7 0 0 0 0 0 0 10 0 0 10 0 0 0 0 0
i8 0 0 1 0 5 0 0 0 0 0 0 0 0 0 0
i9 10 0 0 10 0 10 0 0 0 10 8 0 0 1 10
ilO 15 15 0 15 0 15 0 15 15 15 15 15 15 15 15
Note: All costs are in rmu’s and il, i4, i6 and i9 are owned facilities
Table 6.6: Parameter data for industrial case study
Price/Cost  Unit  Value
Production lead time days 14
Product lifetime time periods 8
Sales price rmu/batch 2 0
Storage cost rmu/batch 0.1
Lateness penalty rmu/batch 0.1
Changeover cost rmu/batch 2
Backlog decay unitless 0.5
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6.5.2.  Demand Analysis and Risk Constraint Impact
The industrial case is formulated using the single objective model detailed in Section
4.1  and using the data shown above the “base case” problem is solved. The base case 
is  solved  twice,  with  and  without  the risk  constraint activated,  whereby the set  of 
products  that  can  be  produced  in  more  than  one  facility  and  are  seen  to  be  of 
considerable  strategic  importance  includes  pl,  p4,  p6,  plO,  pll  and  pl3.  This  is 
repeated  for  two  other  demand  scenarios,  low  demand  (50%  of  the  base  case 
demand) and high demand (150% of the base case demand).
The computational  results  and key performance measures  are  shown in Table  6.7, 
and  include:  total  product  demand  (kg),  total  product  sales  (rmu),  total  operating 
costs (rmu), total profit (rmu), customer service level (CSL) which is the percentage 
of batches  which  are met  on  time,  average utilisation  (UTIL)  of owned  sites,  and 
sales to demand ratio (S/D) which is the proportion of total demand that is met by the 
end of the fifteen year time horizon.
In the base case the risk constraint is found to result in a 2.7 % increase in operating 
costs due to the extra operating costs (changeover and manufacturing) incurred as a 
result of the additional campaigns required in order to satisfy the risk constraint. The 
impact on sales, profit, CSL and S/D equate to around a 1.5 % drop. This represents 
the operational  cost of the  “piece  of mind” that is gained through the dual  facility 
production,  as  this  hedges  against  facility outages  throughout the  time horizon by 
offering cost  and  time  saving flexibility,  for example,  in the case of a last minute 
production  plan  reconfiguration.  The  impact  of the  risk  constraint  is  seen  to  be 
considerably lower in  the  sales,  cost,  profit,  CSL  and  S/D  measures  (one order of 
magnitude) in the low demand scenario and considerably higher in the high demand 
scenario  (approximately  5  fold),  as  a  result  of the  respective  excess  and  lack  of 
manufacturing  capacity.  This  leads  to  the  conclusion  that  the  decision  whether to 
enforce the risk constraint is restricted by the level of expected product demand. For 
example, in the case of the low and base demand scenarios allowing for risk would 
likely be  acceptable  as  the  impact may well  be  seen to be negligible  from a cost- 
benefit  perspective.  While  in  the  case  of  the  higher  demand  this  would  be
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unacceptable  as  the  77.9%  expected  CSL  would  probably  seem  too  much  of a 
sacrifice given the 10.6% drop from the 87.1% expected CSL.
The changing customer service levels as compared with the total base case demand 
over time are shown for each scenario in Figure 6.1. The most noticeable feature of 
Figure 6.1 is that of the low CSL in both the high demand scenarios (Figure 6.1a (A) 
- without risk and Figure 6.1b (A) - with risk). Until the year 2016 the CSL is well 
below  95%  which  can be  explained by the  trend  in total  demand  shown in Figure 
6.1c. It is also noted that in the “with risk” scenario all CSL’s are lower than in that 
of the “without risk” scenario most notably in the high demand scenario.
Figure  6.2  shows  the  capacity utilisation  for  each  facility for each  of the demand 
scenarios that results in the maximum profit. Facilities il, i4, i6 and i9 are the most 
well utilised facilities in each of the demand scenarios which can be explained by the 
lower cost of manufacturing.  Facilities  i7  and i8  (both  contract manufacturers)  are 
not well utilised mainly due to the fact that they each can only make 2 products in the 
portfolio, which each have relatively low demands. Given the higher costs associated 
with securing CMO capacity, these results highlight that the time booked with these 
CMOs should be renegotiated to avoid paying for idle capacity.
Table 6.7: Performance measures at each demand scenario and the impact of the risk 
constraint  for the industrial case study
Demand Sales Cost Profit CSL UTIL S/D
(kg) (rmu) (rmu) (rmu) (% ) (% )
Low 5.94xlO J 1 .1 9 x l0 4 3.09x102 1.16xl04 99.8 62.3 0.99
Low/risk 5 .9 4 x l0 3 I .l9 x l0 4 3.1 lxlO 2 1.16x 10 4 99.7 63.5 0.99
%Difference 0 -0.1 0.3 -0.1 -0.1 1.9 -0.1
Base 1 .1 9 x l0 3 2 .3 7 x l0 4 1.0 0x l 0J 2 .2 7 x l0 4 99.3 86.4 0.99
Base/risk 1.19x 10 3 2 .3 4 x l0 4 1 .0 3 x l0 3 2 .3 3 x l0 4 97.7 85.4 0.98
%Difference 0 - lJ 2.7 - 1.4 - 1.6 - 1.2 -1.2
High 1.78xlO J 3 .1 7 x l0 4 1.56xlO j 3.02x104 87.1 96.2 0.89
High/risk 1 .7 8 x l0 3 2.99x104 1 .4 1 x l0 3 2 .8 4 x l0 4 77.9 95.3 0.84
%Difference 0 -5.9 9.8 -5.7 -10.6 -1.0 -6.0
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Figure 6.1: Customer service level  for the low (+), base (x) and high (A) demand scenarios 
without (a) & with (b) the risk constraint activated, (c) shows the total base case demand  for
comparison.
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Figure 6.2: Capacity utilisation for each  facility  for the low (+), base (x) and high (A) 
demand scenarios without (a) & with (b) the risk constraint activated. Owned  facilities are
il, i4, i6 and i9.
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6.5.3.  Capacity Analysis
Based  on  the  analysis  conducted  in  the  previous  section  (5.2)  we  assume  that 
allowing  for risk  in  the  problem  formulation  is  a  sensible  strategy.  Hence  for the 
remainder  of  this  work  the  risk  constraint  will  remain  activated  allowing  for 
manufacturing risk.
Figure 6.1b shows the base case with risk (designated by x) and is now considered 
more closely in  order to  determine more specifically the capacity needs and likely 
capacity  management  decisions  in  this  scenario.  The  CSL  base  demand  scenario 
curve shows that from 2006 to 2015 the CSL hovers between 90% and 100%. Figure 
6.3  shows a more detailed view of the CSL between 2006 and 2015 for each of the 
individual products. Although CSL of 90-100% is high, a closer look at the CSL for 
each product reveals that p2, p8. p9, pl2, pl4 and pl5  are not being frilly satisfied. 
This  indicates  that  there  is  insufficient  capacity  to  meet  the  demands  of all  the 
products.  The  fact  that  the  optimisation  results  show  some  product  demands  met 
frilly  and  some  not  at  all  (i.e.  p2  and  p8)  can be  attributed  to  the mathematically 
driven nature of the model whereby the manufacture of the product with the lowest 
costs and the highest volumes is maximised as this represents the most cost-effective 
use of capacity. Products required in low volumes (p2, p8, p9, pl2, pl4 and pl5) are 
avoided  (or  delayed)  partially  due  to  the  size  of the  time  slots  (3  months),  as  a 
commitment of 3 months to produce a small volume of product is inefficient. Table 
6.8  shows a more detailed view of the CSL whereby the CSL for each product for 
each  year is  shown  along with  the  facility that was used  to meet the orders.  This 
gives a better idea of the capacity needs for a given product, more specifically how 
much is needed and when it is needed. The facility used to meet the orders may help 
manufacturers  decide  whether  to  boost  existing  capacity  or  produce  elsewhere  or 
whether contract capacity is being utilised sufficiently.
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Figure 6.3: Average customer service levels for the individual products between 2006 and
2015.
Table 6.8: Actual customer service level  for each product at each year between 2006 and
2015.
Year 2006 2007 2008 2009 2 0 1 0 2011 2 0 1 2 2013 2014 2015
p2 0 0 0 0 0 0 0 0 0 0
p 8 0 0 0 0 0 0 0 0 0 0
p9 0 0 0 0 0 0 0 0 0 il/  100
p !2 0 0 0 0 0 0 0 0 0 il/ 68.6
p l4 0 0 i6/  1 0 0 i6/  100 0 0 0 0 0 i5/  100
p l5 0 0 0 0 0 0 il/  100 i l /1 0 0 i5/ 90.9 i5/  100
Note: i’s denote facilities where products for that order where produced.
6.5.4.  The  Impact  of  Multiple  Objectives  and  Different 
Operating Policies
The model  was  adapted  to  a goal programming formulation as detailed in Section
4.2  to  account  for multiple objectives  where deviations  from target values of each 
objective  were  minimised.  There  are  numerous  policies  which  can be  adopted  to 
guide strategic planning decisions. In our study we assume that all policies have the 
same target levels  for each of the objectives namely the minimisation of costs to a 
target level  of 100,000 rmu’s,  the maximisation of CSL to  a target level  of 100%, 
and  the  fulfilment  of a  capacity  utilisation  target  of 90%  for  all  owned  facilities.
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Here, three different scenarios are adopted which differ in the relative importance set 
for each objective, and are explained below:
•  Cost  policy  (COST):  This  policy  is  that  of the  cost-conscious  decision-maker
who may have  costs  targets  to  meet  and which  cannot be  exceeded under any
circumstances, irrelevant of the CSL achieved. An additional objective includes 
the need to meet set capacity utilisation targets. The weighting of the objectives 
COST:CSL:UTIL in this case is 7:1:2.
•  CSL  policy:  This policy is that of the  customer-conscious decision-maker who
feels  that  the  maximisation  of service  levels  is  of such  great  importance  that
exceeding cost targets to improve CSL is an acceptable sacrifice. An additional 
objective  also  includes  the  need  to  meet  set  capacity  utilisation  targets.  The 
weighting of the objectives COST.CSL.TJTIL in this case is 1:7:2.
•  Compromise policy (COMP): This policy is that of the compromising decision­
maker who would like to meet each of the set goals equally and aims to satisfy 
cost targets  while  achieving high  service levels and meeting utilisation targets. 
The weighting of the objectives COST:CSL:UTIL in this case is 1:1:1.
Note that the utilisation objective is weighted  as 2 in the cost and CSL policies as 
both  the  negative  and  positive  deviations  are  penalised  in  the  objective  function, 
while in the cost policy only the positive deviation is penalised and in the CSL policy 
only the negative deviation is penalised.
Figure 6.4 shows the percentage deviation from the goal targets for each of the base 
case and each of the operating policies and Figure 6.5 shows a plot of the operating 
costs and service levels  for each of the policies.  It should be noted that the highest 
deviation in cost  and utilisation are attained in the base case, where the reason for 
this  is  that  the  base  case  is  modelled  using  the  single  objective  problem 
(maximisation  of profit)  and  does  not  directly  attempt  to  meet  these  objectives. 
Analysis  of the three operating polices  shows that the CSL policy followed by the 
COMP and COST policies achieves the highest service level. While both the COST 
and the COMP policies meet the costs target levels exactly, the CSL policy shows a
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slight deviation 0.5%. All policies sufficiently meet the utilisation target. In terms of 
profit there is no  significant difference relative to the base case as the CSL policy 
matches  the base  case  and  the  COST  and  COMP  policies  make  only a  1%  drop. 
Hence a high profit is still  achieved while also satisfying key cost, CSL, and UTIL 
targets more closely.
Further  computations  were  conducted  for  all  policies  at two  additional  cost target 
levels of 90,000 and  110,000 rmu in order to analyse the problem sensitivity. Figure 
6.6  shows  the  resulting  plot  of operating  cost  and  service  level.  The  aim  in both 
Figures 6.5  and 6.6 is to lie as close to the bottom right hand comer of the graph as 
possible, signifying the lowest costs and highest service level. A similar trend can be 
seen at each of the  cost target levels whereby the CSL policy achieves the highest 
service level,  followed by the COMP  and COST policies and only the COMP  and 
COST policies meet the required cost targets. The difference in performance is more 
evident  as  cost  targets  are  tightened,  reflecting  the  difficulty  of  achieving  high 
service levels at lower costs. This observation motivated further sensitivity studies on 
the  cost  and  service  levels,  which  is  conducted  using  the  COMP  policy  by 
incrementally  changing  the  cost  target  level  and  the  associated  plot  is  shown  in 
Figure  6.7.  This  graph  shows  a  clear trend  of an increase in  service level  with  an 
increase in cost up to  a cost target of 100,000 rmu’s,  at which point service levels 
stagnate at around 98%.  The further increase in cost without an increase in service 
level  is  attributed  to  the  production  of orders  of backlogged batches,  which  even 
though they are of lesser importance than new orders, contribute to cost through late 
penalties and hence are manufactured only if monetary resources are available.
Finally,  while  the  optimisation  framework  presented  can be  used  as  a  production 
planning  tool,  it  is  best  used  as  a  capacity  analysis  tool  for  aiding  strategic 
manufacturing capacity related decisions. In reality demands would not all be due at 
the  end  of the  year,  and  better  demands  forecasts  would  likely  be  available  as 
demand dates neared.
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utilisation (black) goals for the base case, cost, customer service level and compromise 
operating policies and the profit (x) achieved by each policy.
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Figure 6.5: Shows the operating cost and service levels for the base case, cost, customer 
service level and compromise operating policies.
- 133-Chapter 6. Multiobjective Long Term Planning of  Biopharmaceutical Manufacturing Facilities
115.000  n
j
110.000 - j
105.000  J
100.000
g.  95,000 
O
90,000
85,000
92
COST
COST
JA  ▲
CSL
COMP
BASE x
COST  CSL
♦♦
CSL
COIVP
93 94 95  96
CSL (%)
97 98
Figure 6.6: Operating cost and service levels for the base case, cost, customer service level 
and compromise operating policies at different cost targets, 90, 000 (u),  100, 000 (+),and
110, 000 (A), and the base case (x).
125,
120,
115,
110,
105,
100,
95,
90,
85,
80,
75,
000 
000  -| 
000  J
000 J
000  -I 
000 
000 
000 
000 
000 
000  4-  
85
♦
♦
♦
♦
♦
87  89  91  93  95
CSL (%)
97 99
Figure 6.7: Sensitivity study of the operating cost and service levels for the compromise
policy.
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6.6. Conclusions
An  optimisation-based  framework  for  long  term  planning  of  biopharmaceutical 
manufacture has been presented, and tested on an industrial case study. The problem 
was first solved  as  a single objective problem,  where profit was maximised,  and a 
capacity  analysis  was  conducted  to  determine  where  additional  capacity would be 
needed.  The  problem  was  then  extended  to  allow  for multiple  objectives  via goal 
programming,  namely  operating  costs,  customer  service  levels  and  capacity 
utilisation  of owned  facilities.  Three  different  operating  policies  were  compared, 
namely a cost biased (COST), service level biased (CSL) and a compromising policy 
(COMP).  CSL was found to outperform all polices in achieving the highest service 
level. Only the COST and COMP policies met cost targets with COMP achieving the 
higher  service  level  of the  two  approaches.  Sensitivity studies  were  conducted  on 
cost targets and showed a similar trend to that noted above, with the trend becoming 
more evident with lower cost targets. Further sensitivity analysis was conducted on 
the COMP  scenario  considering different cost targets and monitoring service levels 
which were  found  to  increase with increasing operating  costs  and hence monetary 
resources eventually reaching a plateau. Capacity analysis of an industrial case study 
has been shown to give decision makers a better idea of what their existing capacity 
situation is and where it may need capacity increases or improvements. The approach 
has also been demonstrated to help evaluate different operating polices and quantify 
operational performance at different monetary resource levels.
6.7. Nomenclature
Indices
b timeblock
dev negative (neg) or positive (pos) goal deviation
g goals: cost, csl (customer service level), util (capacity utilisation)
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i  facility
p  product
t, e time periods
Sets
DT set of time periods in which product demands are due.
IPP set of facilities i manufacturing product p.
OS set of owned facilities.
Pit set of products p produced by facility i.
RS set of product which must be produced in at least two differem
facilities.
TBb set of time periods in a time block b.
Th set of time periods t in which facility i is available for use.
Parameters
c ip storage capacity of product p at facility /, batches
P)pt demand of product p at time period t
GTg aspired goal target for goal g
r iP production rate of product p at facility i, batches per unit time
Ht available production time horizon over time period t
rp  max 
J-ip maximum production time for product p
P   min
lip minimum production time for product p
ydip yield conversion factor, kilograms per batch
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WTg,dev  Archimedean weight of goal deviation
aip  lead time for production of first batch of product p at facility i
C P  life time of product p , number of time periods t
vp  unit sales price for each batch of product p
rjp  unit cost for each batch produced of product p
y/P  unit cost for each new campaign of product p
dp  unit cost charged as penalty for each late batch of product p
pp  unit cost for each stored batch of product p
n  rate of backlog decay
Binary Variables
Yipt  1  if product p is produced over period t at facility i;  0 otherwise
YiPbnew  product p is produced over block b at facility /; 0 otherwise
Zipt  1   if a new campaign of product p at facility i is started in period t\ 0
otherwise.
Continuous Variables
lipt  amount of product p stored over period t at facility i
GDg >  dev  actual goal difference for each goal deviation
GDg dev°rm   normalised goal difference for each goal deviation 
GLg  achieved goal level for goal g
GLg0rm   normalised goal level for goal g
GLTgt  achieved goal level for goal g at time period t
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GLIgi  achieved goal level for goal g at facility i
Kipt  amount of product p produced over period t at facility i (kg)
Prof  expected operating profit
Spt  amount of product p which is sold over period t
Sumd  sum of adverse deviations
Tipt  production time for product p at time period t  at facility i
Tfitot  total production time over period t at facility i
Wpt  amount of product p wasted over period t
Apt  amount of product p which is late over period  t
Integer Variables
Bipt  amount of product p produced over period t at facility i (batches)
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Commercial Considerations for the 
Development of a Software Tool for 
Production Planning of 
Biopharmaceutical Manufacture
7.1. Introduction
In this chapter, an implementation plan of a potential commercialisation route for the 
work  generated  in  this  EngD  is  presented.  The  development  of  the  model, 
appropriate software architecture, implementation issues, estimated project resource 
requirements  and  potential  benefits  are  discussed.  The  model  implementation  is 
based on a typical biopharmaceutical industry production planning problem, whereby 
a  biopharmaceutical  manufacturer  wishes  to  optimise  the  production  plans  of  a 
biomanufacturing  facility  or  network  of  facilities  using  a  hybrid 
simulation/optimisation approach.
- 139-Chapter 7. A Software Tool for Production Planning of  Biopharmaceutical Manufacture
7.2. Model Development
The  EngD  project  presented  in  this  thesis  was  collaborative  between  UCL’s 
department of Biochemical Engineering and BioPharm Services UK. Its objective is 
to provide biopharmaceutical manufacturers with an optimisation framework for the 
production  planning  of  multiproduct  facilities.  An  intellectual  property  (IP) 
agreement  for the  rights  to  the  resulting mathematical  formulations  was  drawn up 
and agreed by all parties involved.
After  considerable  academic  and  industrial  surveying  in  close  collaboration  with 
BioPharm  Services  UK,  the  project  was  defined.  Over  the  subsequent  four years, 
mathematical  formulations  along with algorithms for their solution were developed 
and  tested  on  realistic  example  industrial  problems.  The results  were presented  at 
both national and international conferences.
7.3. Model Architecture
The first stage in taking the project from a theoretical mathematical formulation to a 
practical  industrially  applicable decision  support tool  is  embedding the model  in a 
practical/familiar  software  application  infrastructure.  The  components  of  any 
potential system should include the following:
•  A  simulation  package  for  the  detailed  formulation  of  problem  features  and 
graphical representation of the results (e.g. Extend, Promodel).
•  A database or spreadsheeting application for the specification of input parameters 
and a platform for the return of generated results (e.g. Microsoft’s Access).
•  A modelling environment for the specification of the mathematical optimisation 
model (e.g. GAMS or ILOG’s OPL development studio).
•  An  optimisation  solver  for  the  solution  of  the  MILP  models  (CPLEX  or 
XPRESS).
- 140-Chapter 7. A Software Tool for Production Planning of Biopharmaceutical Manufacture
The selected applications must have a compatible application programming interface 
(API)  for  software  integration.  An  API  is  the  interface  that  a  computer  system, 
library or application provides in order to allow requests for service to be made of it 
by  other  computer  programs  and  to  allow  data  to  be  exchanged  between  them. 
Relevant  example  API’s  include:  open  database  connectivity  (ODBC),  component 
object model (COM) and programming languages C and C++.
A detailed survey of commercial optimisation tools was conducted, and included an 
assessment  of  features,  pricing  information  and  interfacing  capabilities.  An 
assessment  for  tool  selection  and  a  solver  comparison  were  also  conducted 
(Appendix 1).
A diagrammatical representation of the required software infrastructure is shown in 
Figure 7.1 below.
Simulation Package 
(e.g. Extend)
Final
Solution
Database 
(e.g. Access)
Optimization Solver 
(e.g. CPLEX)
Modelling 
Environment 
(API) (e.g. GAMS)
Figure 7.1. A diagrammatic representation of the information flow within the software
infrastructure.
An explanation of steps 1  —  5 in Figure 7.1 is given below:
1.  Once problem inputs (parameters) have been specified and appropriately set up in 
the  database  system,  the  data  is  imported  by  the  modelling  environment.  The 
database communicates with the modelling environment via an API to set up the 
problem and perform the optimisation.
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2.  A  preformulated  model  with  appropriate  data  import/export  commands  then 
accepts  the  input  data  and  submits  the problem with the relevant  solution  and 
display commands/conditions to the solver.
3.  Upon  solution  termination/convergence  (either  by  achieving  required  solution 
quality or exceeding allowable solution time) a solution is returned and sent to 
the database system for appropriate data manipulation.
4.  The  data  is  submitted  to  the  simulation  package  for validation  of the  solution 
feasibility/quality,  the  simulation  should  be  dynamically/programmatically 
scripted to match the problem.
5.  The final solution output may be in the form of raw data to a database system for 
further  manipulation  and/or  graphical  interpretation  via  a  Gantt  chart,  e.g. 
Microsoft PROJECT.
7.4.  Project Implementation
An  example  implementation  scenario  is  presented  which  involves  a  client  (e.g.  a 
large-scale  biopharmaceutical  manufacturer)  who  approaches  a  team  of 
biopharmaceutical industry consultants for the development of a production planning 
tool.
A chronological implementation plan of the project’s key phases is presented and has 
a similar structure to a typical software development project as shown below:
7.4.1.  Phase 1: User Requirements Analysis
•  Client visit (1): Consultants visit client site to gain understanding of detailed user 
specifications.
•  Timing: Create a project schedule.
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•  Contracts:  Establish  a  project  contract  covering  key  issues  such  as 
confidentiality, financials, delivery and penalties.
•  Basic  Functional  Spec:  A  basic  functional  specification  of  the  software  is 
developed to meet the requirements of the client.
7.4.2.  Phase 2: System Design and Development
•  Client  visit  (2):  Consultants  visit  client  site to  qualify that  the  functional  spec 
meets client requirements. Information and data collection.
•  Full  Functional  Spec:  A  fully  functional  specification  of  the  product  is 
developed.
•  Validation: Product is validated using historical data.
•  Testing: product must conform to standard alpha and beta testing standards.
•  Documentation:  Appropriate  product  user  manual/documentation  must  be 
developed and validated.
7.4.3.  Phase 3: Operation and Maintenance
•  Client visit (3): Deployment at client site: Handover of product and installation at 
client site.
•  Training: Users must be trained at client site.
•  Maintenance:  Agreements  for appropriate maintenance at contract specification 
stage may or may not be included (Quality assurance guarantees).
7.4.4.  Project Costing
Resource requirements  and  costs have been estimated based on a typical  industrial
project,  and  presented  for  all  phases  of implementation.  An  approximate  project
costing was based on some assumptions as shown below:
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•  Consultants conducting the work are charged at £50 per man hour and assumed 
to work a 40 hour week.
•  We  assume  the  consulting  company  conducting  the  work  owns  a  copy of all 
necessary developmental  software tools/licences.  Hence  client is  charged  for  a 
copy  of  an  end  user  (runtime)  product  licence  and  does  not  include  annual 
maintenance or support fees.
•  No mark up is included in the cost estimate as this will depend on the consulting 
company’s business strategy.
•  A survey of optimisation tools was conducted and aids the developer in gaining a 
better understanding of available software capabilities. This was not charged.
•  Table 7.1  shows the approximate project costing which totals £47,  980 and total 
project duration of 20 weeks.
Table 7.1. Project costing and task durations.
All costs in UK pounds
Task Resource
(labour is calculated as man-weeks)
Cost (£ - British pounds)
Phase 1: User Requirements Analysis (Duration: 7 weeks)
Client visit (1) Consultants  1  week 2,000 +  1000 (expenses)
Basic functional  spec M icrosoft A ccess (database) 130
Basic functional  spec Extend (sim ulation package) 50 (run time licence)
Basic functional spec G A M S (m odelling system ) 1,600
Basic functional spec X PR E SS (solver) 3,200
Basic functional spec G UI (external consultants  1  w eek) 1,000
D evelopm ent work Consultants 5  w eeks 10,000
Phase 2: System design and development (Duration: 11 weeks)
Client visit (1) Consultants  1  w eek 2,000 +  1,000 (expenses)
D evelopm ent work Consultants 8 weeks 16,000
Docum entation Consultants 2  weeks 4,000
Phase 3: Operation & Maintenance (Duration: 2 weeks)
Client visit (1) Consultants  1  w eek 2,000 +  1,000 (expenses)
Training Consultants  1  w eek 2,000 +  1,000 (expenses)
TOTAL COST (Total duration: 20 weeks) 47,980
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7.5. Potential Benefits to Client
Manufacturers  wishing  to  improve  their  planning  and  scheduling  decisions  can 
potentially achieve vast financial benefits by improving capacity utilisation and cost 
effectiveness.  Saraph  (2001)  reports  direct benefits  from  a  2  month  long  capacity 
analysis  project  of  a  Bayer  Corporation  biomanufacturing  facility  amounting  to 
$1,100,000. It has been estimated (Mallik et ai, 2002) that a typical mammalian cell- 
culture facility can increase annual revenues by $380 million with a 25% increase in 
plant  utilisation.  Thus  these  examples  further  reinforce  the  possible  savings 
improvements in scheduling and planning decisions can help achieve.
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8.1.  Introduction
In the biopharmaceutical  industry each step of any process with a direct impact on 
the  final  product must be validated by the  appropriate regulatory authority for the 
geographic region where it will be licensed. Validation is defined by the FDA (Food 
and Drug Administration)  as  “Establishing documented evidence which provides  a 
high degree of assurance that a specific process will consistently produce a product 
meeting its pre-determined specifications and quality attributes”. Validation requires 
the  enforcement  of  manufacturing  guidelines  and  regulations.  In  the 
biomanufacturing  industry  a  process  is  said  to  be  compliant  with  Good 
Manufacturing  Practice  (GMP),  a  set  of regulations,  codes,  and  guidelines  for the 
manufacture  of  drugs,  medical  devices,  diagnostic  products,  foods  products  and 
Active Pharmaceutical Ingredients (APIs).
Aside  from  validation being  a legal  requirement,  it  also brings many benefits to  a 
manufacturer. Some typical benefits of the validation process include:
•  Increasing the understanding of a system or process.
•  Ensuring the safety and efficacy of a manufactured product.
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•  Producing evidence of and enforcing set quality control (QC) criteria.
•  Enhancing the credibility of analytical data if a batch is questioned.
Given  the  nature  of  this  EngD  thesis,  the  following  section  will  focus  on  the 
validation of software systems.
8.2.  Software Validation
Software validation  cannot be  ignored  as  it may influence  a part or all  of a given 
process.  Any  software  system  which  performs  a  regulated  function must  have  its 
production, control, review and operation validated.
General guidelines for manufacturing software validation are presented in the Good 
Automated  Manufacturing  Practice  (GAMP)  guidelines.  Whether  applied  within 
GMP  (Good  Manufacturing  Practice),  GCP  (Good  Clinical  Practice)  GLP  (Good 
Laboratory Practice) or GDP (Good Distribution Practice) these validation guidelines 
provide the user and/or supplier of a software system with a valuable framework for 
the production and use of compliant validated bioprocess software.
An overview of the validation process is shown below:
•  Planning: Prepare a written validation plan.
•  Specification: Specify and agree what is required. Perform design reviews.
•  Test planning:  Prepare document to describe how the equipment/system is to be 
tested (includes Installation qualification (IQ), operational qualification (OQ) and 
performance qualification (PQ)).
•  Testing: Perform tests and collect results (IQ, OQ and PQ).
•  Review  and  Report:  Review results to  show that system performs  as specified,
report conclusions, plus any reservations.
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Some benefits of the GAMP validation process include:
•  Reducing time and costs taken to achieve compliant systems.
•  Eliminating the need for expensive retrospective validation.
•  Providing better visibility of projects to ensure delivery on time, on budget, and 
to agreed quality standards.
•  Clarifying the division of responsibility between the user and the  supplier.
•  Providing  cost  benefits,  by  aiding  the  production  of  systems  that  are  fit  for
purpose and meet user and business requirements.
The validation procedures and benefits shown above are applicable to the majority of 
automated  systems  in  the  biopharmaceutical  industry.  However,  not  all  software 
employed within the biopharmaceutical industry performs a regulated function.
8.3.  Decision Support Systems
Regulatory  authorities  enforce  only  that  systems  which  perform  a  “regulated” 
function  must  be  validated,  examples  include  automated  and  online  control  and 
operation software.
The work presented in this thesis does not perform a regulated function and hence 
falls into the category of decision support systems, which includes systems such as 
planning, scheduling, process simulation and supply chain optimisation tools, which 
are  often  used  for  “what  if’  decision  making  analysis  or  for  the  generation  of 
production plans or operating schedules. Such tools do not have a direct effect on the 
manufacturing process  as they are only used to aid the decision maker or operator. 
Hence,  such  tools  are  exempt  from  the  bioprocess/biomanufacturing  validation 
process.
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Decision  support  systems  will  however generally be expected to undergo  software 
validation in the final stages of their development, where it is generally referred to as 
software testing.  Software testing is a process used to help identify the correctness, 
completeness,  security  and  quality  of newly  developed  computer  software.  These 
tests  include  standard  testing  such  as  alpha  and beta testing which is used  for the 
debugging of software and ensuring user specified requirements are met.
While, implementation of the work generated in this EngD will not require validation 
directly, there are some important considerations which are affected by the validation 
process. Some indirect validation issues are discussed below:
•  Manufacturing specific considerations:  modelling of the relevant manufacturing 
consideration  must  be  accounted  for.  e.g.  if a  certain  facility  is  validated  to 
certain specifications, such as suite specific product manufacturing, this must be 
represented accurately or production plans will be infeasible.
•  Decision  support  not  decision-making:  many  validation  related  issues  are  not 
accounted for in the modelling framework. While a given production plan may be 
optimal in the mathematical  sense, issues such as the risk of contamination and 
the  high  validation  costs  associated  with  frequent  changeover  may  not  be 
accounted for.
8.4. Conclusions
The  validation  process  is  a  legal  requirement,  with  many  benefits  to  the 
manufacturer,  however is not applicable to  decision support systems such as those 
presented in this EngD thesis.  However,  as with the majority of software products, 
decision support svstems are required to meet certain software testing standards, and 
those used in the biomanufacturing industry are no exception.
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Operating  multiproduct  facilities  in  the  biopharmaceutical  sector  poses  several 
challenges  for  planning  and  scheduling.  Significant  economic  benefits  may  be 
expected  if these  can  be  overcome  (Gosling,  2003).  A  survey  of academic  work 
involving  the  application  of mathematical  programming to  production planning in 
the process industries identified a distinct lack of work in bioprocessing. Hence, the 
aim  of this  thesis  was  to facilitate  the  biopharmaceutical industry’ s strategic and 
operational decision-making by applying mathematical programming techniques for 
production  planning  o f biopharmaceutical  manufacturing facilities.  Towards  that 
goal,  a number of optimisation-based frameworks have been developed in order to 
assist decision-makers  in the biopharmaceutical  industry.  The key contributions of 
the thesis are summarised in Section 9.1, while Section 9.2 suggests promising new 
directions for future research work.
9.1. Contributions of this Thesis
The contributions of this thesis will be presented for each of the research Chapters 
(3-8) and are as follows.
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9.1.1.  Medium term Planning of Biopharmaceutical 
Manufacture
The aim of Chapter 3 was the determination of the optimal medium term production 
plans  for  a  multiproduct,  multi-suite  biopharmaceutical  manufacturing  facility by 
capturing  the  characteristic  bioprocessing  features  of  the  production  planning 
problem in the biopharmaceutical industry.
A mathematical programming approach using a mixed  integer linear programming 
(MILP)  formulation  for  medium  term  planning  of biopharmaceutical  manufacture 
was  presented.  An  improved  formulation  was  used  to  represent  and  solve  two 
illustrative  examples.  The  solutions  obtained using the mathematical programming 
approach  were  compared  to  those  generated  by  an  industrial  rule  based  (IRB) 
approach which demonstrated the value of the proposed approach. In both examples 
considered, the mathematical programming approach was shown to outperform IRB 
in terms of profitability.  The profitability achieved by MP was considerably higher 
demonstrating  the  necessity  for  calculated  decisions  regarding  campaign 
changeovers  and  inventory  profiles.  This  confirmed  the  ineffectiveness  of  IRB 
approaches  for  solving  larger  more  complex  planning  problems.  The  proposed 
mathematical  programming  approach  offers  an  improved  alternative  to  industrial 
rule-based methods for medium term planning of biopharmaceutical manufacture and 
presents  biomanufacturers  with  a  business  decision  support  tool  to  aid  in 
production/capacity planning and obtaining longer term strategic decisions.
9.1.2.  Medium term Planning of Biopharmaceutical 
Manufacture under Uncertainty
The  challenges  of  incorporating  the  impact  of  uncertainty  in  biopharmaceutical 
manufacturing production plans were addressed in Chapters 4 and 5.  Mathematical 
programming  formulations  were  developed  and  assessed  for  their  suitability  in 
determining  the  optimal  medium  term  production  plans  for  a  multiproduct 
biopharmaceutical  manufacturing  facility  given  uncertain  fermentation  titres. 
Solutions  were  required  to  be  achieved  within  a  reasonable  computational  time 
without compromising significantly the quality of the obtained solution.
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9.1.2.1.  Medium term Planning of  Biopharmaceutical Manufacture 
using Two-Stage Programming
Initially,  the  problem  was  formulated  as  a  two-stage  programming  model  and  an 
iterative algorithm was proposed for the problem’s  efficient solution.  The example 
problems presented in Chapter 4 were all solved using a deterministic model, a full- 
space  two-stage  programming  model,  a  rolling  horizon  algorithm  and  a proposed 
construction/improvement algorithm (CON/IMP).  The impact of uncertainty on the 
solution  schedules  was  quantified  for both  examples  via Monte  Carlo  simulation. 
The results  showed  that  CON/IMP  consistently  matched  or  exceeded the  solution 
quality  achieved  by  the  full  space model  and  the  rolling horizon  algorithm  while 
making considerable  improvements  on the  deterministic model.  This  is  a valuable 
framework  for  biomanufacturers  wishing  to  improve  their  medium  term  decision 
making  capabilities  by  incorporating  and  addressing  the  impact  of  uncertain 
parameters within their manufacturing schedules. The approach would also likely be 
of much  value  in  other  applications  of two-stage  programming  as  it  is  relatively 
generic in its nature.
9.1.2.2.  Medium term Planning of  Biopharmaceutical Manufacture 
using Chance Constrained Programming
An alternative mathematical optimisation-based framework for capturing uncertainty 
was presented in Chapter 5. As an alternative to multiscenario type representations a 
chance  constrained  approach  was  proposed  for tackling variability in  fermentation 
titres when planning biopharmaceutical manufacture. The approach was able to make 
considerable computational savings and resulted in very good quality solutions when 
compared with the two-stage programming approach proposed in Chapter 4. Chance 
constrained programming was demonstrated to be a powerful approach for tackling 
uncertainty as  it was  able to  generate  solutions of the  same order of magnitude of 
those achieved using the deterministic model even for larger problems.
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9.1.3.  Long term Strategic Planning of Biopharmaceutical 
Manufacture
The deterministic medium term planning model presented in Chapter 3 was extended 
to  account for long term  capacity management of biopharmaceutical  facilities. The 
model  was  tested  on  an  industrial  case  study  to  gain  a  better  understanding  of 
existing  capacity  capabilities  and  the  quantification  of  the  impact  of  different 
strategic operating polices on capacity decisions.
The problem was  initially solved  adopting a single objective problem formulation, 
where  profit  was  maximised,  and  a  capacity  analysis  was  conducted  to  determine 
where additional capacity would be needed. The problem was then extended to allow 
for  multiple  objectives  via  goal  programming,  namely  operating  costs,  customer 
service levels  and  capacity utilisation of owned facilities.  Three different operating 
policies were compared, namely a cost biased, service level biased and an unbiased 
compromising policy.  The policies were used to demonstrate the differing strategic 
objectives  of biopharmaceutical  manufacturers  and  for  the  evaluation  of different 
operating polices and quantification of operational performance at different monetary 
resource levels.  Sensitivity studies were used to illustrate the impact of changes in 
operating costs on customer service levels.
Given  the  considerable  costs  and  risks  associated  with  capacity  planning  in  the 
biopharmaceutical industry, the multiobjective optimisation framework presented has 
demonstrated  potential  as  a  useful  aid  in  strategic  decision-making  for  long  term 
planning  of biopharmaceutical  manufacture.  Biopharmaceutical  strategic  decision­
makers  are  required  to  make  considerable  investments  in  capacity  or  financial 
commitments to contract manufacturers years in advance and hence would find such 
information invaluable in aiding both production and capacity planning decisions.
9.1.4.  EngD Commercialisation
An  implementation  plan  of  a  potential  commercialisation  route  for  the  work 
generated in this EngD was presented in Chapter 7. The development of the model, 
appropriate software architecture, implementation issues, estimated project resource
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requirements and potential benefits were discussed. The model implementation was 
based on a typical biopharmaceutical industry production planning problem, whereby 
a  biopharmaceutical  manufacturer  wished  to  optimise  the  production  plans  of a 
biomanufacturing  facility  or  network  of  facilities  using  a  hybrid 
simulation/optimisation approach.
9.1.5.  Validation Issues
Validation issues relating to this EngD were presented in Chapter 8.  In light of the 
nature  of  this  EngD,  issues  relating  to  the  validation  of  software  products  and 
decision support systems within the biopharmaceutical industry were discussed here.
9.2.  Recommendations for Future Work
The research presented in this thesis has identified a number of issues that need to be 
further  investigated  in  order  to  develop  more  comprehensive  optimisation-based 
frameworks  for  production  planning,  capacity  planning  and  general  capacity 
management of biopharmaceutical manufacture.
9.2.1.  Deterministic Models
The  deterministic  MILP  model  for  medium-tem  planning  of  biopharmaceutical 
manufacture  proposed  in  this  thesis  was  applied  to  a  number  of  examples  to 
demonstrate its applicability. However there remain some concerns pertaining to the 
models solution time which increases exponentially with small increases in problem 
complexity.  In  order  for  this model  to  be  combined  directly with  frameworks  for 
optimisation under uncertainty such as  those proposed in Chapters 4  and 5  of this 
thesis,  further  work  is  necessary  towards  developing  more  efficient  solution 
procedures for this proposed deterministic model. Tighter problem formulations may 
be required.
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Another  potential  avenue  for  further  work  is  multiscale  modelling  of 
biopharmaceutical  manufacture,  e.g.  the  integration of the proposed medium  term 
planning  model  with  short  term  scheduling  models  such  as  that  of Kondili  et  al. 
(1993)  given  that  such  models  have  been  successfully  applied  to  bioprocess 
scheduling  in  the  past  (Samsatli  and  Shah,  1996).  Integration  of  long  term 
planning/supply  chain  formulations  with production planning  in the medium  term 
would  also  be  a valuable  exercise.  This  would be the next logical  step  in a more 
holistic  integrated  decision  making  framework  for  planning  and  scheduling  of 
biopharmaceutical manufacture.
9.2.2.  Medium term Planning of Biopharmaceutical 
Manufacture under Uncertainty
Chapter 4  and  5  were  concerned with  generating production plans  given uncertain 
manufacturing  conditions  in  the biopharmaceutical  industry.  A  reduced  version of 
the  deterministic  model  was  extended  to  allow  for  variable  fermentation  titres. 
Further work using discrete-event simulation for the validation of solution schedules 
via Monte Carlo simulation would also provide a more accurate understanding of the 
impact of uncertainty on solution schedules.
Two different optimisation-based frameworks for tackling the problem of production 
planning  under  uncertainty  were  developed,  namely  a  two-stage  programming 
approach and a chance constrained programming approach. Issues relating to further 
development of them are discussed below.
9.2.2.1.  Two-Stage Programming
The construction/improvement-based  algorithm developed for the efficient solution 
of  the  combinatorial  problem  resulting  from  the  two-stage  programming 
formulations  showed much promise in reducing the solution time while generating 
very good quality solutions. However it was only tested on problems involving one 
uncertain parameter (fermentation titre). There would be much value in extending the 
functionality  of  the  approach  to  tackle  problems  with  additional  uncertain 
parameters,  for  example,  variable  demands.  The  development  of  an  alternative
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efficient solution algorithm by modifying the algorithm developed in this thesis may 
present  challenges  as  the  problem  size  increases  with  increasing  uncertain 
parameters.
The algorithm presented is somewhat generic and would hence likely be of value in 
other applications of two-stage programming whereby an insertion/construction type 
approach  could  be  leveraged.  Construction/improvement type  algorithms have not 
previously  been  adopted  in  planning  and  scheduling  under  uncertainty  or  related 
applications within the field of decision-making under uncertainty.
9.2.2.2.  Chance Constrained Programming
The  Chance  constrained  formulation  presented  in  Chapter  5  allowed  only  for 
uncertain fermentation titres, hence further work is also required on the formulation 
of models  based  on  chance  constrained  programming  that  allow  for  an  increased 
level of detail when tackling uncertainty.  Once of the main challenges envisaged in 
the  development  of  new  chance  constrained  programming  formulations  is  the 
complexity that arises due to the joint probability distribution functions which result 
from the consideration of multiple uncertain parameters.
9.2.3.  Strategic Planning Models
The  optimisation-based  framework  for  long  term  strategic  planning  proposed  in 
Chapter  6  was  used  for  production  planning  of bulk  product  manufacture  across 
multiple sites. There would potentially be much value in extending this approach to 
include not only bulk product manufacture but also  secondary manufacturing steps 
(filling  and  packaging).  The  approach  can  also  be  extended to  allow  for different 
geographic locations through the incorporation of transportation costs  and taxation 
features  for  an  improved  representation  of  the  supply  chain/multi-site  planning 
problem.  Given  the  considerable  detail  required,  a  simulation-based  optimisation 
framework  combining mathematical  programming and discrete-event  simulation is 
envisaged for tackling the complete supply chain problem.
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Another feature of interest in this section and which may be incorporated in each of 
the models  considered  in this thesis is multiple production rates  at differing costs. 
The  concept  of  running  a  facility  at  different  rates  resulting  in  differing 
manufacturing  costs  depending  on  capacity  availability  is  a  valid  feature  of 
biopharmaceutical manufacture.
Further work on the multiobjective optimisation formulation proposed would be of 
value, particularly on developing solution procedures for the more efficient solution 
of the problem and including uncertainty in the formulation. Further objectives may 
be included  in  the  stochastic version of the problem,  such as  financial/market risk 
and robustness.  Further experimentation with goal programming as a multiobjective 
optimisation approach would also be warranted as alternative approaches to weighted 
goal programming such as lexicographic and Chebyshev goal programming were not 
exhausted.
A  number  of  optimisation-based  frameworks  for  production  planning  of 
biopharmaceutical  manufacture  have  been  developed  and  tested.  Historical  trends 
show the biopharmaceutical industry to be slow adopting such decision support tools, 
but more recently there are indications that the adoption of such tools is accelerating. 
Such approaches are envisaged to be more widespread by the end of the decade as 
market pressures  continue to increase and the biopharmaceutical industry begins to 
mature.
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Appendix 1
Assessment of Optimisation Tools for Model 
Commercialisation
Basic Assumptions
The assumption with all the products selected for this survey is that they are:
•  Capable of handling MILP optimisation models.
•  Compatible with Microsoft’s Windows.
•  Not limited by problem size (i.e. a maximum number of variables).
•  Required only for a single site (licensing).
•  Tables A.l  and A.2 show comparisons of modelling environments and solvers. 
Background on survey conducted
The  tools  shown  above  were  selected  from  a  list  of tools/vendors  compiled  for 
OR/MS  Today’s  2005  Linear programming software survey (copyright ©  2005  by 
the  Institute  for  Operations  Research  and  the  Management  Sciences.  All  rights 
reserved) as well as direct communication with the vendors.
The  modelling  environments  considered  in  this  survey have  all  been described  as 
either:
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•  M:  Modelling  environment:  These  packages  are  typically  designed  around  a 
computer  modelling  language  for  expressing  optimisation  models,  and  offer 
features for reporting, model management and application development. They are 
often bundled with commercially available solvers at discounted prices and hence 
allow for straight forward benchmarking, e.g. GAMS, AMPL.
•  MI:  Integrated  modelling  environment:  These  integrated  systems  provide  a 
modelling environment usually geared towards their own solvers, and a graphical 
user interface (GUI) for better model management and debugging, and are often 
termed  development  studios.  Some  include  a particularly  easy to  use  GUI  for 
straightforward intuitive model building, reducing the volume and complexity of 
associated  computer  programming  challenges.  An  example  of this  is  ILOG’s 
OPL Studio.
•  Solvers: Commercial and compatible mixed integer programming (MIP) solvers.
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Table  A.l:  Comparison  of modelling  environments  (*M -  Modelling  environment,  MI - 
Modelling environment with integrated solvers).
\  i Pricing ($) /
| Product  j Brief 
i (Vendor)  \ Description*
j Compatible 
| Solvers
Read/write 
spreadsheets 
and databases
API’s (annual
P-a)
Developer
License
maintenance^
End  User 
License
AIMMS/  MI | CPLEX, Yes C++ 7000 i 6000
! (Paragon  Decision {  
I Technology BV)  j
XPRESS COM (15%) (15%)
AMPL/  M :CPLEX, Yes C 4000 4000
; (AMPL  Optimization j 
LLC)  i
XPRESS, 
\ FortMP
COM (0 ) (0 )
; AMPL Studio/AMPL  i M j FortMP, Yes C 4950 4950
COM Object 
: (OptiRisk Systems)  |
| CPLEX, others
j
COM (0 ) (0 )
GAMS  fM CPLEX, Yes GDX API ’3200 (50%)
(GAMS  Development j j XPRESS ;v b i(0 ) |(0 )
i Corporation)  j |
I LOG  OPL  MI jlLOG  CPLEX, Yes COM 1 2 2 0 0 1 2 200
: Development Studio  j j ILOG  Solver, !C++
(1LOG)  j | ILOG Scheduler • |(18%) (18%)
LINGO  MI T l in d o  API ; Yes s c 14995 70%
(LINDO Systems, Inc)  j
\
\ :c++ 1(0 ) (0 )
OML  MI IC-WHIZ Read 1 c 3800 3800
i (The  Bionetics j 
| Corporation)  j j
spreadsheets
only
( (0 ) 1(0 )
TOMLAB  Tm I CPLEX, Yes j Utilises Matlab’s 5 900 900
(Tomlab  Optimization 
Inc)
XPRESS (API,  (Matlab  + 
:COM, C, C++)
(2 0%) 1(2 0 %)
What'sBest  MI LINDO API i Read  &   write jc 4995 70%
i  !
i (LINDO Systems, Inc)  j
j (Excel addi n)
\ | spreadsheets 
ionly
|c++ (0) (0)
Xpress-MP Suite  j MI "[Mosel, Yes {C/C++ 5500 45%
| (Dash Optimization)  j XPRESS, MPL I JAVA, .Net, VB (15%) (15%)Appendices
Table A. 2: Comparison of solvers (0% annual maintenance means that 
maintenance/upgrades and support is optional).
Pricing ($) /
(annual  maintenance^:
Product Brief Products  That  Link  to i Read/write P-a)
(Vendor) Description Product spreadsheets 
and database
Developer
License
Developer
License
C-WHIZ Simplex and MIP AMPL, MPL, GAMS, Reads 2500 2500
(The  Bionetics solver preadsheets (0%) (0%)
Corporation) only
FortMP Simplex,  interior \ AMPL, MPL, Tomlab lead  &  write 2500 2500
(OptiRisk Systems) point,  MIP, 
quadratic
ext only (0%) (0%)
I LOG CPLEX Simplex,  interior ILOG  OPL  Studio, i Reads 14650 14650
(ILOG) point,  MIP, AIMMS,  AMPL, i spreadsheets
network, GAMS, MPL, Tomlab only (18%) (18%)
quadratic
LIN EX) API Simplex  ,  MIP LINGO and What'sBest Read  &  write 4000 70%
(LINDO Systems, Inc) and quadratic 
solver
)  text only (0%) (0%)
XPRESS Solver Engine Simplex,  interior! Excel, Tomlab (Yes 6000 45%
(Frontline Systems Inc) point,  MIP, 
quadratic
(15%) (15%)
Proposed tool selection  i(Adventurous user”
The proposed tools selection assumes that the user has some computer programming 
experience, as GAMS has a relatively steep learning curve and requires a reasonable 
level of modelling skills for use.
In my opinion the best option from a price and performance perspective would be to 
opt for a modelling environment like GAMS, coupled with a solver like XPRESS or 
CP LEX (available directly from GAMS), they are priced as in Table A.3.
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Table A. 3: Associated costs for adventurous user option
Licensing GAMS XPRESS CPLEX
Developer licence $3200 $7000 $6400
Run time Licence $1600 $3200 $3500
These  solvers  are  priced  considerably  lower  than  development  prices  from  the 
original  solver vendors (e.g.  CPLEX from Ilog, developer licence = $14650) as the 
GAMS marketing model provides runtime solvers licences for GAMS only, as they 
are embedded in the GAMS  architecture and allow only solution of GAMS models 
and  only limited  manipulation  of the  solver  options  (which  in most  cases  will be 
sufficient). This also includes no annual maintenance fees.
More user  friendly alternative
An alternative  would be  to  purchase  a user friendly integrated package like  Ilog’s 
OPL  Studio,  this  will  have  a  considerably  lower  learning  curve  for  model 
development as it uses an intuitive optimisation programming language with a much 
less  knowledge  of computer programming required,  reducing  typical  development 
time from weeks to days. A developmental copy of OPL studio with a development 
licence for CPLEX solver would be required for any deployment in an application. 
The  licence  needed  for  the  customer  would  only be  a  run  time  licence.  An  OPL 
development licence must be purchased if any model development is required (along 
with another CPLEX development licence).  Pricing and annual maintenance data is 
shown below in Table A.4.
Table A.4: Associated costs for "more user  friendly alternative ” option
Licensing ILOG OPL ILOG CPLEX
Development Studio Intermediate Fixed
Fixed development development
(Maintenance p/a) (Maintenance p/a)
Developer licence £7,000 (18%) £8,400  (18%)
Run time Licence £7,000 (18%) £4,200 (18%)
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Comparison of  Solver CPLEX and XPRESS
Ilog’s  CPLEX and  Dash optimization’s Xpress  solvers  are the market leaders.  My 
opinion is  that CPLEX is  generally faster and may achieve  slightly better solution 
quality. However, there is a difference in price with XPRESS being a little cheaper.
A performance comparison by GAMS is shown below in Figure A. 1.
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FigureAl: Relative number of instances solved during 1800 s vs. relative gap reached 
during this time (all instances are counted) (from www. zamsworld. ors - benchmarking
exercise).
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